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is essential that the medical profession play a central role in
itically evaluating the evidence related to drugs, devices,
d procedures for the detection, management, or prevention
disease. Properly applied, rigorous, expert analysis of the
ailable data documenting absolute and relative benefits and
sks of these therapies and procedures can improve outcomes
d reduce costs of care by focusing resources on the most
fective strategies. One important use of such data is the
oduction of clinical practice guidelines that, in turn, can
ovide a foundation for a variety of other applications such
performance measures, appropriate use criteria, clinical
cision support tools, and quality improvement tools.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly
gaged in the production of guidelines in the area of
rdiovascular disease since 1980. The ACCF/AHA Task
rce on Practice Guidelines is charged with developing,
dating, and revising practice guidelines for cardiovascular
seases and procedures, and the Task Force directs and
ersees this effort. Writing committees are charged with
sessing the evidence as an independent group of authors to
velop, update, or revise recommendations for clinical
actice.
Experts in the subject under consideration have been
lected from both organizations to examine subject-specific
ta and write guidelines in partnership with representatives
om other medical practitioner and specialty groups. Writing
mmittees are specifically charged to perform a formal
erature review, weigh the strength of evidence for or
ainst particular treatments or procedures, and include
timates of expected health outcomes where data exist.
tient-specific modifiers, comorbidities, and issues of pa-
nt preference that may influence the choice of tests or
erapies are considered. When available, information from
udies on cost is considered, but data on efficacy and clinical
tcomes constitute the primary basis for recommendations
these guidelines.
The ACCF/AHA Task Force on Practice Guidelines makes
ery effort to avoid actual, potential, or perceived conflicts
interest that may arise as a result of industry relationships
personal interests among the writing committee. Specifi-
lly, all members of the writing committee, as well as peer
viewers of the document, are asked to disclose all current
lationships and those 24 months prior to initiation of the
riting effort that may be perceived as relevant. All guideline
commendations require a confidential vote by the writing
mmittee and must be approved by a consensus of the
embers voting. Members who were recused from voting are
ted on the title page of this document. Members must
cuse themselves from voting on any recommendation
here their relationships with industry (RWI) apply. If a
riting committee member develops a new relationship with
dustry during his/her tenure, he/she is required to notify
ideline staff in writing. These statements are reviewed by
e Task Force on Practice Guidelines and all members
ring each conference call and/or meeting of the writing
mmittee, updated as changes occur, and ultimately pub- rehed as an appendix to the document. For detailed informa-
n regarding guideline policies and procedures, please refer
the methodology manual for ACCF/AHA Guideline Writ-
g Committees (1). RWI and other entities pertinent to this
ideline for authors and peer reviewers are disclosed in
ppendixes 1 and 2, respectively. Disclosure information for
e ACCF/AHA Task Force on Practice Guidelines is also
ailable online at (http://www.acc.org/about/overview/
linicalDocumentsTaskForces.cfm).
These practice guidelines are intended to assist healthcare
oviders in clinical decision making by describing a range of
nerally acceptable approaches for diagnosis, management,
d prevention of specific diseases or conditions. Clinicians
ould consider the quality and availability of expertise in the
ea where care is provided. These guidelines attempt to
fine practices that meet the needs of most patients in most
rcumstances. The recommendations reflect a consensus
ter a thorough review of the available current scientific
idence and are intended to improve patient care. The Task
rce recognizes that situations arise where additional data
e needed to better inform patient care; these areas will be
entified within each respective guideline when appropriate.
Patient adherence to prescribed and agreed upon medical
gimens and lifestyles is an important aspect of treatment.
escribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and life-
yles.
If these guidelines are used as the basis for regulatory or
yer decisions, the goal should be improvement in quality of
re and aligned with the patient’s best interest. The ultimate
dgment regarding care of a particular patient must be made
the healthcare provider and the patient in light of all of the
rcumstances presented by that patient. Consequently, there
e circumstances in which deviations from these guidelines
e appropriate.
The guidelines will be reviewed annually by the ACCF/
HA Task Force on Practice Guidelines and considered
rrent unless they are updated, revised, or withdrawn from
stribution.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
Sidney C. Smith, Jr, MD, FACC, FAHA
Immediate Past Chair, ACCF/AHA Task Force on
Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he writing committee conducted a comprehensive search of
e medical and scientific literature through the use of-
bMed/MEDLINE. Searches were limited to publications
ritten in the English language. Compiled reports were
viewed and additional articles were provided by committee
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e following subtopics: acute aortic dissection, ankylosing
ondylitis, aortic dissection and litigation, aortic neoplasm,
rtic tumors, Behçet disease, bicuspid aortic valve, calcified
rta, chronic dissection, coarctation of the aorta, D-dimer,
ssecting aneurysm, Ehlers-Danlos syndrome, endovascular
d aortic aneurysms, medial degeneration, porcelain aorta,
ant cell arteritis, imaging and thoracic aortic disease,
flammatory disease, intramural hematoma, Loeys-Dietz
ndrome, Marfan syndrome, Noonan syndrome, penetrating
rtic ulcer, polycystic kidney disease, thoracic and aortic
eurysms, thoracic aortic disease and patient care, thoracic
rtic disease and surgery, thoracic aorta and Kawasaki
sease, Takayasu arteritis, thoracoabdominal and aorta or
rtic disease, and Turner syndrome. More than 850 refer-
ces were reviewed, with 829 used as the primary evidence
se for the final guideline. The ACCF/AHA Task Force on
actice Guidelines methodology processes were followed to
rite the text and recommendations. In general, published
anuscripts appearing in journals listed in Index Medicus
ere used as the evidence base. Published abstracts were used
ly for emerging information but were not used in the
rmulation of recommendations.
The committee reviewed and ranked evidence supporting
rrent recommendations with the weight of evidence ranked
Level A if the data were derived from multiple randomized
inical trials or meta-analyses. The committee ranked avail-
le evidence as Level B when data were derived from a
ngle randomized trial or nonrandomized studies. Evidence
as ranked as Level C when the primary source of the
commendation was consensus opinion, case studies, or
andard of care. In the narrative portions of these guidelines,
idence is generally presented in chronological order of
velopment. Studies are identified as observational, retro-
ective, prospective, or randomized. For certain conditions
r which inadequate data are available, recommendations are
sed on expert consensus and clinical experience and are
nked as Level C. An analogous example is the use of
nicillin for pneumococcal pneumonia, where there are no
ndomized trials and treatment is based on clinical experi-
ce. When recommendations at Level C are supported by
storical clinical data, appropriate references (including
inical reviews) are cited if available. For issues where
arse data are available, a survey of current practice among
e clinicians on the writing committee formed the basis for
evel C recommendations and no references are cited. The
hema for classification of recommendations and level of
idence is summarized in Table 1, which also illustrates how
e grading system provides an estimate of the size of the
eatment effect and an estimate of the certainty of the
eatment effect.
To provide clinicians with a comprehensive set of data,
henever possible, the exact event rates in various treatment
ms of clinical trials are presented to permit calculation of
e absolute risk difference (ARD), number needed to harm
NH); the relative treatment effects are described either as
ds ratio (OR), relative risk (RR), or hazard ratio (HR)
pending on the format in the original publication. Along SCith all other point statistics, confidence intervals (CIs) for
ose statistics are added when available.
The writing committee recognized that the evidence base
r this guideline is less robust in terms of randomized
inical trials than prior ACCF/AHA guidelines, particularly
ose focused on coronary artery disease (CAD) and heart
ilure. As the reader will discern, much of the evidence base
r this topic consists of cohort studies and retrospective
views, which largely emanate from centers with a special-
ed interest in specific types of thoracic aortic disease. The
riting committee attempted to focus on providing the
actitioner with recommendations for evaluation and treat-
ent wherever possible and where controversy exists, iden-
ed as such in the text.
The writing committee acknowledges the expertise of the
ghly experienced and effective practice guidelines staff of
e ACCF and AHA. The writing committee chair also
knowledges the commitment and dedication of the diverse
riting committee members who were able to put aside issues
specialty “turf” and focus on providing the medical
mmunity with a guideline aimed at optimal patient care.
.2. Organization of the Writing Committee
he guideline was written by a committee comprised of
perts in cardiovascular medicine, surgery, radiology, and
rsing. For many of the previous ACCF/AHA practice
idelines, writing expertise has been available within these 2
ganizations. Because of the broad scope and diversity of
oracic aortic diseases, as well as the specialists who treat
ch patients, the ACCF and AHA sought greater involve-
ent from many specialty organizations. Most, but not all,
ecialty organizations that represent the major stakeholders
ring for patients with thoracic aortic diseases provided
riting committee members and financial support of the
oject, and they are recognized as marquee level partners
ith the ACCF and AHA. These organizations included the
merican Association for Thoracic Surgery (AATS), Amer-
an College of Radiology (ACR), American Stroke Associ-
ion (ASA), Society of Cardiovascular Anesthesiologists
CA), Society for Cardiovascular Angiography and Inter-
ntions (SCAI), Society of Interventional Radiology (SIR),
ciety of Thoracic Surgeons (STS), and Society for Vascu-
r Medicine (SVM). The American College of Emergency
ysicians (ACEP) and the American College of Physicians
CP) were also represented on the writing committee.
here additional expertise was needed, the scientific councils
the AHA were contacted for writing committee represen-
tives. Representation was provided or facilitated by the
ouncils on Cardiovascular Nursing, Cardiovascular Surgery
d Anesthesia, Cardiovascular Radiology and Intervention,
d Clinical Cardiology, Council for High Blood Pressure
esearch, and Stroke Council.
.3. Document Review and Approval
his document was reviewed by 3 outside reviewers nomi-
ted by the ACCF and 2 outside reviewers nominated by the
HA, as well as 1 or 2 reviewers from each of the following
ganizations: the AATS, ACP, ACEP, ACR, ASA, SCA,
AI, SIR, STS, and the SVM. It was also reviewed by 6
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CCF Catherization Committee and 1 content reviewer from
e ACCF Interventional Council. All reviewer RWI infor-
ation was collected and distributed to the writing committee
d is published in this document (see Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and the AATS,
CR, ASA, SCA, SCAI, SIR, STS, and SVM and was
dorsed by the North American Society for Cardiovascular
aging.
.4. Scope of the Guideline
he term “thoracic aortic disease” encompasses a broad range
degenerative, structural, acquired, genetic-based, and trau-
atic disease states and presentations. According to the
ble 1. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a
commendations have been written in full sentences that express a complete
e rest of the document (including headings above sets of recommendations),
rease readers’ comprehension of the guidelines and will allow queries at theenters for Disease Control and Prevention death certificate agta, diseases of the aorta and its branches account for 43 000
47 000 deaths annually in the United States (2). The precise
mber of deaths attributable to thoracic aortic diseases is
clear. However, autopsy studies suggest that the presenta-
n of thoracic aortic disease is often death due to aortic
ssection (AoD) and rupture, and these deaths account for
ice as many deaths as attributed to ruptured abdominal
rtic aneurysms (AAAs) (3). The diagnosis of acute thoracic
oD or rupture is often difficult and delayed, and errors in
agnosis may account for deaths otherwise attributed to
rdiac arrhythmia, myocardial infarction (MI), pulmonary
bolism, or mesenteric ischemia.
The University HealthSystem Consortium (UHC) is an
liance of more than 100 academic medical centers and
filiate hospitals. UHC’s Clinical DataBase/Resource Man-
ence
rent subpopulations, such as sex, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
suggested phrases to use when writing recommendations. All guideline
, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
ual recommendation level.of Evid
in diffe
ation wi
selves t
effective
list of
thought
woulder allows comparison of patient-level risk-adjusted out-
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riting committee with a summary of recent information
sed on ICD-9 codes for thoracic aortic disease–related
spitalizations from the Clinical DataBase/Resource Man-
er (Tables 2A and 2B). This data table demonstrates a high
mber of hospital discharges (more than 135 000) for
oracic, abdominal, thoracoabdominal, and “unspecified”
rtic aneurysms in the 5-year period between 2002 and
07. Subcategories include those with dissection, those with
pture, and those with neither. In the most recent 1-year
riod assessed (fourth quarter 2006 through third quarter
07), there were nearly 9000 cases representing all patients
ith thoracic aortic disease discharged from UHC hospitals.
lthough these data are unavailable for the entire United
ble 2A. ICD-9 Procedure Codes For Aortic Aneurysms
rtic Aneurysm
tegory Dissection Ruptured
No Mention of
Rupture
oracic 441.01 441.1 441.2
dominal 441.02 441.3 441.4
oracoabdominal 441.03 441.6 441.7
rtic (unspecified) 441.00 441.5 441.9
Table courtesy of UHC Clinical DataBase/Resource Manager.
ble 2B. Number of Discharges by Year by Category of Aortic A
C Clinical Database*
rtic Aneurysm
tegory 2002q4–2003q3 2003q4–2004q3 2004q4–2005q3
oracic
Dissection 1607 1683 2028
Ruptured 187 225 219
No mention of
ture
3086 4026 4953
Subtotal 4880 5934 7200
dominal
Dissection 553 630 747
Ruptured 651 657 720
No mention of
ture
12 075 13 280 15 882
Subtotal 13 279 14 567 17 349
oracoabdominal
Dissection 583 587 674
Ruptured 150 129 110
No mention of
ture
1091 1183 1472
Subtotal 1824 1899 2256
rtic (unspecified)
Dissection 223 310 326
Ruptured 9 3 15
No mention of
ture
310 385 505
Subtotal 542 698 846
tal No. of
ses
20 525 23 098 27 651
tal No. of
atient
charges
2679334 2777880 3018141
UHC indicates University HealthSystem Consortium.
*Note: Year-to-year increases are due in part to changes in number of reportTable courtesy of UHC Clinical DataBase/Resource Manager.ates, they provide important estimates of the magnitude of
e prevalence of thoracic aortic disease. Additional informa-
n regarding the patient admission source, particularly those
ith acute presentations, is pertinent to the discussion regard-
g interinstitutional transfer (see Section 17.2).
Most patients with significant thoracic aortic disease will
directed to specialized practitioners and institutions. How-
er, the importance of early recognition and prompt treat-
ent and/or referral for various thoracic aortic diseases by all
althcare professionals provides the rationale for this docu-
ent. This guideline will attempt to provide the practitioner
ith a sufficient description of background information,
agnostic modalities, and treatment strategies so that appro-
iate care of these patients can be facilitated and better
derstood. The goal of this guideline is to improve the health
tcomes and quality of life for all patients with thoracic
rtic disease.
Other practice guidelines developed by ACCF and AHA
dress the management of patients with cardiac and vascular
seases. The ACCF/AHA guidelines on peripheral arterial
sease (4) include recommendations for lower extremity,
nal, mesenteric, and abdominal aortic diseases. Data stan-
rds on this topic are currently in development, as is a
actice guideline on extracranial carotid and vertebral artery
sm Among Academic Medical Centers Reporting Data to the
4–2006q3 2006q4–2007q3
5-Year
Total
Category %
Distribution
% of All
Categories
25.9
1 2355 9994 28.5
4 251 1116 3.2
0 6156 23 954 68.3
5 8762 35 064
62.7
867 3664 4.3
702 3464 4.1
818 18 683 77 738 91.6
419 20 252 84 866
8.3
834 3433 30.5
127 673 6.0
1773 7140 63.5
2734 11 246
3.0
339 1541 37.6
9 45 1.1
701 2513 61.3
1049 4099
201 32 797 135 275
222542 3297834 14995731
itals.neury
2005q
232
23
573
828
867
734
17
19
755
157
1621
2533
343
9
612
964
31
3
ing hosp
di
Jo
tio
A
of
di
ou
ar
re
A
m
w
en
be
in
di
do
an
m
vi
m
to
ca
1.
A
cr
•
•
•
•
•
•
•
1
U
A
P
E
A
e35JACC Vol. 55, No. 14, 2010 Hiratzka et al.
April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseseases. The ACCF/AHA guidelines are published in the
urnal of the American College of Cardiology and Circula-
n and are available on both the ACC (www.acc.org) and
HA (my.americanheart.org) Web sites.
This guideline includes diseases involving any or all parts
the thoracic aorta with the exception of aortic valve
seases (5) and includes the abdominal aorta when contigu-
s thoracic aortic diseases are present. Specific disease states
e described in the following sections, and the reader is
ferred to the glossary of terminology in Section 1.5 and
ppendix 3 for abbreviations used throughout the guideline.
The reader will note that several topics or referenced areas
ay appear more than once throughout the guideline. This
ill appear to be redundant to those who choose to read the
tire document, but the writing committee believed that
cause of the multidisciplinary nature of and organizational
volvement in this project, individuals representing specific
sciplines may choose to read and extract portions of the
cument for their own use. Inclusion of the narrative text
d references was thought to be appropriate to facilitate a
ore complete understanding for these disciplines and indi-
duals. Accordingly, the organization of the guideline is
eant to be less of a textbook presentation of the various
pics but rather a more clinically oriented document appli-
ble to a variety of disciplines.
4.1. Critical Issues
s the writing committee developed this guideline, several
itical issues emerged:
Thoracic aortic diseases are usually asymptomatic and not
easily detectable until an acute and often catastrophic
complication occurs. Imaging of the thoracic aorta with
computed tomographic imaging (CT), magnetic resonance
imaging (MR), or in some cases, echocardiographic exam-
ination is the only method to detect thoracic aortic diseases
and determine risk for future complications (see Section 4).
Radiologic imaging technologies have improved in terms
of accuracy of detection of thoracic aortic disease. How-
ever, as the use of these technologies has increased, so also
has the potential risk associated with repeated radiation
exposure, as well as contrast medium–related toxicity.
Whether these technologies should be used repeatedly as a
widespread screening tool is discussed in Section 4. In
addition, the writing committee formulated recommenda-
tions on a standard reporting format for thoracic aortic
findings as discussed in Section 4.5.
Imaging for asymptomatic patients at high risk based on
history or associated diseases is expensive and not always
covered by payers.
For many thoracic aortic diseases, results of treatment for
stable, often asymptomatic, but high-risk conditions are far
better than the results of treatment required for acute and
often catastrophic disease presentations. Thus, the identi-
fication and treatment of patients at risk for acute and
catastrophic disease presentations (e.g., thoracic AoD,
thoracic aneurysm rupture) prior to such an occurrence are
paramount to eliminating the high morbidity and mortality
associated with acute presentations (see Section 8.1).A subset of patients with acute AoD are subject to missed
or delayed detection of this catastrophic disease state.
Many present with atypical symptoms and findings, mak-
ing diagnosis even more difficult (see Sections 8.1.4 and
8.6). This issue has come under greater medical-legal
scrutiny, and specific cases have been widely discussed in
the public domain. Widespread awareness of the varied
and complex nature of thoracic aortic disease presentations
has been lacking, especially for acute AoD. Risk factors
and clinical presentation clues are noted in Section 8.1.4.
The collaboration and cosponsorship of multiple medical
specialties in the writing of this guideline will provide
unique opportunities for widespread dissemination of
knowledge to raise the level of awareness among all
medical specialties.
There is rapidly accumulating evidence that genetic alter-
ations or mutations predispose some individuals to aortic
diseases (see Section 5). Therefore, identification of the
genetic alterations leading to these aortic diseases has the
potential for early identification of individuals at risk. In
addition, biochemical abnormalities involved in the pro-
gression of aortic disease are being identified through
studies of patients’ aortic samples and animal models of
the disease (6,7). The biochemical alterations identified in
the aortic tissue have the potential to serve as biomarkers
for aortic disease. Understanding the molecular pathogen-
esis may lead to targeted therapy to prevent aortic disease.
Medical and gene-based treatments are beginning to show
promise for reducing or delaying catastrophic complica-
tions of thoracic aortic diseases (see Section 9.2).
As noted in Section 18, there are several areas where
greater resources for research and both short- and long-
term outcomes registries are needed.
.5. Glossary of Terms and Abbreviations
sed Throughout Guideline
neurysm (or true aneurysm): a permanent localized dila-
tation of an artery, having at least a 50% increase in
diameter compared with the expected normal diameter of
the artery in question. Although all 3 layers (intima,
media, and adventitia) may be present, the intima and
media in large aneurysms may be so attenuated that in
some sections of the wall they are undetectable.
seudoaneurysm (or false aneurysm): contains blood re-
sulting from disruption of the arterial wall with extrava-
sation of blood contained by periarterial connective tissue
and not by the arterial wall layers (see Section 8.4). Such
an extravascular hematoma that freely communicates with
the intravascular space is also known as a pulsating
hematoma (8–10).
ctasia: arterial dilatation less than 150% of normal arterial
diameter.
rteriomegaly: diffuse arterial dilatation involving several
arterial segments with an increase in diameter greater
than 50% by comparison to the expected normal arterial
diameter.
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the thoracic and abdominal aorta (see Section 9.2.2.3).
bdominal aortic aneurysm (AAA): aneurysm involving
the infradiaphragmatic abdominal aorta.
ortic dissection (AoD): disruption of the media layer of the
aorta with bleeding within and along the wall of the aorta.
Dissection may, and often does, occur without an aneu-
rysm being present. An aneurysm may, and often does,
occur without dissection. The term “dissecting aortic
aneurysm” is often used incorrectly and should be re-
served only for those cases where a dissection occurs in an
aneurysmal aorta (see Section 8.1).
. The Thoracic Aorta
.1. The Normal Aorta
he thoracic aorta is divided into 4 parts: the aortic root
hich includes the aortic valve annulus, the aortic valve
sps, and the sinuses of Valsalva); the ascending aorta
hich includes the tubular portion of the ascending aorta
ginning at the sinotubular junction and extending to the
achiocephalic artery origin); the aortic arch (which begins
the origin of the brachiocephalic artery and is the origin of
e head and neck arteries, coursing in front of the trachea and
the left of the esophagus and the trachea); and the
scending aorta (which begins at the isthmus between the
igin of the left subclavian artery and the ligamentum
teriosum and courses anterior to the vertebral column, and
en through the diaphragm into the abdomen).
The normal human adult aortic wall is composed of 3
yers, listed from the blood flow surface outward (Figure 1):
tima: endothelial layer on a basement membrane with
minimal ground substance and connective tissue.
edia: bounded by an internal elastic lamina, a fenestrated
sheet of elastic fibers; layers of elastic fibers arranged
concentrically with interposed smooth muscle cells;
bounded by an external elastic lamina, another fenestrated
sheet of elastic fibers. apdventitia: resilient layer of collagen containing the vasa
vasorum and nerves. Some of the vasa vasorum can
penetrate into the outer third of the media.
.2. Normal Thoracic Aortic Diameter
1991, the Society for Vascular Surgery created a table
able 3) describing the normal diameter of the adult thoracic
rta based on CT and chest x-ray (12).
Since then, it has been recognized that the “normal aortic
ameter” is influenced by a number of factors, including
tient age, sex, and body size; location of aortic measure-
ent; method of measurement; and the robustness and type of
aging methods used. Hannuksela et al (13) noted that
ameter increased by 0.12 to 0.29 mm/y at each level
easured by CT for 41 men and 36 women aged 18 to 82
ars (Figure 2). Aortic diameter for men was larger than that
r women, but the difference decreased with age. Body mass
dex also affected aortic diameter by 0.27 mm (0.14 to 0.44
m) per unit of body mass index (13).
Aortic diameter gradually tapers downstream from the
nuses of Valsalva. Hager et al (14) examined 46 men and 24
omen without cardiovascular disease (age range 1 to 89
ble 3. Normal Adult Thoracic Aortic Diameters
horacic Aorta
Range of Reported
Mean (cm)
Reported SD
(cm)
Assessment
Method
ot (female) 3.50 to 3.72 0.38 CT
ot (male) 3.63 to 3.91 0.38 CT
cending
male, male)
2.86 NA CXR
id-descending
male)
2.45 to 2.64 0.31 CT
id-descending
ale)
2.39 to 2.98 0.31 CT
aphragmatic
male)
2.40 to 2.44 0.32 CT
aphragmatic
ale)
2.43 to 2.69 0.27 to 0.40 CT, arteriography
CT indicates computed tomographic imaging; CXR, chest x-ray; and NA, not
Figure 1. Aortic pathology associated with thoracic
aortic aneurysm involving the ascending aorta. All
panels are identically oriented with the adventitia at
the top and the intima at the bottom. H&E staining of
aortic sections from a control (a) and a patient (b) with
a TAA demonstrates medial degeneration with the
fragmentation of elastic fibers, accumulation of pro-
teoglycans, and regions of smooth muscle cell loss.
Movat staining of aortic sections from control (c) and
patient with an aneurysm (d) shows fragmentation of
elastic fibers (stained black), loss of smooth muscle
cells (cells stained red and nuclei stained violet), and
accumulation of proteoglycans (stained blue) in the
medial layer. 40 magnification; scale bars represent
500 mcg. H&E indicates hematoxylin and eosin; and
TAA, thoracic aortic aneurysm. Modified from
Milewicz et al (11).plicable. Reprinted with permission from Johnston et al (12).
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasears; mean age 50.2 years) using helical CT (Figure 3). For
ese patients, there was no correlation with weight, height, or
dy surface area, but aortic diameter increased with age and
as larger for men than for women (14).
Two-dimensional echocardiography has been used to de-
e the “normal” range for aortic diameter at the sinuses of
alsalva in different age categories (and stratified by body
rface area) (15). Adjusting for 2 of the key determinants of
rtic diameter allows a more precise characterization of
rtic size in otherwise healthy individuals (15) (Figure 4).
gain, age and sex affected aortic root diameter, but the
fluence of sex was neutralized when diameter was indexed
body surface area (Table 4).
These tables and definitions help define the presence or
sence of a thoracic aortic aneurysm and help define the
reshold for considering further treatment for such patients.
owever, patients with certain genetic syndromes and abnor-
al tissue morphology may in fact have a normal aortic
ameter at the time of acute AoD rupture (see Section 5.1.2).
nother challenge relates to abnormal morphology of one
rtic segment compared with another. For example, if the
ameter of the ascending aorta exceeds the diameter of the
gure 2. Normal diameter and upper limit of ascending and
scending aorta related to age. Reprinted with permission from
annuksela et al (13).rta at the level of the sinuses Valsalva, even if both are
ithin normal range, then the ascending aorta is considered to
enlarged. To adjust for body habitus variation, the use of
rtic diameter indexed to height has been reported to better
dicate surgical timing than might be recommended from
rtic diameter alone for an otherwise asymptomatic patient
ith Marfan syndrome or bicuspid aortic valve (16). When-
er possible, the writing committee has inserted aortic
ameter thresholds for further action, whether the action is
r continued surveillance or for endovascular or surgical
tervention.
. Thoracic Aortic Histopathology
.1. Atherosclerosis
therosclerosis is characterized by intimal lesions called
heromata, or atheromatous or fibrofatty plaques, which
otrude into the arterial lumen and weaken the underlying
edia often associated with calcification. With aging, pres-
ce of risk factors, and genetic predisposition, this
ogresses to complicated lesions with surface defects, hem-
rhage, and/or thrombosis. A 1995 consensus document
om the AHA defines the types and histologic classes of
herosclerosis (17) (Figure 5).
Thoracic aortic atherosclerosis is less common than ab-
minal aortic atherosclerosis, but the clinical importance is
eat. Clinical presentations and problems associated with
rtic atherosclerosis and atheroma are discussed extensively
Section 11.
.2. Aneurysms and Dissections
he pathology associated with thoracic aortic aneurysms and
ssections was initially termed cystic medial necrosis but
is term is a misnomer; the disease is not associated with
crosis of the aorta or with cyst formation. Aortic aneurysm
stopathology, more accurately termed medial degeneration,
characterized by disruption and loss of elastic fibers and
creased deposition of proteoglycans (Figure 1). Typically,
ere are areas of loss of smooth muscle cells in the aortic
edia, but whether there is a total loss of smooth muscle cells
the aortic wall is not clear. There can be atherosclerosis
sions present, but again, these changes are typically super-
Figure 3. Mean aortic diameters (in cm) at various
levels measured by helical CT in 70 adults. Thin lines
represent 2 SDs, representing 95% reference area.
CT indicates computed tomographic imaging; and SD,
standard deviation. Reprinted with permission from
Hager et al (14).
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generation was initially described as a noninflammatory
sease, recent literature supports the presence of inflamma-
ry cell infiltration in this disease (18,19).
The biochemical pathways and proteins involved with
edial degeneration have not been clearly delineated.
owever, multiple studies have found increased immuno-
aining for a subset of matrix metalloproteinases (MMPs)
the media of thoracic aortic aneurysms, particularly
MP-2 and MMP-9 (20 –23). Immunostaining of aortic
edia from patients with Marfan syndrome has demon-
rated increases in MMP-2 and MMP-9, which were
sociated with smooth muscle cells at the borders of areas
medial degeneration and on the surface of disrupted
astic fibers. Elevated MMP-2 and MMP-9 immunostain-
g has been demonstrated in ascending aneurysms from
tients with either tricuspid or bicuspid aortic valves
1,23) and inconsistently in ascending aortic tissue from
tients with tricuspid aortic valves (22). These 2 MMPs
e known to have elastolytic activity. Variable expression
MMPs and tissue inhibitors of MMPs has also been
monstrated in aortic tissue of patients with Marfan
ndrome versus patients without Marfan syndrome (24).
lthough accumulation of proteoglycans in the aortic
edia is another consistent finding in thoracic aortic
ble 4. Sex Differences in Aortic Root Dimensions in Adults
rtic Root
Absolute Values
(cm) Men P Value
nulus 2.60.3 0.001
nuses of Valsalva 3.40.3 0.001
notubular junction 2.90.3 0.001
oximal ascending aorta 3.00.4 0.001
NS indicates not significant.
Adapted from Roman et al (15).eurysms, no studies have determined why this accumu-
tion occurs or whether these are causative in nature.
Medial degeneration is also associated with focal loss of
scular smooth muscle cells. Although there are regions
smooth muscle cell loss, morphometric analysis of
rtic tissue has suggested that hyperplastic cellular re-
odeling of the media in ascending thoracic aortic aneu-
sms may be an initial adaptive response to minimize
creased wall stress resulting from vascular dilatation
5). More recent studies of the aortic pathology associated
ith myosin heavy chain 11, smooth muscle (MYH11), and
tin, alpha 2, smooth muscle aorta (ACTA2) mutations
ading to ascending aortic aneurysms demonstrate a
perplastic response by smooth muscle cells in the aortic
edia. The aortic media in aneurysm tissue taken from
tients harboring mutations in these genes demonstrated
cal hyperplasia associated with smooth muscle cells that
ere remarkable for a lack of structured orientation
rallel to the lumen of the aorta, but instead, the smooth
uscle cells were oriented randomly with respect to one
other (26,27).
.3. Vasculitis and Inflammatory Diseases
variety of inflammatory vasculitides may also result in
oracic aortic disease. These include giant cell arteritis
Figure 4. Sinus of Valsalva diameter, by
body surface area. Left, The 95% normal
confidence limits for aortic root diameter at
the sinuses of Valsalva in relation to body
surface area in adults 40 years of age.
Right, The 95% normal confidence limits for
the proximal ascending aortic diameter in re-
lation to body surface area in adults 40
years of age. SEE indicates standard error of
the estimate. Reprinted with permission from
Roman et al (15).
men
Indexed
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. The pathophysiology of GCA shares important features
ith Takayasu arteritis (28). T-cell clonal expansion sug-
sts a specific antigenic response, which currently re-
ains unelucidated. The inflammatory response, which
gins in the adventitial layer, is marked by augmented
tokine and MMP production causing granuloma forma-
on. Granuloma formation both shields the vessel from the
citing antigen and causes vessel destruction (29). Behçet
sease is a vasculitis affecting both arteries and veins, of
l sizes.
. Imaging Modalities
.1. Recommendations for Aortic Imaging
chniques to Determine the Presence and
rogression of Thoracic Aortic Disease
ASS I
Measurements of aortic diameter should be taken at reproduc-
ible anatomic landmarks, perpendicular to the axis of blood
flow, and reported in a clear and consistent format (see Table
5). (Level of Evidence: C)
For measurements taken by computed tomographic imaging
or magnetic resonance imaging, the external diameter
should be measured perpendicular to the axis of blood flow.
For aortic root measurements, the widest diameter, typi-
cally at the mid-sinus level, should be used. (Level of
Evidence: C)
For measurements taken by echocardiography, the internal diam-
eter should be measured perpendicular to the axis of blood flow.
For aortic root measurements, the widest diameter, typically at
the mid-sinus level, should be used. (Level of Evidence: C) ulcAbnormalities of aortic morphology should be recognized and
reported separately even when aortic diameters are within
normal limits. (Level of Evidence: C)
The finding of aortic dissection, aneurysm, traumatic injury
and/or aortic rupture should be immediately communicated to
the referring physician. (Level of Evidence: C)
Techniques to minimize episodic and cumulative radiation
exposure should be utilized whenever possible. (30,31) (Level
of Evidence: B)
Figure 5. Atherosclerotic lesions. Flow dia-
gram in center column indicates pathways in
evolution and progression of human athero-
sclerotic lesions. Roman numerals indicate
histologically characteristic types of lesions
defined at the left of the flow diagram. The
direction of the arrows indicates the se-
quence in which characteristic morphologies
may change. From Type I to Type IV,
changes in lesion morphology occur primarily
because of increasing accumulation of lipid.
The loop between Types V and VI illustrates
how lesions increase in thickness when
thrombotic deposits form on their surfaces.
Thrombotic deposits may form repeatedly
over varied time spans in the same location
and may be the principal mechanism for
gradual occlusion of medium-sized arteries.
Adapted from Stary et al (17).
ble 5. Essential Elements of Aortic Imaging Reports
The location at which the aorta is abnormal (see Section 2).
The maximum diameter of any dilatation, measured from the external
wall of the aorta, perpendicular to the axis of flow, and the length of the
aorta that is abnormal.
For patients with presumed or documented genetic syndromes at risk for
aortic root disease measurements of aortic valve, sinuses of Valsalva,
sinotubular junction, and ascending aorta.
The presence of internal filling defects consistent with thrombus or
atheroma.
The presence of IMH, PAU, and calcification.
Extension of aortic abnormality into branch vessels, including dissection
and aneurysm, and secondary evidence of end-organ injury (e.g., renal
or bowel hypoperfusion).
Evidence of aortic rupture, including periaortic and mediastinal
hematoma, pericardial and pleural fluid, and contrast extravasation from
the aortic lumen.
When a prior examination is available, direct image to image comparison
to determine if there has been any increase in diameter.
IMH indicates intramural hematoma; and PAU, penetrating atherosclerotic
er.
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If clinical information is available, it can be useful to relate
aortic diameter to the patient’s age and body size. (Level of
Evidence: C)
efinitive identification or exclusion of thoracic aortic dis-
se or one of its anatomic variants requires dedicated aortic
aging. Selection of the most appropriate imaging study
ay depend on patient-related factors (i.e., hemodynamic
ability, renal function, contrast allergy) and institutional
pabilities (i.e., rapid availability of individual imaging
odalities, state of the technology, and imaging specialist
pertise). Consideration should be given to patients with
rderline abnormal renal function (serum creatinine greater
an 1.8 to 2.0 mg/dL)—specifically, the tradeoffs between
e use of iodinated intravenous contrast for CT and the
ssibility of contrast-induced nephropathy, and gadolinium
ents used with MR and the risk of nephrogenic systemic
rosis (32).
Radiation exposure should be minimized (31,33–36). The
sk of radiation-induced malignancy is the greatest in neo-
tes, children, and young adults (31). Generally, above the
e of 30 to 35 years, the probability of radiation-induced
alignancy decreases substantially (30,31). For patients who
quire repeated imaging to follow an aortic abnormality, MR
ay be preferred to CT. MR may require sedation due to
nger examination times and tendency for claustrophobia.
CT as opposed to echocardiography can best identify
oracic aortic disease, as well as other disease processes that
n mimic aortic disease, including pulmonary embolism,
ricardial disease, and hiatal hernia. After intervention or
en surgery, CT is preferred to detect asymptomatic post-
ocedural leaks or pseudoaneurysms because of the presence
metallic closure devices and clips.
We recommend that external aortic diameter be reported
r CT or MR derived size measurements. This is important
cause lumen size may not accurately reflect the external
rtic diameter in the setting of intraluminal clot, aortic wall
flammation, or AoD. A recent refinement in the CT mea-
rement of aortic size examines the vessel size using a
nterline of flow, which reduces the error of tangential
easurement and allows true short-axis measurement of
rtic diameter. In contrast to tomographic methods,
hocardiography-derived sizes are reported as internal diam-
er size. In the ascending aorta, where mural thrombus in
eurysms is unusual, the discrepancy between the internal
d external aortic diameters is less than it is in the descend-
g or abdominal aorta, where mural thrombus is common.
andardization of aortic diameter measurements is important
the planning of endovascular treatment of an aneurysm,
here the diameter of the aorta in the seal zone must be
atched to the diameter of an endograft. Here, the choice of
ternal or external diameter is specified by the manufacturer
the endograft.
.2. Chest X-Ray
outine chest x-ray may occasionally detect abnormalities of
rtic contour or size that require definitive aortic imaging.hest x-ray often serves as a part of the evaluation of patients thith potential acute AoD, primarily to identify other causes
patient’s symptoms, but also as a screening test to identify
dings due to a dilated aorta or bleeding. However, chest
ray is inadequately sensitive to definitively exclude the
esence of AoD in all except the lowest-risk patients and
erefore rarely excludes the disease. Pooled data from 10
udies places the predictive sensitivity of a widened medi-
tinum or an abnormal aortic contour associated with sig-
ficant thoracic aortic disease at 64% and 71%, respectively
7). In the same analysis, however, including all abnormal
diographic findings increased the sensitivity to 90%, sug-
sting that a completely normal chest x-ray does lower the
elihood of AoD and may provide meaningful clinical
formation in very low-risk patients (37). The presence of a
idened mediastinum or other radiographic findings sugges-
e of thoracic aortic disease increases the likelihood of
oD, particularly among patients who lack a clear alternative
urce for their symptoms. In a blinded prospective study of
6 patients who underwent evaluation for acute thoracic
rtic disease, the specificity of chest x-ray for aortic pathol-
y was 86% (38).
For patients with chest trauma, chest x-ray is a poor
reening test for the diagnosis of aortic injury (39–41). A
arply demarcated normal mediastinal contour is sometimes
ed to exclude mediastinal hematoma (suggesting a wide
ediastinum, abnormal mediastinal contour, left apical cap,
ss of the aortic knob, depression of the left main bronchus,
d deviation of an indwelling esophageal tube). However,
ese signs of hemomediastinum are more often false positive
an true positive for aortic injury (40). Figure 6 illustrates the
rmal appearance of the thoracic aorta, and its components,
a posteroanterior chest x-ray.
.3. Computed Tomographic Imaging
T scanning has been used for more than 2 decades to
entify acute AoD and to diagnose and measure other
gure 6. Chest x-ray of a normal thoracic aorta. Arrows indi-
te arch, and arrowheads show ascending and descending
rta.oracic aortic diseases (42) (see Section 5.1). Advantages
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseclude near universal availability—the ability to image the
tire aorta, including lumen, wall, and periaortic regions; to
entify anatomic variants and branch vessel involvement;
d to distinguish among types of acute aortic syndromes
.e., intramural hematoma [IMH], penetrating atherosclerotic
cer [PAU], and acute AoD)—and the short time required to
mplete the imaging process and the 3-dimensional data.
lectrocardiogram (ECG)-gated techniques have made it
ssible to generate motion-free images of the aortic root and
ronary arteries, similar to coronary CT angiographic imag-
g.
Reports of newer-generation multidetector helical CT
anners show sensitivities of up to 100% and specificities of
% to 99% (43–46). Data from the International Registry of
cute Aortic Dissection (IRAD) show that for patients with
rtic dissection, CT was the initially used diagnostic modal-
in 61% of patients and transthoracic echocardiography
TE) and/or transesophageal echocardiography (TEE) was
ed first in 33% of patients. Whether this was because the
gure 7. Axial CT images demonstrating the value of noncon-
st images. Top, Precontrast image demonstrates a high-at-
nuation aortic hematoma indicating an acute aortic event. Bot-
m, Images obtained with intravenous contrast material
monstrate the contrast-filled aortic lumen and the hematoma
a relatively lower attenuation band. CT indicates computed
mographic imaging.st test was insufficient to diagnose dissection or because prditional information about cardiac and aortic valve function
as required is unclear (47).
The sequence for CT performed in the potential setting of
ute AoD generally would include a noncontrast study to
tect subtle changes of IMH (Figure 7), followed by a
ntrast study to delineate the presence and extent of the
ssection flap, identify regions of potential malperfusion,
d demonstrate contrast leak indicating rupture. Imaging of
e vascular tree from the thoracic inlet to the pelvis,
cluding the iliac and femoral arteries, provides sufficient
formation to plan surgical or endovascular treatment, if
eded. Prompt interpretation and communication of findings
the appropriate treating physicians are essential in the acute
tting.
For trauma patients, the sensitivity, specificity, and accu-
cy of contrast-enhanced multidetector CT for traumatic
rtic injury are 96%, 99%, and 99%, respectively (48–50).
he negative predictive value of contrast-enhanced CT ap-
oaches 100% in many studies, most with in-hospital
llow-up of negative CT examinations (36,48,51,52)
igure 8).
An outcome study of 278 patients undergoing contrast-
hanced CT for blunt chest trauma revealed 6 patients with
rta/great vessel injury and confirmed the 100% negative
gure 8. Traumatic aortic rupture secondary to a motor vehicle
ash. Top, Axial CT image demonstrates a traumatic injury with
eudoaneurysm (T) in the proximal descending thoracic aorta,
merous bilateral rib fractures, and small bilateral pleural effu-
ons, with no significant mediastinal hematoma. Bottom, Still
age through the thorax further demonstrates the extent of the
rtic trauma. See the accompanying full cine video for the bot-
m panel. CT indicates computed tomographic imaging.edictive value in the remaining patients using an extensive
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onths (53).
Regarding other thoracic aortic diseases, CT has been
own to have a 92% accuracy for diagnosing abnormalities
the thoracic aorta, in a series of examinations that included
thoracic aneurysms, 3 ruptured thoracic aortic aneurysms,
PAUs, 5 AoDs, and 2 pseudoaneurysms. In addition, CT
rrectly predicted the need for hypothermic circulatory
rest during surgical repair in 94% of patients (54). For
ngenital and inflammatory conditions of the thoracic aorta,
e literature is primarily descriptive, and accuracy data are
t available.
3.1. Computed Tomographic Imaging Technique
lthough nonhelical CT scanners are capable of diagnosing
oracic aortic disease, the technique used is axial step-and-
oot technology. Inherent limitations include slow scan
eed, relatively poor spatial resolution given thicker colli-
ation used to extend the needed craniocaudal coverage, and
herently a noncontiguous dataset. Any patient motion, even
inimal, between the acquisition of each image or cluster of
ages creates a stair-step artifact on multiplanar and
dimensional renderings. Helical CT scanners of 4 and
eater detector rows consistently provide volumetric acqui-
tions of the thoracic aorta. Scanners with 16 and greater
tector rows provide isotropic resolution in the x, y, and z
es, which allows the datasets to be reconstructed in the
timum imaging plane best suited to any individual vessel.
Technical parameters recommended for image reconstruc-
n are slices of 3-mm or less thickness with a reconstruction
terval of 50% or less than the slice thickness at 50% or
eater overlap, tube rotation of 1 second or less, and 120 to
0 kVp (55). ECG gating is particularly useful for ascending rortic disease, eliminating motion artifact at the aortic root
at can simulate an AoD (Figure 9), and allowing evaluation
aortic valve morphology and function, as well as evalua-
n of the proximal coronary arteries. If appropriately ac-
ired, an aorta CT and a complete CT coronary angiogram
n be obtained in 1 CT acquisition. For AoD, the scan
verage should start above the aortic arch and extend at least
the aortoiliac bifurcation, and probably the groin. This is
portant to determine both branch vessel involvement, such
lesion extension into the abdominal aorta and iliac arteries
d characterization and diagnosis of malperfusion syn-
ome, and to evaluate access for percutaneous repair when
ansluminal therapy is being considered. (For further infor-
ation on technique parameters and anatomic coverage, see
e online-only Data Supplement.)
The CT angiographic acquisition uses intravenous contrast
livered at rate of 3 to 5 mL/s by a power injector and
ually followed by a saline bolus. The total volume of
ntrast used should be kept as low as possible, to no greater
an 150 mL.
Although axial sections remain the mainstay of interpreta-
n, 2- and 3-dimensional reconstructions, such as maximum
tensity projection, multiplanar and curved multiplanar ref-
mations, and volume rendering, may augment interpreta-
n and improve communication of the findings (54). To our
owledge, it has not been scientifically shown that the use of
ese tools increases diagnostic accuracy or diagnostic con-
ence among specialists. For example, in 1 study multipla-
r reconstructions when added to axial images alone
anged the interpretation in only 1 case (54). However,
dimensional reconstruction is likely to play an important
Figure 9. Mimic of aortic dissection created by
motion of the aortic root. Top left, Image at the
level of the right pulmonary artery demonstrates a
normal descending thoracic aorta and pseudodis-
section of the ascending aorta due to motion arti-
fact that occurs on non–ECG-gated CT examina-
tions (arrow). Top right, Image at the aortic root
shows a double contour to the aortic root that may
simulate a dissection flap (arrow). Bottom, Still im-
age through the thoracic aorta further delineates
the extent of the motion artifact. See the accom-
panying full cine video. CT indicates computed
tomographic imaging; and ECG, electrocardio-
gram.le in the planning of surgical or endovascular approaches.
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R has been shown to be very accurate in the diagnosis of
oracic aortic disease, with sensitivities and specificities that
e equivalent to or may exceed those for CT and TEE
4,58–62). Like CT, MR provides a multiplanar evaluation
the thoracic aorta, and the examination can be extended in
verage to include the length of the aorta and branch vessels,
om skull base to the toes. Advantages of MR include the
ility to identify anatomic variants of AoD (IMH and PAU),
sess branch artery involvement, and diagnose aortic valve
thology and left ventricular dysfunction without exposing
e patient to either radiation or iodinated contrast. Disadvan-
ges include prolonged duration of imaging acquisition
ring which the patient is inaccessible to care providers;
ability to use gadolinium contrast in patients with renal
sufficiency; contraindication in patients with claustropho-
a, metallic implants, or pacemakers; and lack of widespread
ailability on an emergency basis. Although time-resolved
R techniques are improving, MR often cannot clearly
aracterize the relationship of an intimal flap and aortic root
ructures, specifically the coronary arteries. Likely as a result
these considerations, data from IRAD found that MR was the
ast-used imaging study, used in only 1% of patients as the
itial diagnostic study (63). For traumatic injury and congenital
d inflammatory conditions of the thoracic aorta, the literature
primarily descriptive, and accuracy data are not available.
4.1. Magnetic Resonance Imaging Technique
comprehensive MR examination of the thoracic aorta may
clude many components, including black blood imaging,
ay include basic spin-echo sequences, noncontrast white
ood imaging, contrast-enhanced MR angiography using
dolinium based agents, and phase-contrast imaging. MR of
e thoracic aorta in the acute setting can be shortened to meet
gent patient assessment needs. The use of each is described
ore specifically later. MR examinations have become faster,
ith advances in gradient hardware that have significantly
duced repetition times, resulting in ultrafast MR angiogra-
y techniques. However, MR examinations remain 2 to 4
es longer than CT examinations. MR terminology across
aging vendors is less consistent than that of CT; therefore,
aging sequences are described later as general types of
quences without vendor-specific details (58,59).
4.2. Black Blood Imaging
lack blood imaging, using spin-echo sequences, is used to
aluate aortic anatomy and morphology (such as aortic size
d shape), and the aortic wall for hematoma or other causes
thickening such as vasculitis. They may be repeated after
e administration of gadolinium-based contrast agents to
entify wall enhancement. These sequences should use ECG
ting at end-diastole and may be performed with or without
uble inversion recovery techniques that null the signal from
ood. These sequences generate 2-dimensional images that
n be obtained in the axial, sagittal, and coronal planes, as
ell as the oblique sagittal or “candy cane” view. T1-
eighted gradient echo sequences may be used in place of
ack blood images and are usually performed both before
d after contrast administration. They can be obtained in the
ial, sagittal, and coronal planes. ar4.3. Noncontrast White Blood Imaging
his is performed using either basic gradient echo sequences
the more advanced balanced steady-state free precession
chniques (SSFP) that are T2*weighted and generate images
ith subsecond temporal resolution. Signal is generated from
ood, making it appear white in the absence of contrast.
FP techniques use ultrashort repetition times that require
R scanners with high-performance gradients. For the latter,
in-plane resolution of approximately 2.01.5 mm2 can be
tained using a repetition time of 3.2 ms, TE of 1.6 ms, flip
gle of 60 to 70 degrees, and a 256256 matrix. SSFP
chniques can be performed to generate 2-dimensional,
dimensional, and cine images; the 2-dimensional images
e usually performed in the axial, sagittal, and coronal planes
an interleaved manner and use ECG gating with triggering
end-diastole to generate images in less than 500 ms that do
t require breath holding. Cine SSFP sequences require 7- to
second breath holding and are usually only performed at
ecific anatomic locations of interested, as determined by the
dings on the previously generated images. For patients who
nnot hold their breath, cine SSFP sequences can be per-
rmed without using ECG gating or breath holding but with
bstantially lower spatial and temporal resolution.
4.4. Contrast-Enhanced Magnetic
esonance Angiography
r the thoracic aorta, contrast-enhanced MR angiography is
ually performed with ECG gating. Although this increases
quisition time, it provides motion-free images of the aortic
ot and ascending aorta. For patients without a contraindi-
tion to receiving a gadolinium-based contrast agent,
ntrast-enhanced MR angiography is often the sequence of
oice from which most of the diagnostic information is
tained. Contrast-enhanced MR angiography images are
tained as a 3-dimensional volumetric dataset, which can be
anipulated and viewed in much the same manner as CT
an datasets. Advances in MR, particularly gradient strength,
ve markedly reduced the acquisition times of contrast-
hanced MR angiography possible to subsecond acquisition
es. This temporally resolved subsecond contrast-enhanced
R angiography is particularly useful in critically ill patients
patients who cannot hold their breath, where motion
tifact can degrade other sequences that take longer to acquire,
ith the tradeoff being a reduction of in-plane resolution.
4.5. Phase Contrast Imaging
hese sequences are usually performed to evaluate gradients
ross an area of stenosis, across an intimal or cardiac valve.
age contrast is produced by differences in velocity. Images
e obtained using ECG gating or triggering. Two-
mensional images are generated that center on the area of
ncern. Peak flow and velocity measurements may be calcu-
ted, and time–flow and time–velocity curves are generated.
.5. Standards for Reporting of the Thoracic
orta on Computed Tomography and
agnetic Resonance Imaging
iewing and measuring are best accomplished at a picture
chiving and communications system workstation or an
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129dependent computer workstation, in which the aorta can be
tated into the best orientation to review each segment of the
rta and the aortic branches. This minimizes the chance of
advertently confusing normal structures for vascular abnor-
ality (Figure 10).
gure 10. Left brachiocephalic vein mimics an intramural he-
atoma on CT. Axial CT image demonstrates a low-attenuation
escent of material anterior to the innominate artery. CT indi-
tes computed tomographic imaging.The writing committee believes that specific qualitative and
antitative elements are important to include in reports (Table 5).
Diameter measurements taken from axial images are inher-
tly incorrect unless the artery being measured is perfectly
igned in cross section on the image (Figure 11). It is preferable
make diameter measurements perpendicular to the longitudi-
l or flow axis of the aorta to correct for the variable geometry
the aorta. Suggested standard anatomic locations are noted in
gure 12. The use of standardized measurements helps mini-
ize errant reports of significant aneurysm growth due to
chnique or interreader variability in measuring technique.
.6. Angiography
ngiography provides accurate information about the site of
ssection, branch artery involvement, and communication of
e true and false lumens (60,61). Additionally, angiographic
d catheter-based techniques allow for evaluation and treat-
ent of coronary artery (62) and aortic branch (visceral and
b artery) disease, as well as assessment of aortic valve and
ft ventricular function (60,63).
Disadvantages of angiography compared with other less
vasive modalities include 1) not being universally available
cause it requires the presence of an experienced physician
perform the study; 2) being an invasive procedure that is
e consuming and requires exposure to iodinated contrast;
having poor ability to diagnose IMH given a lack of
Figure 11. Markedly tortuous aorta with thoraco-
abdominal aortic aneurysm demonstrated on (A)
3-dimensional shaded surface display rendering. B
and C represent incorrect measurement of the
aorta on standard coronal and axial images re-
spectively, while D is an image of the aorta per-
pendicular to the centerline or axis of the aorta,
with the arrow demonstrating the correct location
for diameter measurement, which in this case was
7.8 cm.
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseminal disruption; 4) potentially producing false negative
sults when a thrombosed false lumen prevents adequate
acification to identify the dissection; and 5) reported
nsitivities and specificities of angiography for the evalua-
n of acute AoD that are slightly lower than those for the
her less invasive modalities (42,64,65). Thus, CT, MR, and
EE have replaced catheter-based angiography as the first-
e diagnostic tests to establish the presence of the acute
rtic syndrome (60,63,66,67). Multidetector CT has also
rgely replaced angiography for the anatomic studies re-
ired for treatment planning and monitoring of aortic dis-
se (68).
.7. Echocardiography
he aorta and its major branches can be visualized with
hocardiography using a variety of imaging fields as well as
ethods of ultrasound. The suprasternal view is best for
sualizing the aortic arch, whereas the aortic root and
cending aorta are best seen in the left (and sometimes right)
rasternal projection. When involvement of the innominate
tery, left subclavian artery, or left common carotid artery is
spected, orthogonal and longitudinal scanning planes are
lpful. Imaging of the descending thoracic aorta is less
sily accomplished with echocardiography compared with
her imaging modalities. Abdominal scan planes can be used
gure 12. Normal anatomy of the thoracoabdominal aorta with
andard anatomic landmarks for reporting aortic diameter as
strated on a volume-rendered CT image of the thoracic aorta.
T indicates computed tomographic imaging. Anatomic loca-
ns: 1, Aortic sinuses of Valsalva; 2, Sinotubular junction; 3,
id ascending aorta (midpoint in length between Nos. 2 and 4);
Proximal aortic arch (aorta at the origin of the innominate ar-
ry); 5, Mid aortic arch (between left common carotid and sub-
avian arteries); 6, Proximal descending thoracic aorta (begins
the isthmus, approximately 2 cm distal to left subclavian ar-
ry); 7, Mid descending aorta (midpoint in length between Nos.
and 8); 8, Aorta at diaphragm (2 cm above the celiac axis ori-
n); 9, Abdominal aorta at the celiac axis origin. CT indicates
mputed tomographic imaging.visualize the caudal descending aorta. luIn general, TEE is superior to TTE for assessment of the
oracic aorta. Through the use of multiplane image acquisi-
n, 3-dimensional Doppler TEE is safe and can be per-
rmed at the bedside, with a low risk of complications (less
an 1% overall, less than 0.03% for esophageal perforation),
ost of which are related to conscious sedation (69,70).
econstruction of the aorta can be performed. Intraoperative
e of TEE is noted in Sections 14.2.3 and 14.2.4.
7.1. Echocardiographic Criteria for Thoracic
ortic Aneurysms
he echocardiographic diagnosis of thoracic aortic aneu-
sms is determined on demonstration of aortic enlargement
lative to the expected aortic diameter, based on age- and
dy size–adjusted nomograms (Figures 2, 3, 4, and 13). For
her aortic segments, such nomograms have not been devel-
ed, so aortic dilatation is diagnosed when the aorta exceeds
generally agreed to standard diameter (Table 3) or when a
ven aortic segment is larger than contiguous aortic seg-
ent(s) of apparently normal size. Beyond establishing the
esence of aortic enlargement, echocardiography may reveal
sociated cardiac pathology that suggests the underlying
iology of the aortic disease (e.g., bicuspid aortic valve).
7.2. Echocardiographic Criteria for
ortic Dissection
he echocardiographic diagnosis of an AoD requires the iden-
cation of a dissection flap separating true and false lumens
igure 14). However, one of the major limitations of both TTE
d TEE is the frequent appearance of artifacts that mimic a
ssection flap (Figure 15). These usually arise from a mirror
age or reverberation artifact that appears as a mobile linear
hodensity overlying the aortic lumen. It is therefore essential
at the echocardiographer make certain to distinguish true
ssection flaps from such artifacts. The first step is to confirm
e presence of the dissection flap from several angles and from
veral transducer locations. The second step is to confirm that
e dissection flap has a motion independent of surrounding
ructures and that the apparent flap is contained within the aortic
gure 13. Transthoracic echocardiogram of a patient with
arfan syndrome with mitral valve prolapse and 4-cm ascend-
g aortic aneurysm.men (i.e., does not pass through the aortic wall in any view).
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129he third step is to usecolor-flow Doppler to demonstrate
fferential flow on the 2 sides of the dissection flap. Often one
n visualize 1 or more sites of intimal tears, with color-flow
oppler demonstrating sites of flow between the 2 lumens. The
ue lumen typically exhibits expansion during systole and
llapse during diastole. Additional signs of the true lumen
clude little or nospontaneous echocardiographic contrast, sys-
lic jets directed away from the lumen, and forward flow during
stole. The false lumen often exhibits diastolic expansion,
idence of spontaneous contrast, complete or partial thrombo-
s, and reversed, delayed, or absent blood flow. Imaging criteria
r distinguishing the true and false lumens have also been
scribed for intravascular ultrasound (71) and CT (72). Features
at characterize the false lumen of an acute dissection include
e wedgelike angle (the “beak sign”) where the dissection flap
eets the aortic wall, the presence of strandlike structures
cobwebs”) in the lumen, and the lack of a laminar structure in
e outer wall of the lumen.
Associated echocardiographic findings of clinical importance
clude identification of a pericardial effusion. Indeed, it is often
ssible to see a layer of echogenic material within the pericar-
al fluid that is indicative of hemopericardium. Echocardiogra-
y can provide important information about right and left
gure 14. Arch aneurysm with dissection flap. Top, Arch dis-
ction, 2-dimensional view. Bottom, Arch dissection (arrow)
ith color-flow Doppler margination.ntricular function and myocardial ischemia based on assess- went of left ventricular segmental wall motion. On TEE, one can
entify the ostia of the 2 coronary arteries and detect involve-
ent by the dissection flap. Echocardiography also identifies the
esence of aortic regurgitation and permits grading of its
verity. On TEE, the mechanisms of acute aortic regurgitation
n be defined, and these data can be used to guide the surgeon’s
forts to spare the valve at the time of aortic repair.
7.2.1. DIAGNOSTIC ACCURACY OF ECHOCARDIOGRAPHY
R AORTIC DISSECTION
TE has a sensitivity of 77% to 80% and a specificity of 93%
96% for identification of proximal AoD. For distal AoD,
e sensitivity of TTE is lower. TEE improves the diagnostic
curacy substantially, particularly when a patient’s body
ape, chest wall, or concomitant pulmonary disease restricts
e transthoracic windows for aortic imaging. With TEE,
nsitivity for proximal AoD is 88% to 98% with a specificity
90% to 95% (46). A 2006 meta-analysis that evaluated the
agnostic utility of TEE in suspected thoracic AoD included
0 patients from 10 different studies. TEE was shown to
th accurately identify and rule out acute AoD with sensi-
ities and specificities of 98% (95% CI 95% to 99%) and
% (95% CI 92% to 97%), respectively (46).
Major advantages of TEE include its portability (allowing
r bedside patient evaluation), rapid imaging time, and lack
intravenous contrast or ionizing radiation. Additionally,
ssection-related cardiac complications can be evaluated
cluding aortic regurgitation, proximal coronary artery in-
lvement, and the presence of tamponade physiology. Dis-
vantages of TEE include a potential lack of availability
articularly at small centers and during off hours) and
dation requirements that may include endotracheal intuba-
n (73). The accuracy of TEE can be quite operator
pendent. For the very distal ascending aorta and the
oximal aortic arch, TEE may be limited by a blind spot
used by interposition of the trachea and left main bronchus
tween the esophagus and aorta. Small, circumscribed AoDs
IMHs in this region are less well visualized by TEE.
nother limitation of TEE is its inability to visualize the
dominal aorta; if there is concern of a malperfusion
ndrome, an abdominal CT may also be required.
7.2.2. DIAGNOSTIC ACCURACY OF ECHOCARDIOGRAPHY
R ACUTE INTRAMURAL HEMATOMA
H of the aorta has a distinctly different appearance on
hocardiography. In contrast to classic AoD, in IMH there is no
obile intimal flap within the aortic lumen, and in most cases
e aortic lumen has a relatively normal round appearance.
stead, in IMH there is thickening of the aortic wall that is
pically crescentic in shape and extends along a length of the
rta. In some cases it can be difficult to distinguish the wall
ickening of IMH from diffuse aortic atherosclerosis or mural
rombus lining an aortic aneurysm. However, atheroma and
ural thrombus protrude from the aortic intima into the lumen,
us giving both the aortic wall and the lumen an irregular shape,
hereas in IMH the inner lining of the aortic lumen remains
ooth. Moreover, in the presence of intimal calcification, intramu-
l thrombus will present as thickening external to calcification,
hereas mural thrombus will be internal to calcification.
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Disease7.2.3. ROLE OF ECHOCARDIOGRAPHY IN FOLLOWING PA-
ENTS WITH CHRONIC AORTIC DISEASE
iven that TEE is a semi-invasive procedure; it is usually not
eferred for surveillance of patients with thoracic aortic dis-
ses. Also, although TTE is noninvasive, its failure to visualize
nsistently and measure accurately the tubular portion of the
cending thoracic aorta is problematic. It is not typically used to
llow aneurysms in that aortic segment. However, because TTE
es accurately visualize the aortic root, its primary role as an
aging method for serial follow-up is in patients with aortic
sease limited to the root, particularly those with Marfan
ndrome. It is also used, often in conjunction with CT or MR,
observe patients with concomitant structural heart disease,
ch as bicuspid aortic valve, mitral valve prolapse, cardiomeg-
y, or cardiomyopathy.
. Genetic Syndromes Associated With
horacic Aortic Aneurysms and Dissection
.1. Recommendations for Genetic Syndromes
ASS I
An echocardiogram is recommended at the time of
gure 15. Artifact mimicking dissection. Top left, 2-dimensional v
ct not seen in this view.diagnosis of Marfan syndrome to determine the aorticroot and ascending aortic diameters and 6 months thereaf-
ter to determine the rate of enlargement of the aorta. (Level
of Evidence: C)
Annual imaging is recommended for patients with Marfan
syndrome if stability of the aortic diameter is documented. If
the maximal aortic diameter is 4.5 cm or greater, or if the
aortic diameter shows significant growth from baseline,
more frequent imaging should be considered. (Level of
Evidence: C)
Patients with Loeys-Dietz syndrome or a confirmed genetic
mutation known to predispose to aortic aneurysms and aortic
dissections (TGFBR1, TGFBR2, FBN1, ACTA2, or MYH11)
should undergo complete aortic imaging at initial diagnosis
and 6 months thereafter to establish if enlargement is occur-
ring. (74–77) (Level of Evidence: C)
Patients with Loeys-Dietz syndrome should have yearly mag-
netic resonance imaging from the cerebrovascular circulation
to the pelvis. (23,78,79) (Level of Evidence: B)
Patients with Turner syndrome should undergo imaging of the
heart and aorta for evidence of bicuspid aortic valve, coarcta-
tion of the aorta, or dilatation of the ascending thoracic aorta.
(80) If initial imaging is normal and there are no risk factors for
aortic dissection, repeat imaging should be performed every 5
to 10 years or if otherwise clinically indicated. If abnormalities
exist, annual imaging or follow-up imaging should be done.
p right, Color-flow Doppler without margination. Bottom, Arti-iew. To(Level of Evidence: C)
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It is reasonable to consider surgical repair of the aorta in all
adult patients with Loeys-Dietz syndrome or a confirmed TG-
FBR1 or TGFBR2 mutation and an aortic diameter of 4.2 cm or
greater by transesophageal echocardiogram (internal diame-
ter) or 4.4 to 4.6 cm or greater by computed tomographic
imaging and/or magnetic resonance imaging (external diame-
ter). (78) (Level of Evidence: C)
For women with Marfan syndrome contemplating pregnancy, it
is reasonable to prophylactically replace the aortic root and
ascending aorta if the diameter exceeds 4.0 cm. (74) (Level of
Evidence: C)
If the maximal cross-sectional area in square centimeters of
the ascending aorta or root divided by the patient’s height in
meters exceeds a ratio of 10, surgical repair is reasonable
because shorter patients have dissection at a smaller size and
15% of patients with Marfan syndrome have dissection at a
size less than 5.0 cm. (16,76,81) (Level of Evidence: C)
ASS IIb
In patients with Turner syndrome with additional risk factors,
including bicuspid aortic valve, coarctation of the aorta,
and/or hypertension, and in patients who attempt to become
pregnant or who become pregnant, it may be reasonable to
perform imaging of the heart and aorta to help determine the
risk of aortic dissection. (Level of Evidence: C)
1.1. Marfan Syndrome
arfan syndrome is a heritable disorder of the connective
sue with a high penetrance but variable expression. Ap-
oximately 25% of patients do not have a family history and
present new cases due to sporadic mutations for the
ndition. Marfan syndrome results from mutations in the
BN1 gene, with over 600 mutations currently entered into
e FBN1 mutation database causing Marfan syndrome or
lated conditions (http://www.umd.be/). The FBN1 gene
codes fibrillin-1, a large glycoprotein that is secreted from
lls and deposited in the extracellular matrix in structures
lled microfibrils. Microfibrils are found at the periphery of
astic fibers, including the elastic fibers in the medial layer of
e ascending aorta, and in tissues not associated with elastic
ers (82). Only 12% of FBN1 mutations causing Marfan
ndrome have been observed more than once in unrelated
dividuals, a fact that complicates using mutational detection
r diagnosis. A second locus for Marfan syndrome, termed
FS2, was recently identified to be caused by mutations in
e transforming growth factor-beta type II receptor
GFBR2) (83). The phenotype of this locus may overlap for
oeys-Dietz syndrome. The criteria for Marfan syndrome is
sed primarily on clinical findings in the various organ
stems affected in the Marfan syndrome, along with family
story and FBN1 mutations status (84).
The cardinal features of Marfan syndrome involve the
rdiovascular, ocular, and skeletal systems. Patients with
arfan syndrome are highly predisposed to thoracic aortic
eurysm and/or dissection, with virtually every patient with
e syndrome having evidence of aortic disease at some point
ring their lifetime. Other cardiovascular manifestations
clude valvular disease, primarily mitral valve prolapse and wgurgitation (85). Aortic regurgitation can result from dis-
rtion of the aortic valve cusps by an enlarged aortic root.
he skeletal manifestations reflect overgrowth of the long
nes and include arachnodactyly, dolichostenomelia, kypho-
oliosis, dolichocephaly, and pectus deformities. Abnormal-
es in the connective tissues are also manifested as joint
xity, recurrent or incisional hernias, striae atrophica, and
ral ectasia (84). The ocular manifestation that is both
nsitive and fairly specific for Marfan syndrome is ectopia
ntis or lens dislocation. The presence of ectopia lentis is a
rticularly useful clinical finding to differentiate Marfan
ndrome from Loeys-Dietz syndrome (78).
Most patients with Marfan syndrome present with dilata-
n of the aortic root/ascending aorta or Type A dissection.
ternal aortic diameter measured at the sinuses of Valsalva
ovides a baseline for future evaluations because this is the
rtic segment that dilates in Marfan syndrome. Of note,
hocardiographic studies measure the internal diameter,
hereas most patients undergo definitive imaging by CT
d/or MR, which measures the external diameter (expected
be 0.2 to 0.4 cm larger than internal diameter), and external
ameter is the measurement used in most cases to determine
e threshold for surgical repair. There is growing awareness
the importance of relating this measurement to normal
lues based on age and body surface area (15) (Table 4). The
verity of the aortic disease is related to the degree and
gment length of aortic dilatation with dilatation limited to
e sinuses of Valsalva having a less malignant prognosis
an dilatation that extends to the aortic arch (86). After
agnosis, follow-up imaging studies are recommended at 6
onths and then annually if stability is documented based on
e high likelihood of aortic disease progression. In most
ses, TTE can be used to monitor the size of the sinuses of
alsalva.
A subset of patients present with Type B dissection, and a
re patient will present with AAA. The poor outcome of
tients with Marfan syndrome with acute Type B dissections
s led some to advocate early surgical repair (87).
Studies addressing the efficacy of beta blockade in patients
ith Marfan syndrome have shown slower aortic root growth,
wer cardiovascular end points (defined as aortic regurgita-
n, dissection, surgery, heart failure, or death), and im-
oved survival (88). Patients continue to enlarge their aorta
d dissect on therapy, so such medication does not preclude
e need for routine imaging and prophylactic aortic repair
hen the diameter of the aorta warrants repair. It is also
portant to note that significant aortic root dilatation is
rrelated negatively with therapeutic response (88). Recent
udies in a mouse model of Marfan syndrome with aortic
sease similar to that seen in humans showed that treatment
ith losartan normalized aortic root growth (6), and a clinical
ial using losartan in Marfan syndrome patients under the age
25 years is in progress (89,90) (see Section 9.2.1.1).
Surgical repair of the dilated aortic root/ascending aorta for
tients with Marfan syndrome is usually performed at a
reshold of a external diameter of 5.0 cm (91), smaller than
at for other patients because of the greater tendency for
oD at a smaller diameter (see Section 9.2.2.1). Factors that
ill prompt repair at an external diameter of less than 5.0 cm
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasee rapid growth defined as greater than 0.5 cm/y, family
story of AoD at a diameter less than 5.0 cm, or the presence
significant aortic regurgitation.
After prophylactic repair of the ascending aorta, the arch
d descending aorta are sites for later-onset aneurysms and
ssections in patients with Marfan syndrome, prompting the
ed for routine imaging of the arch and descending aorta.
rvival in patients with Marfan syndrome has been signifi-
ntly improved with medical and surgical management of
e aortic disease (76,92,93). The David valve sparing reim-
antation operation for suitable patients undergoing elective
rtic root surgery at centers with a high volume of these
ses has become standard practice (76,92–99), although
me have reported less-optimal long-term results with valve-
aring procedures (100,101).
Pregnant patients with Marfan syndrome are at increased
sk for AoD if the aortic diameter exceeds 4 cm (102) (see
ction 10). All women with Marfan syndrome warrant
equent cardiovascular monitoring throughout pregnancy
d into the puerperium. Limited data on the treatment of
omen with Marfan syndrome who experience dissections
ring pregnancy suggest a better outcome with cesarean
ction with concomitant aortic repair (103).
1.2. Loeys-Dietz Syndrome
he Loeys-Dietz syndrome is an autosomal dominant aortic
eurysm syndrome with involvement of many other systems
8,104). Loeys-Dietz syndrome results from mutations in
ther the transforming growth factor receptor Type I or II
GFBR1 or TGFBR2) genes and the diagnosis is confirmed
rough mutational analysis of these genes (105).
The disease is characterized by the triad of arterial tortu-
sity and aneurysms, hypertelorism and bifid uvula or cleft
late, or a uvula with a wide base or prominent ridge on it.
he arterial tortuousity is most commonly observed in the
ad and neck vessels but can occur in other vessels. These
tients also have a spectrum of other features, which include
e following: velvety and translucent skin, craniosynostosis,
alar hypoplasia, retrognathia, blue sclera, patent ductus
teriosus, skeletal features similar to Marfan syndrome,
ral ectasia, atrial septal defects, developmental delay,
rvical spine abnormalities, and joint laxity. The vascular
sease in these patients is particularly aggressive with a
ean age of death of 26 years (78). Most patients have aortic
ot aneurysms (98%) that lead to AoD. Because there are
ultiple reports of AoD occurring in patients with Loeys-
ietz when the aortic diameter was less than 5.0 cm, repair is
commended at smaller diameters (78) (see Section 5.1). For
ung children with severe systemic manifestations of Loeys-
ietz syndrome, specifically prominent craniofacial features
at are associated with more severe aortic disease, once the
rtic diameter exceeds the 99th percentile for age and the
rtic valve annulus reaches 1.8 to 2.0 cm, prophylactic
rgery allows for the placement of a graft of sufficient size to
commodate growth. Of note, echocardiographic examina-
ns that measure the internal aortic diameter were used in
ese studies to determine the threshold for surgical repair.
Patients with Loeys-Dietz also develop aneurysms of other
ssels (53%), leading to the recommendation that they have dearly MR imaging from the cerebrovascular circulation to
e pelvis. Current studies indicate that aggressive surgical
anagement of the aneurysms in these patients can be
hieved with few complications (23,78). Surgical proce-
res in patients with Loeys-Dietz syndrome are not compli-
ted by tissue fragility (23,79).
1.3. Ehlers-Danlos Syndrome, Vascular Form
Type IV
he vascular form of Ehlers-Danlos syndrome is a rare
tosomal dominant disorder characterized by easy bruising,
in skin with visible veins, characteristic facial features, and
pture of arteries, uterus, or intestines. Rupture of the
strointestinal tract is more likely to occur prior to arterial
pture, and the majority of patients survive the gastrointes-
al rupture (106). Most of the fatal complications are caused
arterial rupture, with most deaths attributable to arterial
ssections or ruptures involving primarily the thoracic or
dominal arteries, including AoDs and ruptures. These
terial ruptures lead to reduced life expectancy, with the
edian survival of only 48 years, and often no aneurysms are
cumented. If the rupture of an artery is life threatening, it
n be surgically repaired, but tissue fragility, tendency to
morrhage extensively, and poor wound healing may com-
icate the surgical repair (107). Whether there is a role for
e repair of unruptured aneurysms in patients with this
ndrome is not clear, which is in contrast to Loeys-Dietz
ndrome, where a role for prophylactic surgical repair of
eurysms is already well established. Nevertheless, when
ese patients present with AoD or aortic root aneurysms,
ccessful aortic surgery can be achieved with careful han-
ing of tissues and resewing of anastomoses with pledgeted
tures (76). Noninvasive vascular imaging is preferred as
tal complications have been associated with invasive imag-
g in these patients (106). The outcome of pregnancy in
omen with Ehlers-Danlos syndrome is poor because of
pture of the gravid uterus and vessel rupture at delivery or
the postpartum period. The diagnosis of vascular Ehlers-
anlos syndrome is based on DNA or protein studies iden-
ying a defect in type III collagen, encoded by the COL3A1
ne.
1.4. Turner Syndrome
urner syndrome is defined as complete or partial absence of
sex chromosome in a phenotypic female, most commonly
, X. Short stature and ovarian failure are the most prevalent
ding, but women with Turner syndrome have an increased
rdiovascular mortality rate from both structural and isch-
ic heart disease, especially AoD (108,109). Between 10%
d 25% of patients with Turner syndrome have a bicuspid
rtic valve. Aortic coarctation is present in approximately
of patients. Determining aortic dilatation in patients with
urner syndrome is difficult because aortic dilatation is based
body surface area so the aortas of patients with Turner
ndrome are expected to be smaller than those of the general
pulation because of the patient’s short stature. If one
fines aortic dilatation as an ascending-to-descending aortic
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urner syndrome had aortic dilatation (110).
The average age of AoD in Turner syndrome was 31 years,
d less than half of the patients survived the event (111).
ata indicate a population-based AoD incidence of 36:100
0 Turner syndrome years (1.4% among individuals with
urner syndrome) compared with 6:100 000 in the general
anish population (112). Therefore, the risk of AoD is much
wer in patients with Turner syndrome compared with
tients with Marfan syndrome or Loeys-Dietz syndrome.
he majority of dissections in women with Turner syndrome
cur in patients with known risk factors for dissection, such
cardiovascular malformations (bicuspid aortic valve or
arctation of the aorta), systemic hypertension, or both.
herefore, the evidence base regarding the value of screening
r aortic disease in women with Turner syndrome is not
ailable. However, there appears to be an increased risk for
ssection in these women, suggesting that imaging of the
art, aorta, and pulmonary veins at the time of diagnosis
ight be valuable (80,113). For patients with no risk factors
r AoD (bicuspid aortic valve, coarctation, dilated aorta),
-evaluation of the aorta has been suggested every 5 to 10
ars or if clinically indicated (e.g., attempting pregnancy
14) or transition to an adult clinic). Patients with risk
ctors for AoD should undergo more frequent imaging.
ecently, studies have not shown an effect of growth hor-
one treatment in women with Turner syndrome on either
cending or descending aortic diameter (113). In addition,
udies have not found any evidence of left ventricular
pertrophy in patients with Turner syndrome who were
eated with growth hormone (115,116).
1.5. Other Genetic Syndromes With Increased Risk
r Thoracic Aortic Aneurysms and Dissections
substantial proportion of patients with Ehlers-Danlos syn-
ome who do not have the vascular form also have aortic
ot dilatation, but the progression of this dilatation to AoD is
re (76,117). Similarly, patients with congenital contractural
achnodactyly or Beals syndrome due to mutations in FBN2
ve had aortic root enlargement without documented pro-
ession to dissection (118,119).
There are other genetic syndromes that have multiple
ports or documentation of thoracic aortic aneurysms lead-
g to Type A dissections. There are multiple case reports of
oD in patients with autosomal dominant polycystic kidney
sease (120,121). Although AoD is a complication of auto-
mal dominant polycystic kidney disease, it is less common
an cerebral aneurysms leading to subarachnoid hemorrhage
this population. There is insufficient information to gauge
e value of routine or screening imaging for these patients.
Similar to autosomal dominant polycystic kidney disease,
ere are multiple reports in the literature of patients with
oonan syndrome who are experiencing AoDs (122–124).
he value of imaging or routine monitoring of these patients
unknown. A review of 200 patients with Alagille syndrome
so identified thoracic aortic disease in a small subset of
ese patients (125). TG1.6. Recommendations for Familial Thoracic Aortic
neurysms and Dissections
ASS I
Aortic imaging is recommended for first-degree relatives of
patients with thoracic aortic aneurysm and/or dissection to
identify those with asymptomatic disease. (126,127) (Level of
Evidence: B)
If the mutant gene (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2,
MYH11) associated with aortic aneurysm and/or dissection is
identified in a patient, first-degree relatives should undergo
counseling and testing. Then, only the relatives with the
genetic mutation should undergo aortic imaging. (Level of
Evidence: C)
ASS IIa
If one or more first-degree relatives of a patient with known
thoracic aortic aneurysm and/or dissection are found to have
thoracic aortic dilatation, aneurysm, or dissection, then imag-
ing of second-degree relatives is reasonable. (126) (Level of
Evidence: B)
Sequencing of the ACTA2 gene is reasonable in patients with
a family history of thoracic aortic aneurysms and/or dissec-
tions to determine if ACTA2 mutations are responsible for the
inherited predisposition. (26,27,77,78,128,129) (Level of Ev-
idence: B)
ASS IIb
Sequencing of other genes known to cause familial thoracic
aortic aneurysms and/or dissection (TGFBR1, TGFBR2,
MYH11) may be considered in patients with a family history
and clinical features associated with mutations in these
genes. (26,27,77,78,128,129) (Level of Evidence: B)
If one or more first-degree relatives of a patient with known
thoracic aortic aneurysm and/or dissection are found to have
thoracic aortic dilatation, aneurysm, or dissection, then refer-
ral to a geneticist may be considered. (Level of Evidence: C)
genetic basis of nonsyndromic familial thoracic aortic
eurysms and dissection has only recently been defined.
milial aggregation studies of patients referred for repair of
oracic aortic aneurysm and dissection that did not have a
netic defect have indicated that between 11% and 19% of
ese patients have a first-degree relative with thoracic aortic
eurysms and dissection (127,130). Patients with a family
story of thoracic aortic aneurysm and dissection present at
younger mean age than do sporadic patients but at a
gnificantly older age than patients with Marfan or Loeys-
ietz syndrome. The disease is primarily inherited in an
tosomal dominant manner with decreased penetrance pri-
arily in women and variable expression (131). These
apping studies have firmly established that there is signif-
ant genetic heterogeneity for familial thoracic aortic aneu-
sm and dissection (i.e., many different genes can be mutated
d cause the same clinical condition) (27,77,129,132–134).
he causative gene has been identified for the following loci:
AD2 is due to TGFBR2 mutations, the mutant gene at 16p
the MYH11 gene, and the TAAD4 defective gene is ACTA2.
The defective gene at the TAAD2 locus for familial
oracic aortic aneurysms and dissection was identified as
FBR2, which is the same gene that is mutated in approx-
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseately two thirds of patients with Loeys-Dietz syndrome.
enetic testing of unrelated families with familial thoracic
rtic aneurysm and dissections demonstrated that TGFBR2
utations were only present in 1% to 5% of families (26). All
families had mutations that affected TGFBR2 arginine 460
the receptor, suggesting that missense mutation was
sociated with familial thoracic aortic aneurysm and dissec-
n (i.e., genotype-phenotype correlation). Although the
ajority of vascular disease in these families involved the
cending aorta, affected family members also had descend-
g aortic disease and aneurysms of other arteries, including
rebral, carotid, and popliteal aneurysms. It is notable that
milar to Loeys-Dietz syndrome, AoDs occur in patients
ith TGFBR2 mutation at diameters less than 5.0 cm, leading
the recommendation that aortic repair be considered at a
ternal diameter by echocardiography of 4.2 cm or greater
8) (see Section 5.1).
A large French family with thoracic aortic aneurysm and
ssection associated with patent ductus arteriosus was used
map the defective gene causing this phenotype to 16p
35). The defective gene at this locus was identified as the
ooth muscle cell–specific myosin heavy chain 11
YH11), a major protein in the contractile unit in smooth
uscle cells (77). Subsequent analysis of DNA from 93
related families with thoracic aortic aneurysm and dissec-
n failed to identify any MYH11 mutations. Sequencing
NA from 3 unrelated families with thoracic aortic aneurysm
d dissection associated with patent ductus arteriosus iden-
ed MYH11 mutations in 2 of these families (26); the
maining family had a TGFBR2 mutation as the cause of the
oracic aortic aneurysm and dissection and patent ductus
teriosus. Therefore, MYH11 mutations are responsible for
milial thoracic aortic aneurysm and dissection associated
ith patent ductus arteriosus and a rare cause of familial
oracic aortic aneurysm and dissection.
A defective gene at the locus 10q23–24 was identified in a
rge family with multiple members with thoracic aortic
eurysm and dissection as ACTA2, which encodes the the
ooth muscle-specific alpha-actin, a component of the
ntractile complex and the most abundant protein in vascu-
r smooth muscle cells (27,136). Approximately 15% of
ble 6. Gene Defects Associated With Familial Thoracic Aortic
fective Gene Leading to
amilial Thoracic Aortic
eurysms and Dissection
Contribution to Familial Thoracic
Aortic Aneurysms and
Dissection
FBR2 mutations 4%
YH11 mutations 1%
TA2 mutations 14%
ACTA2 indicates actin, alpha 2, smooth muscle aorta; MYH11, smooth musc
ceptor type II.milies with thoracic aortic aneurysm and dissection have unCTA2 mutations (27). Features identified in some families
ith ACTA2 mutation included livedo reticularis and iris
cculi, although the prevalence of these features has not
en determined. The majority of affected individuals pre-
nted with acute Type A or B dissections or Type B
ssections, with 16 of 24 deaths occurring due to Type A
ssections. Two of 13 individuals experienced Type A
ssections with a documented ascending aortic diameter less
an 5.0 cm. AoDs occurred in 3 individuals under 20 years
age, and 2 women died of dissections postpartum. Finally,
young men had Type B dissection complicated by rupture
aneurysm formation at the ages of 13, 16, and 21 years.
Identification of the underlying genetic mutation leading to
milial thoracic aortic aneurysms and dissections provides
itical clinical information for the family. First, only family
embers who harbor mutations need to be routinely imaged
r aortic disease. Second, identification of the underlying
utation may lead to different management of the aortic
sease, as is the case for TGFBR2 mutations. In addition to
oviding information to families, identification of genes
ading to familial thoracic aortic aneurysms and dissections
s emphasized the roles of smooth muscle contractile
nction in preventing aortic diseases (11). Individuals who
dergo genetic testing for thoracic aortic disease should
ceive genetic counseling prior to the testing to explain the
plications for the testing for their medical follow-up and
plications for family members.
.2. Summary
he genes leading to nonsyndromic forms of aortic aneu-
sms and dissections are in the early stages of identification.
ables 6 and 7 summarize the current clinical features
sociated with mutations in these genes and recommenda-
ns for when to sequence these genes in families with
ultiple members with familial thoracic aortic aneurysm and
ssection.
Given the familial risk of thoracic aortic aneurysms,
reening the proband’s first-degree relatives with appropri-
e imaging studies is indicated in the absence of identifica-
n of the defective gene leading to the disease.
Because thoracic aortic disease is typically asymptomatic
sm and Dissection
Associated Clinical Features Comments on Aortic Disease
Thin, translucent skin Multiple aortic dissections
documented at aortic
diameters 5.0 cm
Arterial or aortic tortuosity
Aneurysm of arteries
Patent ductus arteriosus Patient with documented
dissection at 4.5 cm
Livedo reticularis Two of 13 patients with
documented dissections
5.0 cm
Iris flocculi
Patent ductus arteriosus
Bicuspid aortic valve
fic beta-myosin heavy chain; and TGFBR2, transforming growth factor-betaAneury
le specitil a life-threatening event (e.g., AoD) occurs, evaluating
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129her family members can potentially prevent premature
aths. Most syndromes and familial forms of thoracic aortic
sease are inherited in an autosomal dominant manner.
herefore, an individual with an inherited predisposition to
oracic aortic aneurysm and dissections has up to a 50% risk
passing on this predisposition to their children, which is the
sis for genetic evaluation of the offspring. In addition,
blings and parents of the patient need to be evaluated for
ssible predisposition to thoracic aortic aneurysm and dis-
ctions. Because of the variable age of onset of aortic disease
familial thoracic aortic aneurysms and dissections, the
riting committee believes that imaging of family members
risk of the disease every 2 years is warranted.
. Other Cardiovascular Conditions
ssociated With Thoracic Aortic
neurysm and Dissection
.1. Recommendations for Bicuspid Aortic
alve and Associated Congenital Variants
Adults
ASS I
First-degree relatives of patients with a bicuspid aortic valve,
premature onset of thoracic aortic disease with minimal risk
factors, and/or a familial form of thoracic aortic aneurysm and
dissection should be evaluated for the presence of a bicuspid
aortic valve and asymptomatic thoracic aortic disease. (Level
ble 7. Genetic Syndromes Associated With Thoracic Aortic An
netic Syndrome Common Clinical Features Gen
rfan syndrome Skeletal features (see text) FBN1
Ectopia lentis
Dural ectasia
eys-Dietz syndrome Bifid uvula or cleft palate TGFBR
mArterial tortuosity
Hypertelorism
Skeletal features similar to MFS
Craniosynostosis
Aneurysms and dissections of other
arteries
lers-Danlos syndrome,
scular form
Thin, translucent skin COL3
Gastrointestinal rupture
Rupture of the gravid uterus
Rupture of medium-sized to large
arteries
rner syndrome Short stature 45,X
Primary amenorrhea
Bicuspid aortic valve
Aortic coarctation
Webbed neck, low-set ears, low hairline,
broad chest
AoD indicates aortic dissection; COL3A1, type III collagen; CT, computed tomo
aging; TEE, transesophageal echocardiogram; TGFBR1, transforming growth fa
*The defective gene at a second locus for MFS is TGFBR2 but the clinicalof Evidence: C) drAll patients with a bicuspid aortic valve should have both the
aortic root and ascending thoracic aorta evaluated for evi-
dence of aortic dilatation. (137–140) (Level of Evidence: B)
icuspid aortic valves is the most common congenital abnor-
ality affecting the aortic valve and the aorta and is found in
to 2% of the population (137). Nine percent of patients
ve family members who also have bicuspid aortic valves
41). The ACC/AHA Valvular Heart Disease Guidelines
ecifically address this condition (5). Of importance to this
ideline, bicuspid aortic valves can be inherited in families
an autosomal dominant condition and may be associated
ith thoracic aortic aneurysm formation. It is important to
te that in these families, members can have thoracic aortic
eurysms in the absence of bicuspid aortic valves (142). The
lves are prone to either aortic valve regurgitation, most
mmonly seen in younger patients, or aortic valve stenosis,
ore common in older patients. Bicuspid aortic valve repair
r regurgitation has excellent long-term results, an important
nsideration in the absence of prosthetic aortic valve alter-
tives in this young population (99,139,140,143). The most
mmon site of fusion of the leaflets is at the left and right
aflet commissure, and less so at the right noncoronary
aflet commissure. The latter is typically more often associ-
ed with aortic valve stenosis. In a study of 2000 patients at
e Cleveland Clinic who underwent bicuspid aortic valve
rgery, 20% had concurrent ascending aortic aneurysms that
quired repair (139,140). AoD is also common, and as many
15% of patients with acute AoD have bicuspid aortic
lves (144), a frequency more common than Marfan syn-
and Dissection
ct Diagnostic Test Comments on Aortic Disease
ns* Ghent diagnostic criteria Surgical repair when the aorta reaches
5.0 cm unless there is a family history
of AoD at 5.0 cm, a rapidly
expanding aneurysm or presence or
significant aortic valve regurgitation
DNA for sequencing
BR1 DNA for sequencing Surgical repair recommended at an
aortic diameter of 4.2 cm by TEE
(internal diameter) or 4.4 to 4.6 cm
by CT and/or MR (external diameter)
ions DNA for sequencing Surgical repair is complicated by
friable tissues
Noninvasive imaging recommended
Dermal fibroblasts for
analysis of type III
collagen
pe Blood (cells) for
karyotype analysis
AoD risk is increased in patients with
bicuspid aortic valve, aortic coarctation,
hypertension, or
pregnancy
imaging; FBN1, fibrillin 1; MFS, Marfan syndrome; MR, magnetic resonance
ta receptor type I; TGFBR2, transforming growth factor beta receptor type II.
ype as MFS is debated.eurysm
etic Defe
mutatio
2 or TGF
utations
A1 mutat
karyoty
graphic
ctor-beome. AoD was present in 12.5% of patients with bicuspid
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaselves with an aortic diameter less than 5 cm, reminiscent of
tients with Marfan syndrome in whom 15% had AoD at a
ze less than 5 cm (16,143).
The writing committee discussed the potential need to
reen relatives of patients who have undergone aortic valve
placement before age 70, as these younger patients were
ore likely to have had bicuspid aortic valve as their primary
thology. However, 40% of women and around one third of
en over age 70 undergoing aortic valve replacement have
cuspid aortic valve disease (145). The yield from screening
latives of younger patients with bicuspid aortic valve
sease compared with relatives of older patients is not
own.
.2. Aberrant Right Subclavian Artery
berrant right subclavian artery, which arises as the fourth
anch from the aorta, courses behind the esophagus in
proximately 80% of patients and causes dysphagia in many
tients (146–149). The dysphagia usually occurs in adults as
e artery enlarges (Kommerell diverticulum) (150,151). In
ost adult patients, the aorta is also abnormal and is prone to
eurysm formation, dissection, and rupture. Surgical treat-
ent in adults involves resection of the aneurysmal segment
the subclavian artery (the diverticulum) and the adjacent
rta and replacement of the aorta with a graft (152). An
ternative treatment is exclusion of the right subclavian
tery origin and adjacent aorta using an aortic endograft,
though long-term follow-up of this endovascular approach
not available and the compression and aneurysm growth
ay continue (153). The distal normal segment of the
bclavian artery is usually not reimplanted into the descend-
g aorta directly but rather revascularized using an interpo-
tion graft or carotid-subclavian bypass. Alternatively, the
bclavian artery can be ligated or coiled distal to the
eurysm, implanting the distal segment into the adjacent
rotid artery in the neck and thus restoring flow to the upper
tremity and the ipsilateral vertebral artery (148,149,152).
.3. Coarctation of the Aorta
oarctation of the aorta is a relatively common abnormality
at occurs in about 40 to 50 of every 100 000 live births, with
2:1 ratio in males versus females. Most lesions are treated
on after birth or in childhood, and adults presenting with
treated coarctation of the aorta are rare. More often,
tients have had previous procedures and present with later
oblems such as heart failure, intracranial hemorrhage,
pertension particularly with exercise, aneurysm formation,
oD, rupture of old repairs, undersized grafts of previous
pairs, and infections. It is of particular importance in
eviously treated patients with some aortic narrowing to
eck for a gradient across the stenosis and for hypertension
ring exercise testing (154).
Untreated coarctation of the aorta has a dismal prognosis,
ith 80% of patients dying from complications associated
ith the coarctation. Approximately one quarter will die from
oD or rupture, one quarter will die from heart failure, one
arter will die from intracranial hemorrhage, and the re-
ainder will die from other complications.Surgical options, depending on the lesion, include subcla-
an artery patch aortoplasty, patch aortoplasty, bypass of the
arctation, tube graft replacement, aneurysm replacement,
stage combined bicuspid valve surgery, and arch and
scending aorta replacement or ascending aorta–to–de-
ending aorta bypass (3). Endovascular balloon dilatation
d stent placement has been used successfully and is
coming a less invasive alternative to conventional open
rgical procedures (155). Occasionally, the adult aorta may
redundant and kinked opposite the ligamentum arteriosum
ithout any pressure gradient, the so-called pseudocoarcta-
n. Aneurysms that require surgical treatment may develop
oximal and distal to the kinked area (156).
.4. Right Aortic Arch
right-sided aortic arch is present in approximately 0.5% of
e population and rarely requires surgical repair. However,
me patients present with dysphagia or asthma-like symp-
ms with expiratory wheezing. CT or MR readily diagnoses
e problem of either tracheal compression or esophageal
mpression with the esophagus enlarged and filled with gas
ove the level of the arch. Felson and Palayew described 2
pes (157).
In Type I, the great vessels come off the right-sided arch in
manner that is a mirror image to normal anatomy; however,
mpression of the esophagus or trachea is caused by an
larged aorta where it crosses the vertebral bodies or by the
scular ring formed by the atretic ductus arteriosus. In Type
, the aberrant left subclavian artery comes off the descend-
g aorta and typically runs posterior to the trachea and
mpresses the trachea. As with an aberrant right subclavian
tery, the proximal segment of the subclavian artery may
large and form a Kommerell diverticulum. Other variations
e also seen but are exceedingly rare. A separate trunk may
ise from the arch, and from this trunk, the innominate,
rotid, and subclavian arteries arise. Another rare finding is
right-sided arch with a stump of left-sided aorta joining the
ght-sided arch after it crosses into the left chest. The stump
the left-sided aorta gives off a branch to the left subclavian
tery. The aorta with right-sided arches is also abnormal and
pically very fragile and prone to AoD, rupture, or aneurysm
rmation. Surgical repair involves resection of the aorta and,
needed, reimplantation or bypass of the aberrant left
bclavian artery.
. Inflammatory Diseases Associated
ith Thoracic Aortic Disease
.1. Recommendations for Takayasu Arteritis
nd Giant Cell Arteritis
e Table 8.
ASS I
Initial therapy for active Takayasu arteritis and active giant
cell arteritis should be corticosteroids at a high dose (pred-
nisone 40 to 60 mg daily at initiation or its equivalent) to
reduce the active inflammatory state. (158,159) (Level of
Evidence: B)
2.
3.
4.
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and giant cell arteritis should be periodically evaluated to
determine disease activity by repeated physical examination
and either an erythrocyte sedimentation rate or C-reactive
protein level. (160,161) (Level of Evidence: B)
Elective revascularization of patients with Takayasu arteritis
and giant cell arteritis should be delayed until the acute
inflammatory state is treated and quiescent. (162) (Level of
Evidence: B)
The initial evaluation of Takayasu arteritis or giant cell arteritis
should include thoracic aorta and branch vessel computed
tomographic imaging or magnetic resonance imaging to inves-
tigate the possibility of aneurysm or occlusive disease in these
vessels. (Level of Evidence: C)
ASS IIa
It is reasonable to treat patients with Takayasu arteritis
receiving corticosteroids with an additional anti-inflammatory
agent if there is evidence of progression of vascular disease,
recurrence of constitutional symptoms, or re-elevation of in-
flammatory marker. (158) (Level of Evidence: C)
.2. Takayasu Arteritis
akayasu arteritis, also known as pulseless disease, is an
iopathic vasculitis of the elastic arteries, involving the aorta
d its branches. Initially described in Japan, the disease is
ble 8. Inflammatory Diseases Associated With Thoracic
rtic Aneurysm and Dissection
mes
Criteria Used in
Diagnosis/Source
When Is Diagnosis
Established?
kayasu
eritis (163)
Age of onset 40 y 3 criteria are
present (sensitivity
90.5%; specificity
97.8%)
Intermittent claudication
Diminished brachial artery
pulse
Subclavian artery or aortic bruit
Systolic BP variation of
10 mm Hg between arms
Aortographic evidence of aorta
or aortic branch stenosis
nt cell
eritis (164)
Age 50 y 3 criteria are
present (sensitivity
greater than 90%;
specificity 90%)
Recent-onset localized
headache
Temporary artery tenderness or
pulse attenuation
Elevated erythrocyte
sedimentation 50 mm/h
Arterial biopsy shows
necrotizing vasculitis
hc¸et
ease (165)
Oral ulceration Oral ulceration plus 2
of the other 3 criteriaRecurrent genital ulceration
Uveitis or retinal vasculits
Skin lesions—erythema
nodosum, pseudo-folliculitis, or
pathergy
kylosing
ondylitis (166)
Onset of pain 40 y 4 of the diagnostic
criteria are presentBack pain for 3 mo
Morning stiffness
Subtle symptom onset
Improvement with exercise
BP indicates blood pressure.und worldwide. In the United States, a review of cases in rylmsted County, Minn, reported a rate of 2.6 cases per
illion persons (158). In the United States, the disease affects
l ethnic and racial groups in proportion to the census with a
oderate Asian overrepresentation. The disease affects
omen approximately 10 times more often than men. Most
mmonly diagnosed in the third decade (i.e., the 20s) of life,
e disease has been found in children and adults in the fifth
cade (i.e., the 40s). Two specific disease distributions have
en reported: Japanese and Indian (167,168).
In the Japanese distribution, the thoracic aorta and great
ssels are most commonly affected. In contrast, in the Indian
pe, the disease most commonly affects the abdominal aorta
d the renal arteries (28). The pathogenesis of Takayasu
teritis remains poorly defined. A T-cell–mediated panarteri-
, the disease proceeds from adventitial vasa vasorum
volvement inward. The antigen for the localized inflamma-
ry process is undefined but likely specific as the T cells
dergo clonal expansion. The outcome process of destruc-
n and fibrotic repair depends on the dominant pathophys-
logic process: destruction yields aneurysms while fibrosis
uses stenosis.
The diagnosis of Takayasu arteritis may be made using the
90 American College of Rheumatology criteria: 1) age of
set younger than 40 years, 2) intermittent claudication, 3)
minished brachial artery pulse, 4) subclavian artery or
rtic bruit, 5) systolic blood pressure variation of greater
an 10 mm Hg between arms, and 6) angiographic (CT, MR)
idence of aorta or aortic branch vessel stenosis (163)
igure 16). When 3 of the criteria are manifest, the sensi-
ity and specificity for diagnosis are 90.5% and 97.8%,
spectively. Laboratory testing may aid in diagnosis. Mark-
s of inflammation, such as C-reactive protein and erythro-
te sedimentation rate, are elevated in approximately 70% of
tients in the acute phase and 50% in the chronic phase of
sease (158).
The clinical manifestations of the disease typically develop
2 phases: acute and chronic. Acutely, the inflammation
sociated with Takayasu arteritis causes a host of constitu-
nal, or “B,” symptoms, such as weight loss, fatigue, night
eats, anorexia, and malaise (158). More chronically, once
e vascular process has endured, patients report symptoms
ferable to the organs involved. In the largest US experience,
ore than half of all patients experienced upper extremity
audication, half had symptoms associated with cerebrovas-
lar insufficiency (vision loss, lightheadedness, stroke), and
third reported carotid artery pain (158). In an Indian series,
pertension as a result of renal artery involvement was the
ost common presenting sign (169).
The aorta itself may develop either aneurysm or stenosis.
a Japanese series of 116 patients with Takayasu arteritis,
arly 32% of the patients had aortic aneurysm formation
70). Most commonly, aneurysm formation developed in the
scending aorta, followed by the abdominal, then ascending
rtic segments. In the National Institutes of Health series of
patients with Takayasu arteritis, 23% had aortic aneurysm
rmation (158). Aneurysms most commonly formed in the
rtic arch or root, abdomen, and then other thoracic seg-
ents. Stenosis of the aorta is more common than is aneu-
sm formation, occurring in 53% of patients in the National
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasegure 16. Takayasu arteritis with involvement of the thoracoabdominal aorta and great vessels as shown on contrast-enhanced CT
d MR examinations. Note narrowing of the arterial lumen and circumferential soft tissue thickening of the walls of the great vessels
d thoracic and abdominal aorta. Panel A, Image through the great vessels with narrowing of the left common carotid and left subcla-
an arteries. Panel B, Mid descending thoracic aorta (arrowheads). Panel C, Aorta just above the diaphragm (arrowheads). Panel D,
frarenal aorta. Panel E, Volume-rendered image from CT demonstrates the extent of involvement. Panel F, Oblique sagittal MR of the
oracic aorta. Panel G, Coronal MR of the abdominal aorta. CT indicates computed tomographic imaging; and MR, magnetic reso-
nce imaging.
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129stitutes of Health series. Any segment of the aorta may be
volved, but the abdominal aortic segment is affected more
an 70% of the time if stenosis is found.
Treatment of Takayasu arteritis begins with inflammation
duction with corticosteroids. Steroids are typically started at
gh dose, 40 to 60 mg daily at initiation to lower the
ythrocyte sedimentation rate or C-reactive protein to nor-
al, and are required for 1 to 2 years to ensure proper disease
eatment (169). Despite the prolonged regimen, nearly half
the patients will relapse during tapering, requiring addi-
nal immunosuppression. Second-line agents that have been
ed include methotrexate, azathioprine, and antitumor ne-
osis factor-alpha agents (158,169). Unfortunately, markers
inflammation are imperfect barometers of disease activity.
isease progression has been shown to occur in the setting of
rmal marker levels (158).
Revascularization for aortic stenosis or aneurysm occurs
r the same indications as in noninflammatory disorders:
condary organ vascular insufficiency or risk of rupture.
here are no randomized trials of percutaneous or surgical
tervention in this disease (158,171–173). Nonrandomized
ports have shown that revascularization of either variety
ay be appropriate, with one caveat. The risk of graft failure
higher in patients with active local inflammation (162).
oreover, the presence of aneurysmal disease itself may be
oblematic. One report documented a 12% incidence of
astomotic aneurysms over 2 decades of follow-up related to
e presence of aneurysms at surgery (174).
.3. Giant Cell Arteritis
CA, also known as temporal arteritis, is an elastic vessel
sculitis involving the aorta and its secondary and tertiary
anches. Distinguishing it from Takayasu arteritis, GCA
fects patients above the age of 50 years, with an incidence
aking in the eighth decade of life (175). The disease affects
omen in a 3:2 ratio to men and has a predilection for those
northern European ancestry (29). In the United States,
idemiologic investigation reports a prevalence of 20 cases
r 100 000 persons. The incidence is higher in Scandinavian
tions but lower in southern Europe, suggesting a genetic
edisposition in certain populations (176).
The clinical presentation of GCA is varied, requiring a
ightened suspicion by clinicians for early diagnosis. Half of
e patients report constitutional symptoms, such as weight
ss, night sweats, malaise, and fever (177). Because of the
edilection for secondary and tertiary thoracic branches of
e aorta, cranial symptoms are common. Scalp tenderness
d headache are present in two thirds of patients and in up
90% of patients with biopsy-proved disease (177). Jaw
audication is common and affects half of the patients, 20%
velop visual changes, and other neurologic symptoms such
stroke or neuropathy occur in nearly one third (29). Visual
anges are particularly important to notice, because early
eatment may prevent permanent blindness. Patients may
port diplopia, amaurosis fugax, or blurriness prior to blind-
ss. Polymyalgia rheumatica characterized by a generalized
flammatory state with proximal muscle involvement is
und in nearly half of patients with GCA (29). Patients with arlymyalgia rheumatica report muscular pain and stiffness,
rticularly on initiation of movement.
Extracranial vascular involvement is less common in GCA
an in Takayasu arteritis, occurring in 25% of patients. In a
-year study of Olmsted County, Minn, that included 168
tients with GCA, aortic aneurysm/dissection was found in
% of the subjects, whereas large-artery stenosis was noted
13% of patients (178). No patient had stenosis of the aorta.
ortic aneurysm formation represents an important marker.
lthough aneurysm formation per se does not reduce survival
mpared with the GCA cohort as a whole, AoD in the setting
an aneurysm reduces survival to an average of 1.1 years
78). Similarly, aortic aneurysm rupture or dissection caused
o thirds of deaths in a series of patients with GCA in
alifornia (179).
The American College of Rheumatology diagnostic criteria
r GCA include 1) age older than 50 years, 2) recent-onset
calized headache, 3) temporal artery pulse attenuation or
nderness, 4) erythrocyte sedimentation rate greater than 50
m/h, and 5) an arterial biopsy demonstrating necrotizing
sculitis (164). Three or more criteria confer a sensitivity
d specificity above 90% for the disease. With intracranial
sease, temporal artery biopsies are diagnostic in up to 80%
cases (180). The rate of positivity declines with initiation
glucocorticoid therapy, but this should not delay treatment
avoid GCA complications. Biopsies performed within 7
ys of steroid initiation retain a high diagnostic yield (181).
The pathophysiology of GCA shares important features
ith Takayasu arteritis (28). GCA is marked by a T-cell
onal expansion suggesting a specific antigenic response,
hich currently remains unelucidated. The inflammatory
sponse, which begins in the adventitial layer, is marked by
gmented cytokine and MMP production causing granuloma
rmation. Granuloma formation both shields the vessel from
e inciting antigen and causes vessel destruction. The in-
mmatory environment within the vessel wall with the
ssible formation of aneurysms or vessel stenosis is histo-
gically identical to that of Takayasu arteritis. Because of the
ultiyear cyclical nature of disease incidence, some have
sited an infectious etiology (29).
Corticosteroids represent the standard in therapy for pa-
nts with GCA (182). The typical treatment regimen in-
udes starting prednisone dose of 40 to 60 mg daily, although
cent evidence suggests a similar efficacy with 30 to 40 mg
ily (183). Therapy is typically required for 1 to 2 years to
oid recurrence, although the dose may be tapered beginning
to 3 months after initiation. Patients commonly report
eling much better rapidly but, as with Takayasu arteritis,
w vascular involvement may occur in up to half of patients
eated with steroids (184). In contrast to Takayasu arteritis,
ditional immunomodulatory agents do not seem to modu-
te the disease’s progress. Methotrexate studied in a double-
ind, placebo-controlled study as an adjunct to prednisone
d not reduce morbidity, erythrocyte sedimentation rate
vel, or cumulative prednisone dose (184a). Revasculariza-
n recommendations follow the same pattern as in Takayasuteritis.
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1937, Hulusi Behçet described his eponymous syndrome
sed on a set of 3 symptoms: uveitis, aphthous stomatitis,
d genital ulcers. Most common in Turkey, with a preva-
nce of 80 to 370 cases per 100 000 persons (185,186), the
sease is much less common in the United States, with an
timated prevalence of 1 to 3 cases per million persons
87). The diagnostic criteria were established by the Inter-
tional Group for Behçet’s disease and require oral ulcer-
ion and 2 of these 3 lesions: recurrent genital ulceration,
eitis or retinal vasculitis, or skin lesions, such as erythema
dosum, pseudofolliculitis, or pathergy (188). In addition to
ese cardinal manifestations, vascular involvement may
cur in one third of patients. A small vessel vasculitis
mmonly associated with the human leukocyte antigen
LA) B51 allele (187), Behçet disease is 1 of 2 vasculitides
at may also involve veins. Venous involvement is most
mmonly superficial thrombophlebitis, but deep vein throm-
sis in the vena cava, varices, and cerebral sinuses has been
ported (189). The small vessel involvement of Behçet
sease may result in nonvascular complaints, such as ery-
ema nodosum, arthritis, and gastrointestinal involvement
ith diarrhea, gastrointestinal bleeding, or perforation (187).
reatment of Behçet disease varies based on the manifesta-
n of disease. Systemic corticosteroids are the typical
erapy for those with vascular involvement.
Specifically with regard to vascular manifestations of
ehçet disease, any artery or vein, large or small, systemic or
lmonary, may be involved by the vasculitic process. Aortic
stopathology shows lymphocytic infiltration mixed with
stiocytes and eosinophils with giant cells around vasa
sorum of media and adventitia. Destruction of media leads
aneurysm formation and may proceed to pseudoaneurysm
rmation and rupture. Aneurysm formation may occur in
ultiple sites and in different sites over a period of follow-up.
neurysm, stenotic lesions, and occlusion of brachiocephalic
teries may occur with or without aortic involvement.
lthough aortic involvement is unusual for patients with
ehçet vasculitis, aneurysm rupture can be unpredictable and
tal (190,191). With regard to surgical repair, anastomotic
eudoaneurysms often occur (12.9% within 18 months in 1
ries) and may be related to ongoing inflammatory changes
the area of anastomotic suture lines (192). Endovascular
pair with stent grafts has also been described (193).
.5. Ankylosing Spondylitis
pondyloarthropathies)
he group of diseases labeled spondyloarthropathies are
ked by the strong association of major histocompatibility
mplex HLA B-27 and the absence of rheumatoid factor
94,195). Several features are common to the spondyloar-
ropathies, including sacroilitis, inflammatory arthritis or
thesitis (inflammation of tendon insertions), associations
ith inflammatory bowel disease or psoriasis, and aortitis and
art block (195).
Ankylosing spondylits is the most common variant and
ten begins with back pain and stiffness in the second or
ird decade of life. It affects men 2 to 3 times as often as cromen, worsens with inactivity, and commonly takes years
r the diagnosis to be made (196). The diagnosis requires 4
the 5 criteria: onset of pain at younger than 40 years, back
in for longer than 3 months, morning stiffness, subtle
mptom onset, and improvement with exercise (197). Pa-
nts may also report constitutional symptoms, such as
alaise or fever. Acute anterior uveitis is reported in up to
% of patients. Aortic root and aortic valve involvement are
ported in up to 80% of patients (198). When involved, the
rtic valve may have a nodular appearance, and aortic
lvular regurgitation is present in nearly half of the patients
98). Treatment of aortic root expansion and aortic valvular
normalities is the same as for other conditions.
.6. Infective Thoracic Aortic Aneurysms
fection (due to bacterial, fungal, viral, spirochetal, or
bercular organisms) is a rare cause of thoracic aortic
eurysms. Originally named mycotic endarteritis by Osler
99), the terms infected aneurysm or infectious aortitis are
w used more commonly, because the majority of etiologic
ents are nonfungal. Saccular aneurysms are most common,
t infected aneurysms can be fusiform and often even
eudoaneurysms. The ascending thoracic aorta, aortic arch,
d descending thoracic aorta can all be affected, as can
osthetic aortic grafts and aortic homografts. Typically, the
tes of infected aneurysms are opposite the great vessels in
e aortic arch or opposite the visceral ateries in the abdomen.
here are several mechanisms by which the aortic infection
ay arise. First, there may be contiguous spread from
jacent thoracic structures, such a mediastinitis, abscess,
fected lymph nodes, infectious pericarditis, empyema, or
ravertebral abscess. Second, there may be septic emboli
om underlying bacterial endocarditis. Third, there may be
matogenous dissemination of bacteria in the setting of
psis or intravenous drug abuse. Infection most often arises
a diseased aorta, either in a preexisting aneurysm, at the
te of an atherosclerotic plaque, or at the site of some
cidental or iatrogenic aortic trauma. Indeed, infected tho-
cic aortic aneurysms may arise as a late complication of
rdiac surgery, often associated with postoperative medias-
itis, typically at the sites of aortic cannulation or anasto-
otic suture lines (200,201).
Various organisms can infect the aorta, with most infec-
ns being bacterial. Staphylococcus aureus and Salmonella
e the organisms most commonly identified (202–204).
neumococcus and Escherichia coli are relatively common
am-positive and gram-negative pathogens, respectively.
Treponema pallidum, the gram-negative spirochete bacte-
um that causes syphilis, as well as other Treponema species,
n cause infected aortitis, with the ascending thoracic aorta
ost often involved. However, in syphilitic aortitis, thoracic
rtic aneurysm does not appear for 10 to 25 years after the
itial spirochetal infection. Fungal infections of the aorta,
ith either Candida or Aspergillus, occur less often (205) and
pically occur in the setting of impaired immunity, such as
tients with systemic illness, human immunodeficiency
rus, or prior organ or bone marrow transplant.
Indeed, patients with impaired immunity are also at in-
eased risk of tuberculous aortitis attributable to mycobac-
te
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ceedingly rare, but the incidence may rise as the prevalence
tuberculosis rises worldwide. Tuberculous aortitis typically
fects the distal aortic arch and descending thoracic aorta,
ely because the aorta is thought to become infected via
rect extension from continuous infected lymph nodes,
pyema, or pericarditis (206).
Finally, there appears to be an independent association
tween human immunodeficiency virus and ascending tho-
cic aortic dilatation, although its mechanisms are poorly
derstood (207,208). Moreover, the incidence of frank
eurysms remains extremely low.
. Acute Aortic Syndromes
cute aortic syndromes consist of 3 interrelated conditions
ith similar clinical characteristics and include AoD, IMH,
d PAU (209).
.1. Aortic Dissection
1.1. Aortic Dissection Definition
oD is defined as disruption of the media layer of the aorta
ith bleeding within and along the wall of the aorta resulting
separation of the layers of the aorta. In the majority of
tients (90%), an intimal disruption is present that results in
acking of the blood in a dissection plane within the media.
his may rupture through the adventitia or back through the
tima into the aortic lumen (Figure 17). This classic dissec-
n results in a septum, or “flap,” between the 2 lumens
igure 18). The false lumen may thrombose over time
igure 19). While on noninvasive imaging, 15% of patients
ith aortic dissection syndromes have an apparent IMH
ithout evidence of an intimal tear, autopsy studies show
ly 4% have no visible intimal tear; indeed, at the time of
rgery a tear is found in most patients (210,211). Occasion-
ly, AoD originates from a small atheromatous ulcer that is
fficult to identify. On the other hand, extensive atheroma-
us disease of the aorta may lead to PAU or a localized IMH.
The true incidence of acute AoD is difficult to define for 2
incipal reasons: 1) acute AoD can be rapidly fatal, and
hen patients die prior to hospitalization, death may be
roneously attributed to another cause and 2) acute AoD is
equently missed on initial presentation, and early mortality
ong this group may be misclassified as non–dissection
lated. Population-based studies suggest that the incidence of
ute AoD ranges from 2 to 3.5 cases per 100 000 person-
ars, which correlates with 6000 to 10 000 cases annually in
e United States (75,212,215–217). A review of 464 patients
om IRAD reported a mean age at presentation of 63 years,
ith significant male predominance (65%) (47). The preva-
nce of AoD appears to be increasing, independent of the
ing population, as noted by Olsson and colleagues (218),
ho found the incidence of AoD among Swedish men has
creased to 16 per 100 000 men yearly. It may be that 2 to
times as many patients die from AoD than from ruptured
AA; approximately 75% of patients with AAA will reach an
ergency department alive, whereas for AoD, the prognosispears to be worse, with 40% dying immediately, 1% per deur dying thereafter, and between 5% and 20% dying during
shortly after surgery (219–221). Furthermore, only 50% to
% will be alive 5 years after surgery depending on age and
derlying etiology (222). Because AoD tends to occur in
eas of aneurysmal dilatation, treatment of aneurysms before
ssection occurs is important to long-term survival (3) (see
ction 8.1).
Regarding time from onset of initial symptoms to time of
esentation, acute dissection is defined as occurring within 2
eeks of onset of pain; subacute, between 2 and 6 weeks
om onset of pain; and chronic, more than 6 weeks from
set of pain.
1.2. Anatomic Classification of Aortic Dissection
natomically, acute thoracic AoD can be classified according
either the origin of the intimal tear or whether the
ssection involves the ascending aorta (regardless of the site
origin). Accurate classification is important as it drives
gure 17. Classes of intimal tears. I. Classic dissection with
timal tear and double lumen separated by septum. Communi-
tion between lumens is typically in descending aorta at
eared-off intercostal arteries or distal reentry site. II. IMH. No
timal tear or septum is imaged but is usually found at surgery
autopsy. DeBakey Types II and IIIa are common extent of this
sion. III. Intimal tear without medial hematoma (limited dissec-
n) and eccentric aortic wall bulge. Rare and difficult to detect
TEE or CT. Patients with Marfan syndrome prone to this
pe. May result in aortic rupture or extravasation. IV. PAU usu-
ly to the adventitia with localized hematoma or saccular aneu-
sm. May propagate to Class I dissection, particularly when
volving ascending aorta or aortic arch. V. Iatrogenic (catheter
giography or intervention)/traumatic (deceleration) dissection.
T indicates computed tomographic imaging; IMH, intramural
matoma; PAU, penetrating atherosclerotic ulcer; and TEE,
nsesophageal echocardiography. Figure reprinted with per-
ission from the Cleveland Clinic Foundation. Legend adapted
m Svensson et al (212), Chirillo et al (213), and Murray et al
14).cisions regarding surgical versus nonsurgical management.
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasehe 2 most commonly used classification schemes are the
eBakey and the Stanford systems (Figure 20). For purposes
classification, the ascending aorta refers to the aorta
oximal to the brachiocephalic artery, and the descending
rta refers to the aorta distal to the left subclavian artery.
The DeBakey classification system categorizes dissections
sed on the origin of the intimal tear and the extent of the
ssection:
Type I: Dissection originates in the ascending aorta and
propagates distally to include at least the aortic arch and
gure 18. Type A aortic dissection and extent of involvement dep
ough the flap appears to disappear in the infrarenal, it is actually
ads) and it is clearly present caudally in the common iliac arterie
all thickening (arrowheads) indicates ischemia in Panel I. Panel A
ove the diaphgram. Panel E, At the level of the celiac axis. Pane
on iliac arteries. Panel I, Image through the mid abdomen at narr
e to bowel ischemia caused by apposition of the flap against th
s. CT indicates computed tomographic imaging; F, false lumen; atypically the descending aorta (surgery usually recommended). thType II: Dissection originates in and is confined to the
ascending aorta (surgery usually recommended).
Type III: Dissection originates in the descending aorta and
propagates most often distally (nonsurgical treatment usu-
ally recommended).
– Type IIIa: Limited to the descending thoracic aorta.
– Type IIIb: Extending below the diaphragm.
The Stanford classification system divides dissections into
categories, those that involve the ascending aorta and those
n axial CT images from the cranial to caudal direction. Al-
ressed against the anterior wall of the aorta in Panel G (arrow-
nel H. Hemopericardium (asterisk) is visible in Panel D. Bowel
arch. Panel B, Mid thorax. Panel C, Aortic root. Panel D, Just
d kidneys. Panel G, Infrarenal aorta. Panel H, Proximal com-
dow/level settings demonstrates small bowel wall thickening
s of the celiac axis and superior and inferior mesenteric arter-
true lumen.icted o
comp
s in Pa
, Aortic
l F, Mi
ow win
e originat do not.
• •
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129Type A: All dissections involving the ascending aorta
regardless of the site of origin (surgery usually recom-
mended) (Figures 18 and 20).Type B: All dissections that do not involve the ascending
aorta (nonsurgical treatment usually recommended). Note
involvement of the aortic arch without involvement of the
Figure 19. Type A Aortic dissection with throm-
bosed false lumen and left renal artery involvement
depicted on axial CT images. Demonstrates
marked narrowing of the true lumen, patent right
renal artery arising from the true lumen (bottom
left, arrow), and narrow left renal artery com-
pressed by thrombus in the false lumen, with sec-
ondary decreased enhancement of the left kidney
compared with the right kidney. Top left, At the
level of the left main coronary artery. Top right, At
the celiac axis. Bottom left, At the right renal artery
(arrow). Bottom right, At the left renal artery (ar-
row). *Thrombus in false lumen. CT indicates com-
puted tomographic imaging; L, left kidney; and R,
right kidney.
Figure 20. Aortic dissection classification:
DeBakey and Stanford Classifications. Re-
printed with permission from the Cleveland
Clinic Foundation.
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseascending aorta in the Stanford classification is labeled as
Type B (Figure 21).
At this time, there is no unanimity regarding which
assification system is the ideal one to use. Some of the
riting committee members believe that a more pragmatic
proach is to refer to the dissection involving the aorta as
ther proximal or distal to the left subclavian artery. Others
the writing committee do not use this approach. Thus, if a
tient has an arch dissection even without ascending aortic
volvement, then immediate surgery would be recommended
some, if feasible and the patient is viable. Others on the
riting committee would select medical management if the
tient has only an arch dissection without proximal exten-
on, malperfusion, or bleeding, as long as repeat imaging
monstrates stability. If there is evidence of malperfusion or
eeding in such a patient, then the writing committee would
ually select a surgical approach.
The intimal tear and AoD can also be categorized into
asses that may have a bearing on treatment (212,213)
igure 17).
1.3. Risk Factors for Aortic Dissection
isk factors for AoD include conditions that result in aortic
edial degeneration or place extreme stress on the aortic wall
able 9). Two thirds to three quarters of patients have
pertension, which is often uncontrolled. Genetic predispo-
tion (see Section 5) to AoD can occur in the context of a
ndrome, such as Marfan syndrome or Loeys-Dietz syn-
ome, or can be inherited in families in the absence of
ndromic features (3). IRAD data showed that of patients
der 40 years of age with AoD, 50% had a history of Marfan
ndrome (223). Other congenital or genetically based dis-
ses as well as inflammatory conditions associated with a
gher risk of AoD are noted in Sections 6.3, 6.4, and 7.
First and foremost, a family history of thoracic aortic
eurysm is an important risk factor. In 2 separate clinical
udies, 13% to 19% of patients without an identified genetic
ndrome with thoracic aortic aneurysms had first-degree
latives with thoracic aortic aneurysms or AoD (127,130).
he term “familial thoracic aortic aneurysm and dissection
ndrome” is often applied (see Section 5). In taking a history
r thoracic aortic disease, one should be careful to distin-
ish a history of an abdominal aortic aneurysm from a
oracic aortic aneurysm. Many people, even healthcare
oviders, mistakenly use the terms AAA or triple A for anyrtic aneurysm, regardless of location. Clarifying that the
eurysm was thoracic rather than abdominal affects one’s
nsideration of risk. Also, one must consider the potential
derlying diagnosis when a patient reports a family history
“sudden death” or “heart attack” when there was no
nfirmatory autopsy. If the patient’s father, at the age of 45,
d sudden onset of chest pain and then died moments later,
ere is a chance that the death may have been from an acute
oD rather than an acute MI.
The history may reveal syndromic causes of thoracic aortic
eurysm and dissections, especially Marfan, Loeys-Dietz,
d vascular Ehlers-Danlos syndromes. In some cases, pa-
nts have only some of the features of Marfan or Loeys-
ietz syndrome, rather than the full-blown clinical syndrome,
Figure 21. Type B aortic dissection with mediasti-
nal hematoma and pleural blood. Ruptured Type B
aortic dissection with mediastinal hematoma (*)
and pleural blood. Left, Flap arises in the proximal
descending thoracic aorta, with faint contrast-en-
hanced blood adjacent to the site of rupture out-
side the confines of the aortic wall (arrow). Right,
At the level of the aortopulmonary window. FL in-
dicates false lumen; PL, pleural blood; and TL, true
lumen.
ble 9. Risk Factors for Development of Thoracic
rtic Dissection
nditions associated with increased aortic wall stress
Hypertension, particularly if uncontrolled
Pheochromocytoma
Cocaine or other stimulant use
Weight lifting or other Valsalva maneuver
Trauma
Deceleration or torsional injury (e.g., motor vehicle crash, fall)
Coarctation of the aorta
nditions associated with aortic media abnormalities
Genetic
Marfan syndrome
Ehlers-Danlos syndrome, vascular form
Bicuspid aortic valve (including prior aortic valve replacement)
Turner syndrome
Loeys-Dietz syndrome
Familial thoracic aortic aneurysm and dissection syndrome
Inflammatory vasculitides
Takayasu arteritis
Giant cell arteritis
Behc¸et arteritis
Other
Pregnancy
Polycystic kidney disease
Chronic corticosteroid or immunosuppression agent administration
Infections involving the aortic wall either from bacteremia or extension
of adjacent infection
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129a history of any phenotypic features, such as mitral valve
olapse or pectus excavatum, should prompt consideration
thoracic aortic aneurysms or dissections (224,225). Bicus-
d aortic valve is a strong risk factor for ascending thoracic
rtic aneurysms, as well as coarctation of the aorta. In
dition, a history of extreme exertion or emotional distress
ay preceed the onset of pain (226).
1.4. Clinical Presentation of Acute Thoracic
ortic Dissection
he clinical presentation of acute AoD spans a spectrum from
e overt with classic pain and physical examination findings
the enigmatic as a painless process with few physical
anifestations of the disease (Table 10). Given its exceed-
gly high mortality, clinicians must maintain a high index of
spicion for acute AoD, as noted in Section 8.6 (Figure 22).
1.4.1. SYMPTOMS OF ACUTE THORACIC
RTIC DISSECTION
tients with acute aortic syndromes often present in a similar
shion, regardless of whether the underlying condition is
oD, IMH, PAU, or contained aortic rupture. Pain is the most
mmonly reported presenting symptom of acute AoD re-
rdless of patient age, sex, or other associated clinical
mplaint (228–235). Pooled data from over 1000 patients in
studies found that the pain of acute dissection is perceived
abrupt in onset in 84% of cases (95% CI 80% to 89%) and
severe intensity in 90% of cases (95% CI 88% to 92%)
36). Although classically described as having a tearing or
pping quality, registry data suggest patients are more likely
describe the pain of acute dissection as sharp or stabbing
1% to 64%, respectively) and that report of a migrating
ality to pain is highly variable (12% to 55%) (228,236).
in may subsequently ease or abate, leading to a false
ble 10. International Registry of Acute Aortic Dissection
AD) Physical Findings of 591 Patients With Type A
rtic Dissection
esenting Hemodynamics and Clinical Findings Frequency/Finding
pertensive 32%
rmotensive 45%
potensive 14%
ock 13%
rdiac tamponade 5%
urmur of aortic insufficiency 45%
lse deficits 26%
ricardial friction rub 2%
rebrovascular accident 8%
hemic peripheral neuropathy 3%
hemic spinal cord damage 2%
hemic lower extremity 10%
ma/altered consciousness 12%
ngestive heart failure 5%
st blood pressure systolic, mean 130 mm Hg
st blood pressure diastolic, mean 75 mm Hg
Adapted from Pape et al (227).assurance on the part of the patients and physicians. thPain location and other associated symptoms reflect the
te of initial intimal disruption and may change as the
ssection extends along the aorta or involves other arteries or
gan systems (236). Data from 464 patients enrolled in
AD found that patients with Type A dissections most
equently present with chest pain (80%), more commonly
scribed as anterior (71%) than as posterior (32%) (228).
lthough less common, patients with Type A dissection
port back pain (47%) and abdominal pain (21%), presum-
ly as a result of antegrade dissection into the descending
rta (228). In contrast, patients with Type B dissections are
ost likely to present with back pain (64%) followed by chest
d abdominal pain (63% and 43%, respectively) (228).
me patients present with abdominal pain in the absence of
est pain or with only painful or numb lower extremities
lated to end-organ ischemia. In 1 retrospective study of 44
tients ultimately diagnosed with acute thoracic AoD, the
cation of the patient’s pain was highly predictive of the
inician’s suspicion for acute AoD; dissection was suspected
86% of patients who presented with chest and back pain,
% of those who presented with chest pain alone, and only
of those primarily abdominal pain (237).
Although uncommon, acute AoD may present without pain
38–240). In a separate analysis of 977 IRAD patients, 63
tients (6.4%) presented without pain (241,242). This group
patients was noted to be older and more likely to present
ith syncope, stroke, or congestive heart failure than were
tients with painful dissection (241). Patients on steroids and
tients with Marfan syndrome may be more prone to present
ithout pain (243).
1.4.2. PERFUSION DEFICITS AND END-ORGAN ISCHEMIA
rfusion deficits as a result of dissection-related obstruction
aortic branch vessels have long been recognized as a
mmon clinical manifestation, resulting in organ complica-
ns at initial presentation (Table 11). End-organ involve-
ent in acute thoracic AoD can occur via several mecha-
sms. Most occlusions are caused by obstruction by the
ssection flap, which can either prolapse across a vessel
igin without entering it (dynamic obstruction) or directly
tend into a vessel (static obstruction) (244) (Figure 18).
ther causes include postobstructive arterial thrombosis,
bolism to branches of either the true or false lumen, direct
mpression of an aortic branch artery or adjacent structures
an expanding false lumen (245), rupture or leakage of the
lse lumen into contiguous structures, and occlusion or
ssection of coronary arteries and/or aortic valve distortion
ading to heart failure.
Physical examination is insensitive to renal and mesenteric
chemia early in the course of acute AoD. Elevated serum
eatinine or refractory hypertension may be due to renal
chemia but may represent the clinical baseline in a patient
ith poorly documented or inadequately treated prior medical
nditions. Serologic markers of mesenteric ischemia may
t be present until hours after onset.
Combined data from over 1500 patients in 16 studies foundat pulse deficits were present in 31% of cases (95% CI 24%
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Disease39%) and, when present, were strongly suggestive of AoD
ositive likelihood ratio 5.7; 95% CI 1.4 to 23) (37) and
edict increased risk. Of 513 cases of Type A dissection,
tients with perfusion deficits were more likely to present
ith hypotension, shock, neurologic deficits, and tamponade
d were more likely to have higher rates of hospital
mplications and mortality (41% versus 25%, P0.0002)
46). Furthermore, overall mortality rates correlated with the
gure 22. Acute surgical management pathway for AoD. *Addition
ssection; CABG, coronary artery bypass graft surgery; CAD, coro
ophageal echocardiogram.mber of pulse deficits present, likely as a reflection of the patent of vascular compromise and associated end-organ
chemia (246). Similarly, of 118 patients with Type A acute
ssection, limb ischemia (defined as loss of pulse with
sociated pain and neurologic symptoms) was present in 38
ses (32%) (247). The presence of limb ischemia was
sociated with an increased likelihood of other end-organ
chemia (i.e., cerebral, visceral, or coronary) and a signifi-
nt increase in overall mortality (247). Among the 38
appropriate’ based on Patel et al. (226a) AoD indicates aortic
rtery disease; TAD, thoracic aortic disease; and TEE, trans-of ‘if
nary atients with limb ischemia, in-hospital mortality was 45%
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alperfusion (247).
These studies underscore the clinical importance of an
equate vascular examination to help both identify the
sease and stratify risk once the diagnosis is established.
very patient being evaluated for possible acute AoD should
ve pulses checked in all extremities to identify the presence
perfusion deficits. In patients with acute limb ischemia
rsus those without, renal and mesenteric malperfusion were
arly 2-fold more frequent and mortality was twice as high,
rther highlighting the importance of this finding (248).
1.5. Cardiac Complications
he heart is the most frequently involved end organ in acute
oD involving the ascending aorta. In distinction to other
d-organ pathology, most cardiac complications are a direct
sult of dissection-related disruption of normal anatomic
lationships (215,245).
1.5.1. ACUTE AORTIC REGURGITATION
cute aortic regurgitation is the most commonly recognized
rdiac complication of Type A dissection (228–234), occur-
ng in 41% to 76% of cases (228–232). Three distinct
ssection-related mechanisms for acute aortic valve incom-
tence have been identified, and they can occur in combi-
tion: 1) acute dilatation of the aortic root by an expanding
lse lumen, resulting in incomplete aortic valve closure; 2) a
ssection extending into the aortic root and disrupting aortic
lve commissural attachments, resulting in valve leaflet
olapse; and 3) a portion of dissection flap prolaping through
e aortic valve in diastole, preventing adequate leaflet
osure (235). Clinical manifestations of dissection-related
rtic regurgitation span the spectrum from only a hemody-
mically insignificant diastolic murmur to congestive heart
ilure and cardiogenic shock (236,249).
1.5.2. MYOCARDIAL ISCHEMIA OR INFARCTION
yocardial ischemia or infarction is an infrequent but serious
ble 11. End-Organ Complications of Acute Aortic Dissection
pe End-Organ Complication
rdiovascular Aortic insufficiency
Syncope
Pericardial tamponade
Myocardial ischemia or infarction
Congestive heart failure
urologic Ischemic stroke or transient ischemic attack
Peripheral neuropathy
Paraplegia/paraparesis
Spinal ischemia
lmonary Pleural effusion
Aortopulmonary fistula with hemorrhage
strointestinal Mesenteric ischemia or infarction
Aortoenteric fistula with hemorrhage
nal Renal failure
Renal ischemia or infarction
tremities Limb ischemiamplication of acute AoD. Registry and review data suggest ofat ECG evidence of myocardial ischemia was present in up
19% of patients with acute AoD, whereas pooled data from
8 patients in 9 different studies found that acute MI was
esent in 7% of cases (95% CI 4% to 14%) (37,47,250).
oronary artery flow can be compromised by an expanding
lse lumen compressing the proximal coronary or by exten-
on of the dissection flap into the coronary artery ostium
51).
Clinically, a dissection-related cardiac malperfusion syn-
ome may present with ECG changes that are indistinguish-
le from those of primary myocardial ischemia or infarction,
creasing the likelihood of misdiagnosis and inappropriate
erapeutic intervention (252).
1.5.3. HEART FAILURE AND SHOCK
eart failure is a relatively uncommon complication of AoD,
und to occur in approximately 6% of cases (236). In this
tting, heart failure may result from acute aortic insuffi-
ency, acute myocardial ischemia or infarction, or cardiac
mponade. Registry data suggest that patients with acute
oD complicated by heart failure are often atypical in their
esentation, frequently leading to a delay in diagnosis (236).
he largest study to evaluate heart failure in acute AoD
cluded 1069 patients from the IRAD database and found
at patients with AoD and concomitant heart failure were
ore likely to present in shock but were less likely to
mplain of chest pain and that, when chest pain was present,
e pain was more often mild and less often abrupt in onset
36).
1.5.4. PERICARDIAL EFFUSION AND TAMPONADE
ricardial pathology is a frequent complication of acute
ype A AoD and can occur via 2 distinct mechanisms
7,253–256). Most commonly, transudation of fluid across
e thin wall of an adjacent false lumen into the pericardial
ace leads to a hemodynamically insignificant pericardial
fusion (256), which is present in about one third of patients
57). Less often, the dissected aorta ruptures directly into the
ricardium, leading rapidly to tamponade physiology and
modynamic compromise (245,258,259). Cardiac tampon-
e is diagnosed in 8% to 10% of patients presenting with
ute Type A AoD and is an ominous clinical predictor of
or outcomes (260), as well as the leading cause of mortality
this group (47,215,231). Consequently, the presence of
rdiac tamponade should prompt truly urgent aortic repair
60).
1.6. Syncope
ncope is a well-recognized dissection-related complaint
curring in approximately 13% of cases (242,261) with
ultiple potential etiologies, including: 1) cardiac (e.g.,
vere aortic regurgitation, ventricular outflow obstruction,
rdiac tamponade), 2) vascular (e.g., impaired cerebral
ood flow and aortic baroreceptor activation); 3) neurologic
.g., vasovagal in response to pain), and 4) volume-related
.g., false lumen rupture into the pleural space) causes
40,261–267). Regardless of its etiology, syncope in the
tting of AoD increases the risk of near-term adverse events.
a review of 728 cases of acute AoD, patients with a history
syncope were significantly more likely to die than were
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0.01) (242). Additionally, patients who presented with
ncope more frequently had associated cardiac tamponade,
roke, decreased consciousness, and evidence of spinal cord
chemia (242).
1.7. Neurologic Complications
cute AoD frequently presents with dissection-related neu-
logic complications. Pooled data from more than 1300
tients in 13 studies that included both Type A and B
ssections found that neurologic symptoms were reported in
% (37). Neurologic complications may result from hypo-
nsion, malperfusion, distal thromboembolism, or nerve
mpression (251,253,254). In a recent study of 102 patients
ith Type A AoD, 29% had neurologic symptoms on initial
esentation (253); of those with neurologic symptoms, 53%
d ischemic stroke (predominantly right hemispheric) and
% had ischemic neuropathy (described as limb pain with
nsory or motor deficit) (253).
Last, although uncommon, acute paraplegia as a result of
inal cord malperfusion has been described as a primary
anifestation of thoracic AoD, occurring in 1% to 3% of
tients (215,251,253,254,268,269).
Of clinical note, up to 50% of dissection-related neurologic
mptoms may be transient and as many as one-third of
tients with neurologic symptoms present without com-
aints of chest pain, complicating appropriate diagnosis and
eatment (253,255,256,262,269–271).
1.8. Pulmonary Complications
eural effusion, the most common pulmonary complication
acute AoD, is noted in 16% of cases at presentation (37);
hereas large effusions may result from leaking of blood
om the aorta into the pleural space, small effusions are
pically a nonhemorrhagic exudate believed to be inflamma-
ry in origin (37,272–275).
Other pulmonary complications of acute AoD include
ssection-related compression of the pulmonary artery and
velopment of an aortopulmonary fistula, either of which
ay present with dyspnea as a prominent symptom (276–
8). Hemoptysis, noted in 1 study in 3% of patients
esenting with thoracic AoD, may result from compression
lung parenchyma by an expanding false lumen or via direct
eurysmal rupture into the lung, leading to massive hemop-
sis and death (215,279,280).
1.9. Gastrointestinal Complications
esenteric ischemia is the most common gastrointestinal
mplication of acute AoD (228) and can result from malp-
fusion or systemic hypotension. It is the most common
use of death among those with Type B AoD. Mesenteric
chemia is associated with abdominal pain, but pain may be
nspecific and out of proportion to the physical examination
the abdomen, so the cause of pain often goes unrecognized
rly on. Unfortunately, by the time serum markers of bowel
chemia or infarction turn positive, it is often too late to
lvage the bowel or the patient. Therefore, it is essential to
viligant for mesenteric ischemia in every patient with
ute AoD and associated abdominal pain. mGastrointestinal hemorrhage is a rare but potentially cata-
rophic complication of acute AoD (281–283). Dissection-
lated gastrointestinal bleeding may present with limited
eeding as a result of mesenteric infarction or as massive
morrhage secondary to an aortoesophageal fistula or false
men rupture into proximal small bowel (281–283). Al-
ough rare, dissection-related gastrointestinal hemorrhage
ould be in the differential of all patients presenting with
eeding and complaints of thoracic or abdominal pain.
1.10. Blood Pressure and Heart Rate Considerations
lood pressure abnormalities are common in patients present-
g with acute thoracic AoD. About half of patients are
pertensive at presentation, with 71% of Type B patients
ving a systolic blood pressure greater than 150 mm Hg
rsus only 36% of Type A patients (284–287). Conversely,
arly 20% present with either hypotension or shock (37).
ypotension and shock can result from cardiac tamponade,
rtic hemorrhage, severe aortic insufficiency, myocardial
chemia or infarction, true lumen compression by distended
lse lumen, or an intra-abdominal catastrophe. Of more than
00 patients with acute AoD, those with hypotension on
mission were found more likely to have neurologic com-
ications; myocardial, mesenteric, or limb ischemia; and
ath (249).
Accurate systemic blood pressure measurement may be
mplicated by dissection-related occlusion of aortic branch
teries, resulting in erroneously low blood pressure readings
the affected limb. Accordingly, blood pressures may need
be measured in both arms and, at times, both legs to
termine the highest central blood pressure.
1.11. Age and Sex Considerations
cute AoD presentation varies with patient age and sex. In
1 IRAD patients, 7% were younger than 40 years. Com-
red with patients 40 years of age and older, this group was
ss likely to have a history of hypertension and significantly
ore likely to have Marfan syndrome, bicuspid aortic valve,
a history of prior aortic surgery (223). Clinically, young
tients in this study were more likely to describe pain as
rupt in onset but less likely to be hypertensive at presen-
tion (25% versus 45%) (223). In contrast, a separate study
IRAD data evaluating 550 patients with Type A dissection
und that among patients more than 70 years of age (32% of
tal), typical symptoms (abrupt onset of pain) and signs
urmur of aortic regurgitation or pulse deficits) were sig-
ficantly less common, suggesting that extra vigilance may
required to identify acute AoD in young and elderly
tients (288).
Sex appears to affect the presentation of acute AoD as well.
a study of 1078 patients enrolled in IRAD, 32% were
omen. Women were older; were less likely to present within
hours of symptom onset, to complain of abrupt onset of
in, and to have a pulse deficit; and were more likely to
esent with either altered mental status or congestive heart
ilure. Consequently, women were less likely to be diag-
sed within 24 hours of symptom onset and had significantly
gher in-hospital mortality (30% versus 21%, P0.001) than
en (289).
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mong acute aortic syndromes, acute dissection is the most
mmon, but approximately 10% to 20% of patients (290–
2) with a clinical picture of dissection exhibit an IMH via
aging without identification of blood flow in a false lumen
an intimal lesion. Some believe IMH arises from hemor-
age of the vasa vasorum located within the medial layer of
e aorta (293,294), whereas others argue that the hematoma
ises from microscopic tears in the aortic intima. The
sulting hematoma may then propagate in an antegrade or a
trograde manner, producing symptoms that may be impos-
ble to differentiate clinically from those of a classic AoD
1). IMH has a variable radiologic appearance (Figure 23)
cording to the area of the aorta involved. In some cases,
H may be associated with a PAU (see Section 8.2 or 8.3).
Clinically, IMH most commonly occurs in the descending
rta and in older patients. Pain is characteristic of IMH,
hereas malperfusion and pulse deficit are much less likely
an with classic AoD (295,296).
Imaging criteria of IMH are based on the appearance of
esh thrombus in the aortic wall. These include crescentic or
rcular thickening of the aortic wall with maximal thickness
eater than or equal to 7 mm on TEE without intimal flap or
ar or longitudinal flow in the false lumen. The thickened
all has a higher tissue density than unenhanced blood on CT
d is without enhancement after contrast on the CT/MR
90,296–298). When the term IMH is used strictly, no
timal defect such as a tear or an ulcer is present. But in
actice, the term is used loosely to mean a thrombosed false
men regardless of a small intimal defect. The distinction is
gure 23. Intramural hematoma demonstrated as a low-attenuatio
ft, Axial image at the level of the aortic arch. Top middle, Throug
tery with narrowing of the aortic lumen. Bottom left, Oblique sag
ithout the use of ECG gating). Bottom right, Coronal reformatted
ma, and an incidental infarenal aortic aneurysm. CT indicates corther blurred by the facts that the intimal defect may be tivbtle and difficult to exclude and that some patients with
H begin with a CT scan that shows a thrombosed false
men with no apparent intimal defect and then over the
urse of 1 or 2 months develop 1 or more distinct ulcerlike
mmunications (299,300). Because of this overlap in imag-
g findings, it is difficult and perhaps somewhat arbitrary to
se treatment on the appearance of the CT snapshot of the
rta in its disease progression.
The natural history of IMH is variable. The hematoma may
tirely resolve (10%) (301), it may convert to a classic
ssection, or the aorta may enlarge and potentially rupture.
he clinical behavior of IMH varies according to the location
d mimics that of classic AoD. IMH involving the ascending
rta has a high, early risk of complication and death with
edical treatment alone, and surgery is usually indicated.
H involving the descending aorta may be treated with
ood pressure control, and the use of beta blockers has been
own to improve the long-term survival rate (296). Conver-
on of the IMH to a more classic picture of dissection occurs
3% to 14% of cases involving the descending aorta
97,298,302,303) and in 11% to 88% of cases involving the
cending aorta (302–305), with that figure increasing with
creased length of follow-up. Progressive increase in aortic
ameter has been demonstrated by serial imaging studies
98,306). In 1 study, the mortality after 2 years of patients
ith acute proximal Type A IMH versus that of patients with
assic dissection was not significantly different (307). An-
her group found improved actuarial survival rates at 1, 2,
d 5 years in patients with IMH versus classic dissection:
%, 90%, and 90% versus 67%, 66%, and 62%, respec-
d of hematoma (arrows) in the aortic wall on CT images. Top
id thorax. Top right, At the level of the superior mesenteric
ormatted image through the thorax (note band artifact evident
through the abdomen demonstrate the length of the hema-
tomographic imaging; and ECG, electrocardiogram.n ban
h the m
ittal ref
imageely, for Type A (304), and 100%, 97%, and 97% versus
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Disease%, 79%, and 79%, respectively, for Type B (297). Song et
also described increased risk for complications or mortality
r patients with IMH involving the ascending aorta when
cending aortic diameter is greater than 4.8 cm or IMH
ickness is greater than 11 mm (308).
.3. Penetrating Atherosclerotic Ulcer
U refers to an atherosclerotic lesion with ulceration that
netrates the internal elastic lamina and allows hematoma
rmation within the media of the aortic wall (309). This
sion sets the stage for development of IMH, AoD, or frank
ssel rupture (309) (Figure 24). Anatomically PAUs develop
aortic segments where atherosclerotic changes are most
mmon and therefore are localized to the descending tho-
cic aorta in over 90% of cases (310). When viewed
ngentially, the classic appearance of the lesion is a
ushroom-like outpouching of the aortic lumen with over-
nging edges, resembling a gastric ulcer, as depicted on a
rium study (Figure 24). The typical patient is elderly
sually over 65 years of age) and has hypertension and
ffuse atherosclerosis, who presented with chest or back pain
t without signs of aortic regurgitation or malperfusion. Less
mmonly, patients presented only with signs of distal
bolization (311). Asymptomatic patients may also be
und with aortic lesions that are indistinguishable, by imag-
g criteria, from PAUs (310,311).
Two entities can mimic PAUs. A branch artery pseudoan-
rysm represents a small collection of flowing blood within
otherwise thrombosed aortic false lumen, which is created
an injury to a small branch artery during the propagation
the IMH (312). These are usually incidental findings, are
stinguished from ulcers by the apparent absence of a
mmunication with the aortic lumen by CT, and do not
ually require specific treatment. A dissection entry or
entry tear may develop in an area of IMH as detected by
veral imaging studies over a period of several months
97,299,300,306).
.4. Pseudoaneurysms of the Thoracic Aorta
eudoaneurysms of the thoracic aorta are frequently related
deceleration or torsional trauma to the aorta from motor
hicle accidents, falls, and sports injuries (3,313–319).
ortic pseudoaneurysms are relatively rare, with posttrau-
atic pseudoaneurysms having an incidence of 3% to 4%
ter blunt trauma (51). Other pseudoaneurysms may occur callowing aortic surgery, catheter-based interventions, or
netrating trauma. Pseudoaneurysms often have a slim
eck” that leads to the “aneurysm” that corresponds to
ints of penetration and containment (320). Aortic infections
ycotic aneurysms) and penetrating ulcers may also result in
eudoaneurysms (see Section 9.2.2). Penetrating injuries are
ually repaired immediately whenever recognized and fea-
ble (317,318,321).
.5. Traumatic Rupture of the Thoracic Aorta
UK survey of all motor vehicle accident fatalities found
at approximately 20% of patients had an autopsy finding of
ruptured aorta, emphasizing the importance of traumatic
pture of the aorta (TRA). In the United States, there are
ound 40 000 motor vehicle deaths annually, and it is likely
at around 8000 of the victims had TRA. It is estimated that
ly 9% to 14% of patients with TRA reach a hospital alive
d only 2% ultimately survive. In this survey, 29% were
volved with frontal impact crashes and 44% were involved
ith side impact crashes (318,319).
Parmley and colleagues (318) noted the correlation of high
sk of early death and the sites of TRA on the basis of
topsies in 275 deaths from unrelated aortic rupture. In 45%,
e tear was at the aortic isthmus; 23%, in the ascending
rta; 13%, in the descending aorta; 8%, in the transverse
rta; 5%, in the abdominal aorta; and 6%, multiple sites.
Examination of the patient usually reveals signs similar to
ose of coarctation of the aorta with arm blood pressure
gher than leg blood pressure, delay between radial versus
moral artery pulsation, and a harsh interscapular murmur
). Evidence of polytrauma is, however, common.
The best method for detection of a TRA is debated. A chest
ray with a nasogastric tube in position has 80% sensitivity
r suggesting TRA by showing displacement of the naso-
stric tube by the hematoma. However, signs of hemome-
astinum are more often false positive than true positive
0). Even when present, mediastinal blood is less likely to be
e to arterial/aortic injury than to less-consequential venous
eeding. A biplane contrast aortogram may fail to detect the
ar until the development of a pseudoaneurysm. TEE may be
ed, but if dilatation has not occurred, the diagnosis may still
in doubt. CT is used but is not absolutely certain to
tablish the diagnosis. In questionable cases, intravascular
trasound can also be used (3,322,323) (Figure 8). Realisti-
Figure 24. Penetrating atherosclerotic ulcer of the
proximal descending thoracic aorta. Axial CT im-
ages at the level of the aortopulmonary window
(left) and at the level of the left pulmonary artery
(right) demonstrate a small penetrating ulcer (long
arrow, U) that extends beyond the expected con-
fines of the aortic lumen with adjacent IMH both at
the level of the ulcer itself and that extends a few
centimeters caudally in the wall of the descending
thoracic aorta (short arrows). CT indicates com-
puted tomographic imaging; IMH, intramural he-
matoma; and U, penetrating ulcer.lly, the imaging sequence often depends on the stability of
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juries. Sometimes, this may even fail to detect the tear, and
e study may have to be repeated at a later date to detect the
ar.
.6. Evaluation and Management of Acute
oracic Aortic Disease
6.1. Initial Evaluation and Management
6.1.1. RECOMMENDATIONS FOR ESTIMATION OF PRETEST
SK OF THORACIC AORTIC DISSECTION
ASS I
Providers should routinely evaluate any patient presenting with
complaints that may represent acute thoracic aortic dissection
to establish a pretest risk of disease that can then be used to
guide diagnostic decisions. This process should include spe-
cific questions about medical history, family history, and pain
features as well as a focused examination to identify findings
that are associated with aortic dissection, including:
a. High-risk conditions and historical features (47,127,223,
261) (Level of Evidence: B):
• Marfan syndrome, Loeys-Dietz syndrome, vascular
Ehlers-Danlos syndrome, Turner syndrome, or other con-
nective tissue disease.
• Patients with mutations in genes known to predispose
to thoracic aortic aneurysms and dissection, such as
FBN1, TGFBR1, TGFBR2, ACTA2, and MYH11.
• Family history of aortic dissection or thoracic aortic
aneurysm.
• Known aortic valve disease.
• Recent aortic manipulation (surgical or catheter-based).
• Known thoracic aortic aneurysm.
b. High-risk chest, back, or abdominal pain features (37,47,
215,223,261,264,288) (Level of Evidence: B):
• Pain that is abrupt or instantaneous in onset.
• Pain that is severe in intensity.
• Pain that has a ripping, tearing, stabbing, or sharp
quality.
c. High-risk examination features (37,47,253,257,261,324)
(Level of Evidence: B):
• Pulse deficit.
• Systolic blood pressure limb differential greater than 20
mm Hg.
• Focal neurologic deficit.
• Murmur of aortic regurgitation (new).
Patients presenting with sudden onset of severe chest, back,
and/or abdominal pain, particularly those less than 40 years of
age, should be questioned about a history and examined for
physical features of Marfan syndrome, Loeys-Dietz syndrome,
vascular Ehlers-Danlos syndrome, Turner syndrome, or other
connective tissue disorder associated with thoracic aortic
disease. (223) (Level of Evidence: B)
Patients presenting with sudden onset of severe chest, back,
and/or abdominal pain should be questioned about a history of
aortic pathology in immediate family members as there is a
strong familial component to acute thoracic aortic disease.
(223) (Level of Evidence: B)
Patients presenting with sudden onset of severe chest, back,
and/or abdominal pain should be questioned about recent seaortic manipulation (surgical or catheter-based) or a known
history of aortic valvular disease, as these factors predispose
to acute aortic dissection. (Level of Evidence: C)
In patients with suspected or confirmed aortic dissection who
have experienced a syncopal episode, a focused examination
should be performed to identify associated neurologic injury or
the presence of pericardial tamponade (see Section 8.1.6).
(Level of Evidence: C)
All patients presenting with acute neurologic complaints
should be questioned about the presence of chest, back,
and/or abdominal pain and checked for peripheral pulse defi-
cits as patients with dissection-related neurologic pathology
are less likely to report thoracic pain than the typical aortic
dissection patient (253) (see Section 8.1.7). (Level of Evi-
dence: C)
6.1.2. LABORATORY TESTING
veral plasma markers have been investigated for their
ility in the evaluation of acute AoD. Plasma smooth muscle
yosin heavy chain protein, D-dimer, and high-sensitivity
-reactive protein have shown diagnostic promise, although a
ck of large prospective studies precludes a recommendation
garding their use (325–328).
Elevation of D-dimer levels occurs with intravascular
tivation of the coagulation cascade and secondary fibrino-
sis and in conditions such as venous thromboembolism,
psis, disseminated intravascular coagulation, malignancies,
cent trauma or surgery, and acute MI and following
rinolytic therapy. The ACEP has published guidelines
garding the use of certain D-dimer assays to rule out
lmonary embolism in low-risk patients (329).
Regarding the potential role of plasma D-dimer levels to
reen for AoD, significant elevations of D-dimer were seen
all 24 patients with documented acute AoD involving
ther the ascending or descending thoracic aorta regardless
time from presentation, ranging from 1 to 120 hours (325).
meta-analysis of 11 studies (330) noted that the pooled
nsitivity of D-dimer in 349 patients with documented acute
oD was 94% (95% CI 91% to 96%) with specificity ranging
om 40% to 100%. Two patients had limited ascending aortic
H without intimal flap and had negative D-dimer assays
31).
Some authors (325,332) recommend that D-dimer assays
performed in all patients where clinical suspicion exists, to
lp identify those who do not require definitive imaging
udies. However, the efficacy and safety of this strategy have
t been tested in a large clinical trial, and several caveats
ould apply. The negative likelihood ratio provided by the
ost sensitive D-dimer assay is not of sufficient magnitude to
ovide useful information in high-risk individuals and there-
re cannot be used to “rule out” the disease in this group.
linical scoring systems to identify the true pretest probabil-
for AoD in individual patients have not been developed or
lidated, thus limiting an accurate determination of the true
osttest” probability associated with a negative D-dimer
sult. Finally, there are reports of negative D-dimer assays
sociated with ascending aortic IMH or a thrombosed false
men, such that further studies are needed regarding the
nsitivity of D-dimer levels to detect the presence of IMH or
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commend serum D-dimer screening for all patients being
aluated for AoD.
Where a high level of suspicion for acute AoD exists,
boratory testing aimed at presurgical screening (blood
unt, serum chemistries, coagulation profiles, and blood type
d screen) may reduce preoperative delays.
6.1.3. RECOMMENDATIONS FOR SCREENING TESTS
ASS I
An electrocardiogram should be obtained on all patients who
present with symptoms that may represent acute thoracic
aortic dissection.
a. Given the relative infrequency of dissection-related coro-
nary artery occlusion, the presence of ST-segment eleva-
tion suggestive of myocardial infarction should be treated
as a primary cardiac event without delay for definitive
aortic imaging unless the patient is at high risk for aortic
dissection. (37,47,333) (Level of Evidence: B)
The role of chest x-ray in the evaluation of possible thoracic
aortic disease should be directed by the patient’s pretest risk
of disease as follows:
a. Intermediate risk: Chest x-ray should be performed on all
intermediate-risk patients, as it may establish a clear
alternate diagnosis that will obviate the need for definitive
aortic imaging. (Level of Evidence: C)
b. Low risk: Chest x-ray should be performed on all low-risk
patients, as it may either establish an alternative diagnosis
or demonstrate findings that are suggestive of thoracic
aortic disease, indicating the need for urgent definitive
aortic imaging. (Level of Evidence: C)
Urgent and definitive imaging of the aorta using transesoph-
ageal echocardiogram, computed tomographic imaging, or
magnetic resonance imaging is recommended to identify or
exclude thoracic aortic dissection in patients at high risk for
the disease by initial screening. (42–46,67,73) (Level of
Evidence: B)
ASS III
A negative chest x-ray should not delay definitive aortic imag-
ing in patients determined to be high risk for aortic dissection
by initial screening. (Level of Evidence: C)
6.1.4. RECOMMENDATIONS FOR DIAGNOSTIC
AGING STUDIES
ASS I
Selection of a specific imaging modality to identify or exclude
aortic dissection should be based on patient variables and
institutional capabilities, including immediate availability.
(Level of Evidence: C)
If a high clinical suspicion exists for acute aortic dissection but
initial aortic imaging is negative, a second imaging study
should be obtained. (212) (Level of Evidence: C)
6.1.5. RECOMMENDATIONS FOR INITIAL MANAGEMENT
ASS I
Initial management of thoracic aortic dissection should be
directed at decreasing aortic wall stress by controlling heart
rate and blood pressure as follows:a. In the absence of contraindications, intravenous beta
blockade should be initiated and titrated to a target heart
rate of 60 beats per minute or less. (Level of Evi-
dence: C)
b. In patients with clear contraindications to beta blockade,
nondihydropyridine calcium channel-blocking agents
should be used as an alternative for rate control. (Level of
Evidence: C)
c. If systolic blood pressures remain greater than 120 mm Hg
after adequate heart rate control has been obtained, then
angiotensin-converting enzyme inhibitors and/or other va-
sodilators should be administered intravenously to further
reduce blood pressure that maintains adequate end-organ
perfusion. (Level of Evidence: C)
d. Beta blockers should be used cautiously in the setting of
acute aortic regurgitation because they will block the
compensatory tachycardia. (5) (Level of Evidence: C)
ASS III
Vasodilator therapy should not be initiated prior to rate control
so as to avoid associated reflex tachycardia that may increase
aortic wall stress, leading to propagation or expansion of a
thoracic aortic dissection. (Level of Evidence: C)
6.1.6. RECOMMENDATIONS FOR DEFINITIVE MANAGEMENT
ASS I
Urgent surgical consultation should be obtained for all
patients diagnosed with thoracic aortic dissection regard-
less of the anatomic location (ascending versus descending)
as soon as the diagnosis is made or highly suspected. (Level
of Evidence: C)
Acute thoracic aortic dissection involving the ascending aorta
should be urgently evaluated for emergent surgical repair
because of the high risk of associated life-threatening compli-
cations such as rupture. (47) (Level of Evidence: B)
Acute thoracic aortic dissection involving the descending
aorta should be managed medically unless life-threatening
complications develop (i.e., malperfusion syndrome, progres-
sion of dissection, enlarging aneurysm, inability to control
blood pressure or symptoms). (285,288,334–337) (Level of
Evidence: B)
arly identification of acute thoracic dissection is challeng-
g. During the initial evaluation, the correct diagnosis of
oD has been made in only 15% to 43% of patients initially
ought to have the disease (215,237,252). Factors that may
pede accurate diagnosis of AoD include the following:
Acute AoD is often believed to be a rare disease (2.9 to 3.5
cases per 100 000 person-years) (215,217), whereas the
incidence of acute MI is several orders of magnitude
greater (more than 200 cases per 100 000 person-years)
(338). Data previously cited in this guideline from UHC
suggest that acute AoD is not “rare.” Some common
explanations that clinicians give for this underlying belief
include the following:
a. It is difficult for clinicians to effectively separate
patients with AoD from the multitude of other patients
who present to emergency departments and primary
2.
3.
4.
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much more often not due to acute AoD.
b. Front-line medical providers may have little direct
experience with acute AoD and are unlikely to be
aware of the subtleties of its presenting signs and
symptoms.
c. Institutional multidisciplinary pathways developed for
other emergencies such as ST-elevation myocardial
infarction (STEMI) or acute stroke have not generally
existed for acute AoD.
In contrast to other more common cardiovascular emer-
gencies, acute AoD may occur in younger patients. Accu-
rate identification of acute AoD; however, requires that
clinicians recognize on a routine basis that the disease may
present in younger patients. Case reports exist of children
as young as 3 years of age presenting with acute AoD
(105).
Acute AoD may present with a wide range of unusual
manifestations that do not conform with classic “textbook
findings.” (339–341)
There are no well-studied, rapidly available, and effective
screening tests for acute AoD.
.2. Evaluation and Management Algorithms
e provided algorithms guide the initial evaluation of
tients whose presentations are concerning for AoD and the
nagement of patients in whom the diagnosis of acute
racic AoD is confirmed. Although clinicians may ulti-
tely choose to deviate from the pathway for patient-
cific reasons, the algorithms provide a framework with
ich to quickly diagnose (Figure 25) and provide early
nagement (Figure 26) of AoD. This decision model is
ported by several large studies that indicate a targeted
tory and physical examination are likely to identify the
st majority of patients who present with acute AoD,
gesting that adequate screening need not be time intensive
technology dependent (47,215,264). Using a target history
d physical examination, patients can be placed into 1 of 3
egories: 1) those with immediately apparent acute AoD
uiring emergent surgical evaluation and expedited aortic
aging, 2) those whose presentation is concerning for acute
D and in the absence of a clear alternative diagnosis
uire expedited aortic imaging, and 3) those whose clinical
sentation is not initially suggestive of acute AoD but may
nefit from aortic imaging in the absence of a likely
ernative diagnosis at the completion of the initial evalua-
n.
Several high-risk conditions (Figure 25, T2–1) greatly
rease the likelihood that presenting complaints that could
a result of acute AoD.
Pain (Figure 25, T2–2) is the most commonly reported
senting symptom of acute AoD regardless of patient age,
, or other associated clinical complaint (37,47,215,
3,242,264,289). Pain described as abrupt or instantaneous
onset, that is severe in intensity, or that has a ripping or
ring quality establishes a high pretest probability for AoD
,261).
The combination of 2 or more high-risk features (Figure
, T3) is strongly suggestive of acute AoD. accThe presence of a single high-risk feature (i.e., high-risk
ndition, pain, or physical examination) may trigger imme-
te concern for acute AoD; however, other diagnostic
nsiderations may exist. Pain with high-risk features, al-
ugh suggestive of acute AoD, may occur as a result of an
ernate disease process (Table 12). For patients who are
termined to have an intermediate probability of acute AoD
the basis of initial bedside assessment, Figure 25, T4,
vides a pathway for further evaluation.
Figure 25, T5, provides a pathway for further evaluation of
tients without any high risk features. Delay in diagnosis
d increased mortality is common in this group
1,288,289).
For patients presenting with new ST-segment elevations on
initial ECG and without high-risk AoD features, imme-
te coronary angiography and reperfusion therapy (i.e.,
ombolysis or percutaneous coronary intervention) are in-
ated (333). However, if coronary angiography is per-
med and no culprit coronary lesion is identified, then
ure 25, T6, provides a pathway to dedicated aortic
aging. As approximately 40% of chest films in acute AoD
k a widened mediastinum, and as many as 16% are normal,
absence of radiographic abnormalities does not exclude
diagnosis of AoD (37,47) (Figure 25, T7).
Missed or delayed diagnosis of acute AoD is most com-
nly ascribed to an incorrect working diagnosis of acute
ronary syndrome, a condition that may require a prolonged
e interval to correctly identify (i.e., serial cardiac biomark-
) and whose management with antiplatlet and antithrombin
ents may cause harm to the patient with AoD. For patients
th an intermediate-risk profile for acute AoD and who do
t have diagnostic STEMI but who are being evaluated for
possible acute coronary syndrome, aortic imaging may
tect AoD prior to the administration of antiplatelet and
tithrombin agents (Figure 25, T8).
Unexplained hypotension is present in approximately 20%
patients with acute AoD (37,47). Similarly, a widened
diastinum on chest x-ray strongly suggests the need for
ditional definitive diagnostic aortic imaging, particularly in
tients without a clear alternative explanation for their
senting complaint (342) (Figure 25, T9).
Some patients with acute AoD present without any high-
k features, making early diagnosis difficult. If a clear
ernative diagnosis is not established after the initial eval-
tion, then obtaining a diagnostic aortic imaging study,
rticularly in patients with advanced age (older than 70
ars), syncope, focal neurologic deficit, or recent aortic
nipulation (surgery or catheter based), should be consid-
d (47,242,253,288,343) (Figure 25, T10).
Multidetector CT with contrast, TTE, and MR all provide
eptable diagnostic accuracy for the diagnosis of acute AoD.
patients with hemodynamic instability, requiring close mon-
ring, bedside TEE is preferred to avoid moving the patient out
the acute care environment (Figure 25, T11).
The most recent comparative study with nonhelical CT, 0.5
sla MR and TEE showed 100% sensitivity for all modal-
s, with better specificity of CT (100%) than for TEE and
(44). A recent meta-analysis that evaluated the diagnostic
uracy of TEE, helical CT, and MR for suspected AoD
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseund that all 3 imaging techniques provided equally reliable
agnostic values (46). Accordingly, selection of an imaging
odality is influenced by individual patient variables and
stitutional capabilities.
The diagnosis of acute AoD cannot be excluded defini-
ely based on the results of a single imaging study.
lthough TEE, CT, and MR are all highly accurate for the
aluation of acute AoD; false-negative studies can and do
cur (47) (Figures 9 and 15). If a high clinical suspicion
ists for acute AoD but initial aortic imaging is negative,
rongly consider obtaining a second imaging study (Figure
gure 25. AoD evaluation pathway. ACS indicates acute coronary
rvous system; CT, computed tomographic imaging; CXR, chest
EMI, ST-elevation myocardial infarction; TAD; thoracic aortic dis, T12). er6.3. Initial Management
nce the diagnosis of AoD or one of its anatomic variants
MH or PAU) is obtained, initial management is directed at
iting propagation of the false lumen by controlling aortic
ear stress while simultaneously determining which patients
ill benefit from surgical or endovascular repair (Figure 26).
6.3.1. BLOOD PRESSURE AND RATE CONTROL THERAPY
ortic wall stress is affected by the velocity of ventricular
ntraction (dP/dt), the rate of ventricular contraction, and
ood pressure. Initial medical stabilization using beta block-
ome; AoD, aortic dissection; BP, blood pressure; CNS, central
EKG, electrocardiogram; MR, magnetic resonance imaging;
nd TEE, transesophageal echocardiogram.syndr
x-ray;s controls these 3 parameters by reducing heart rate and
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129ood pressure to the lowest amounts that will still maintain
equate end-organ perfusion (61). Reasonable initial targets
e a heart rate less than 60 bpm and a systolic blood pressure
tween 100 and 120 mm Hg (61).
Intravenous propranolol, metoprolol, labetalol, or esmolol
an excellent choice for initial treatment. In patients who
ve a potential contraindication to beta blockade (e.g., those
gure 26. Acute AoD management pathway. AoD indicates aortic
E, transthoracic echocardiogram.ith asthma, congestive heart failure, or chronic obstructive (vlmonary disease), esmolol may be a viable option given its
tremely short half-life. Use of labetalol, which is both an
pha- and beta-receptor antagonist, offers the advantage of
tent heart rate and blood pressure control from a single
ent, potentially eliminating the need for a secondary
sodilator. In patients who are unable to tolerate beta
ockade, nondihydropyridine calcium channel antagonists
tion; BP, blood pressure; MAP, mean arterial pressure; anddissecerapamil, diltiazem) offer an acceptable, although less-
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasetablished, alternative (61). Beta blockers, verapamil, or
ltiazem for rate control in patients with significant aortic
gurgitation may be problematic because of deleterious
fects on reflex tachycardia.
6.3.2. ADDITIONAL ANTIHYPERTENSIVE THERAPY
is frequently difficult to reduce blood pressure to optimum
vels (285–287,344–346). In 1 study, patients required a
edian of 4 different antihypertensive drugs (347). In addi-
n to beta blockade, vasodilators may be required to control
ood pressure. Intravenous sodium nitroprusside is the most
tablished agent and offers the advantage of being rapidly
ratable (61). Nicardipine (348), nitroglycerin, fenoldopam,
d various other intravenous antihypertensive agents are
propriate for this situation. Vasodilator therapy without
ior beta blockade may cause reflex tachycardia and in-
eased force of ventricular contraction leading to greater
rtic wall stress and potentially causing false lumen propa-
tion (42). Following initial stabilization with intravenous
tihypertensives, most patients will require long-term anti-
pertensive treatment including the use of a beta blocker
us additional classes of agents. Angiotensin-converting
zyme inhibitors or angiotension receptor blockers may
tard aortic dilatation and their use may be indicated as
tlined in Section 9.2.1.1.
6.3.3. PAIN CONTROL
dequate pain control is essential in the setting of acute AoD
decrease sympathetic mediated increases in heart rate and
ood pressure. Appropriate use of intravenous opiate anal-
sia will help augment the effects of rate control and
sodilator agents.
6.3.4. HYPOTENSION
edical management options for all forms of dissection-
ble 12. Differential Diagnosis for High-Risk Pain or
amination Features
est pain
● Acute myocardial infarction
● Pulmonary embolism
● Spontaneous pneumothorax
● Esophageal rupture
dominal pain
● Renal/biliary colic
● Bowel obstruction/perforation
● Non–dissection-related mesenteric ischemia
ck pain
● Renal colic
● Musculoskeletal pain
● Intervertebral disk herniation
lse deficit
● Non–dissection-related embolic phenomena
● Non–dissection-related arterial occlusion
cal neurologic deficit
● Primary ischemic cerebrovascular accident
● Cauda equina syndromelated hypotension are limited. Volume administration ti- usated to improvement of blood pressure is a reasonable first
proach. Vasopressors can be added, if needed, to maintain
equate perfusion but have the potential to cause further
lse lumen propagation. Inotropic agents are likely to in-
ease the force and rate of ventricular contraction and
erefore increase sheer stress on the aortic wall.
Pericardiocentesis for dissection-related hemopericardium
s been associated with recurrent pericardial bleeding and
sociated mortality (307,349,350). Several articles from the
sian literature suggest that pericardiocentesis may be safe in
e setting of acute Type A IMH (351,352). Other cardiac
mplications that may result in hypotension include severe
ssection-related aortic regurgitation, true lumen obstruction
a compressing false lumen, and acute MI. All require
finitive operative management. Hypotension or shock in
e setting of AoD may also result from contained rupture of
e false lumen into adjacent structures (i.e., pleural space or
ediastinum), a scenario that also mandates immediate op-
ative intervention.
Ultimately, hypotension or shock in the acute AoD patient
ggests the need for immediate operative management. For
tients with hemopericardium and cardiac tamponade who
nnot survive until surgery, pericardiocentesis can be per-
rmed by withdrawing just enough fluid to restore perfusion.
6.3.5. DETERMINING DEFINITIVE MANAGEMENT
the clinically stable patient, the decision for surgical versus
edical management of patients with acute AoD is based
imarily on the location of the dissection as described by the
anford and DeBakey classification systems (61,353) (see
ction 8.1.2). A prompt cardiac surgical consultation pro-
des the best management resource, regardless of location of
e AoD, as it is impossible to predict which complications
ay develop or when they may occur.
6.4. Recommendation for Surgical Intervention for
cute Thoracic Aortic Dissection
ASS I
For patients with ascending thoracic aortic dissection, all of
the aneurysmal aorta and the proximal extent of the dissec-
tion should be resected. A partially dissected aortic root
may be repaired with aortic valve resuspension. Extensive
dissection of the aortic root should be treated with aortic
root replacement with a composite graft or with a valve
sparing root replacement. If a DeBakey Type II dissection is
present, the entire dissected aorta should be replaced.
(Level of Evidence: C)
hen a Type A AoD involves the aortic root, resuspension of
e valve with preservation of the aortic sinuses and excision
the sinuses and resuspension of the valve within a
lyester graft are suitable options. If the aortic root is
lated, or if there is extensive dissection and disruption of the
rtic sinuses, replacement with a composite graft is neces-
ry.
6.5. Endovascular Interventions
ndovascular stent grafts are not approved for AoD involving
e ascending aorta or aortic arch. Endovascular stent grafts
ed for descending thoracic aortic dissection is discussed in
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lar interventions are discussed in Section 9.
6.6. Principles of Treatment for Intramural
ematoma and Penetrating Atherosclerotic Ulcer
he goals of treatment are to prevent aortic rupture or
ogression to classic AoD, allow patient stabilization before
gent surgery, and reduce complexity of unavoidable aortic
rgery. Aggressive medical treatment usually includes, par-
ularly in symptomatic patients, beta blockers and other
tihypertensive therapy. Indications for open or endograft
eatment are based on the anatomic features of the lesion,
inical presentation and course, patient comorbidities, and
atomic constraints related to endograft technology. Treat-
ent by endografts or open aortic reconstruction can be
scussed in the context of 3 overlapping aortic lesions:
timal defect without IMH, intimal defect with IMH, and
H without an intimal defect.
6.6.1. INTIMALDEFECTWITHOUT INTRAMURALHEMATOMA
hese are localized lesions and may involve a limited
gment of the aorta. They are often an incidental finding. By
aging criteria, they include uncomplicated aortic ulcers,
ebs, and eccentric or saccular aneurysms of the aorta. They
e treated as saccular aneurysms based on their maximum
ameter and clinical feature (212,306,354). These lesions
n be treated with open reconstruction and are the most
itable of the 3 groups for treatment by endografts, if in the
scending thoracic aorta. They involve a limited segment,
hich can easily be excluded from the circulation, as long as
ere is an adequate distance from a critical branch artery.
hen these limited dissections involve the ascending aorta,
ergency surgery is indicated as for other types of AoD
ecause rupture or cardiac tamponade can occur
12,306,354).
6.6.2. INTIMAL DEFECT WITH INTRAMURAL HEMATOMA
he intimal defect again presents a target lesion for endovas-
lar treatment in the descending thoracic aorta, but the
sociated IMH involves a longer segment of aorta than the
st category. If the patient becomes asymptomatic in re-
onse to aggressive medical treatment, it may be possible to
lay endovascular or open reconstruction until the IMH has
absorbed and organized. (Of note, some writing committee
embers have observed healing of IMH such that immediate
construction was not required but have continued to follow
at small number of patients closely.) Two considerations
fect the length of aorta bordering the intimal defect, which
to be included in the segment targeted for treatment.
vidence of adjacent atheromatous wall should favor more
tensive treatment of the aorta with longer endografts,
cause radiographic imaging underestimates shallow ulcer-
ed atheromas, and the ulcer typically arises in a bed of
heromatous intima. Treatment with longer endografts pro-
des a safety margin against undertreating the intimal defect.
he second consideration is the extent of associated IMH.
he self-expanding endograft may tear through the intimal
rface into underlying thrombosed false lumen. When treat- saent of this lesion in the acute stage is clinically necessary
.g., persisting pain, evidence for expansion or rupture,
mpromise of critical branches), it is preferable to anchor
e endograft in the noninvolved wall above and below the
timal defect.
6.6.3. RECOMMENDATION FOR INTRAMURAL HEMATOMA
ITHOUT INTIMAL DEFECT
ASS IIa
It is reasonable to treat intramural hematoma similar to aortic
dissection in the corresponding segment of the aorta. (Level of
Evidence: C)
s noted earlier, some authors suggest treating IMH as an
oD in the corresponding aortic territory. Others recommend
vasive treatment regardless of location or aortic diameter
54). However, small patient series, incomplete anatomic
scription of case material, and lack of explicit anatomic or
inical guidelines indicating open or endovascular aortic
pair make it difficult to generalize from the literature.
The absence of an intimal defect, which can serve as a
rget lesion, presents a diagnostic as well as treatment
allenge. Intimal tears can be extremely subtle, depending
the size of the intimal tear and the amount of intramedial
rombus, which can sometimes fill the cavity flush with the
rtic lumen. The intimal tear may be remote in the aorta
spite leaking into the chest. IMH in a normal caliber aorta
ithout an apparent intimal tear precludes limited treatment
a target lesion. There are no data supporting prophylactic
plantation of endografts covering the entire descending
rta, yet in unusual circumstances one may be forced to
opose such treatment. IMH in an aneurysmal aorta presents
particularly urgent problem, because this complication may
a precursor to aneurysm rupture. Although the literature
ves no compelling guidelines for treatment, the writing
mmittee believes that treatment of IMH corresponding to
eatment of AoD in the corresponding segment of the aorta
reasonable.
.7. Treatment for the Management of
aumatic Aortic Rupture
he management of blunt TRA is evolving (3,318,319,
5,356). On the basis of the report by Parmley and col-
agues (318), most surgeons have recommended immediate
rgical repair. However, when other serious traumatic inju-
es are present including head injuries and long bone or
lvic fractures, immediate surgery may not be feasible or
ay be dangerous. Multiple studies appear to show that if
reful blood pressure control is used, many patients can be
eated initially conservatively and then undergo operation
ce their other injuries have been stabilized (3,321,357–
9). In a review by Svensson et al (359) of 44 patients
itially treated with careful blood pressure control who
bsequently had delayed open surgery, there were no oper-
ive deaths. This approach has also been reported as being
fe by Pate and colleagues and others (3,321,357,358). Thus,
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseselected patients at high risk for other injuries and
eeding, delayed repair of traumatic contained rupture of the
rta may be an option.
The open surgical repair of TRA has evolved over time.
a meta-analysis of 596 TRA patients by Svensson et al
59), the highest mortality rate was noted with cardiopul-
onary bypass (16.7%), the rate was less with shunts
1.4%), and the rate was lowest with a simple “clamp and
w” approach (5.8%, P0.01). There was no difference in
e risk of postoperative paralysis. Subsequently, von
ppell and colleagues (360) reviewed 1742 patients and
und the risk of death was 18.2% with cardiopulmonary
pass, 11.9% for distal perfusion with atriofemoral by-
ss, 12.3% for shunts, and 16% for the “clamp and sew”
ethod. The respective paralysis rates were 2.4%, 1.7%,
.1%, and 19.2%, respectively. The key factor in open
pairs has been to keep the total aorta cross-clamp time to
short a period as possible, especially less than 45
inutes (3,359,361–364).
The latest evolution in managing TRA is the use of
dovascular deployed graft covered stents. Although
dovascular stent grafting has not been prospectively
udied for this clinical scenario, US Food and Drug
dministration–approved devices are being used “off la-
l,” with considerable success reported based on retro-
ective studies. In a collected series of 284 patients
ported in the literature, Lettinga-van de Poll and col-
agues reported the procedure-related mortality was 1.5%,
7% had endoleaks, and 14.4% had procedure-related
mplications (358,365–370). In a multicenter study of 30
tients with 100% implantation success, 6% to 7% of
tients died, 1 had a stroke (3.3%), and 1 had partial stent
llapse (3.3%) (370). Reporting bias of favorable results
ay be an issue regarding interpretation of the safety and
ficacy of this approach.
The problems with endovascular grafting for TRA have
cluded the need to cover the left subclavian artery; the acute
arp angle of the distal aortic arch, particularly in young
tients; and the lack of sufficiently small prostheses for use
young patients. The size and angle problem can result in
e “bird beak” deformity, where the proximal edge of the
ent is not in contact with the aortic wall and can result in
ting or collapse of the stent (366) (Figure 27). Similarly,
hen the stent graft is larger than the aortic diameter,
folding of the stent and collapse can occur. On cross-
ctional views, the stent graft has the appearance of a
agrammatic heart.
Over time, it is hoped newer iterations of endografts will
developed that are better able to accommodate the
gulation of the distal arch and are smaller. It is unlikely
at a prospective randomized study will be performed for
is because of the small number of patients who make it
any surgical center and because initial results with
dografting of TRA, with exception of the problems
sted earlier, have been reasonable. The Expert Opinion
ommittee of the Society of Thoracic Surgeons and the
merican Association of Thoracic Surgeons suggested that
th acute and chronic ruptures be considered for treat-
ent with endografts. Some measures of caution must be alken because these are young patients who may be
bjected to cumulative radiation exposure with multiple
T scans and because the long-term durability of endo-
scular stent grafts is not known (371).
. Thoracic Aortic Aneurysms
ost thoracic aortic aneurysms are caused by degenerative
sease resulting in dilatation of the aorta (Figure 28). The
cidence of thoracic aortic aneurysms is estimated to be
creasing and there are around 10.4 cases per 100 000
rson-years (372).
Risk factors for development of thoracic aortic aneurysms
clude hypertension, smoking, and chronic obstructive pul-
onary disease. In addition, several genetic syndromes with
predisposition for thoracic aortic aneurysms have been
entified and are listed in Section 5. Thoracic aortic aneu-
sms are also associated with bicuspid aortic valve (see
ction 6.1) and other congenital cardiovascular anomalies
ee Section 6) and inflammatory diseases (see Section 7).
me thoracic aortic aneurysms are due to an inheritance of
predisposition for the disease, termed familial thoracic
rtic aneurysm syndrome (see Section 5.1.6), and still others
e idiopathic.
Many patients with a thoracic aortic aneurysm are asymp-
matic and diagnosed by chest x-ray or CT scan obtained for
her reasons. An aneurysm may cause compressive symp-
ms on adjacent structures including hoarseness, from left
current laryngeal nerve stretching; stridor, from tracheal or
onchial compression; dyspnea, from lung compression;
sphagia, from esophageal compression; and plethora and
ema, from superior vena cava compression. Aortic valve
gurgitation may develop due to aortic root or ascending
rtic dilatation and result in heart failure. Neck and jaw pain
ay occur with aortic arch aneurysms, whereas back, inter-
apular, and/or left shoulder pain may occur with descending
oracic aortic aneurysms. Embolization of atherosclerotic
bris with end-organ symptoms may occur. Finally, acute
ndromes including dissection or rupture without dissection
ay occur with potentially catastrophic outcomes as de-
ribed in Section 8.5.
Thoracic aortic aneurysms may involve different seg-
ents of the aorta. The ascending thoracic aorta and/or
ot is most commonly involved, with the descending aorta
volved less often. Involvement of the aortic arch occurs
only 10%. The etiology, natural history, and treatments
ffer somewhat for aneurysms in each location. In Marfan
ndrome, aneurysms typically arise in the aortic root, a
ocess often referred to as annuloaortic ectasia. Because
e leaflets of the aortic valve are suspended within the
ot, successful repair of the aortic root may require
rformance of a valve-sparing root repair or, in some
ses, a composite aortic graft.
The average rate of expansion of thoracic aortic aneurysms
estimated to be 0.10 to 0.42 cm/y (373–375). Medical and
rgical treatment considerations and selection criteria are
ted in Section 9.2.
A leaking or ruptured aneurysm (see Section 9.1.2.1) mayso present as chest pain with hypotension due to hemor-
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aortoesophageal fistula may manifest as gastrointestinal
morrhage (377). An unusual manifestation reported is a
moptysis from a ruptured ascending aortic aneurysm erod-
g into the left lung bronchus (378).
Further anatomic classifications refer to segments of the
scending thoracic aorta and thoracoabdominal aorta
vided into subsections according to the extent of the
sease that is replaced at the time of surgery. These
tents have an important influence on the risk of death
d complications after surgery or stenting (Figure 29)
gure 27. Beaking of thoracic endoprosthesis. Top left, Baseline
atic pseudoaneurysm several cm distal to the left subclavian arte
mm, and distal to the pseudoaneurysm measured 21 mm. Top
eter cuff distally and a 26 mm  10 cm thoracic endograft prox
esent (arrow), with lack of conformity of the proximal endograft w
as covered intentionally to exclude the pseudoaneurysm, which d
wing implantation of the endografts shows collapse of the leadin
ntimeters more caudally, the endograft remains collapsed poste
w). Bottom middle, Thoracic aortography confirms posterior colla
ht, After placement of a self-expanding z-stent in the proximal e
en reexpanded and the pseudoaneurysm was once again exclud
nded and the pseudoaneurysm has remained excluded for 3 yeaee Section 9.2.2.3)..1. General Approach to the Patient
1.1. Recommendation for History and Physical
xamination for Thoracic Aortic Disease
ASS I
For patients presenting with a history of acute cardiac and
noncardiac symptoms associated with a significant likelihood
of thoracic aortic disease, the clinician should perform a
focused physical examination, including a careful and com-
plete search for arterial perfusion differentials in both upper
and lower extremities, evidence of visceral ischemia, focal
c aortography in left anterior oblique projection shows a trau-
rtic diameter proximal to the left subclavian artery measured
, Thoracic aortography following deployment of a 23-mm-di-
Considerable beaking of the leading edge of the endograft is
tight inner curve of the aortic arch. The left subclavian artery
ot opacify. Top right, CT examination of the chest 2 days fol-
of the endograft (arrow). Bottom left, On a CT slice several
lly, resulting in revascularization of the pseudoaneurysm (ar-
f the endograft and reopening of the pseudoaneurysm. Bottom
ft and reballooning of the endoprostheses, the endograft has
though beaking persists, the endograft has remained fully ex-
ollow-up. CT indicates computed tomographic imaging.thoraci
ry. Ao
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imally.
ith the
oes n
g edge
rolatera
pse o
ndogra
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(339–341) (Level of Evidence: C)
he physical findings of thoracic aortic diseases may be
btle indirect manifestations of uncommon underlying ge-
tically predisposing conditions. In evaluating the evidence
se for physical examination of patients with thoracic aortic
sease, there are no controlled or blinded experimental
search studies that have stratified patients into different
eatment categories based on physical findings.
For all patients with thoracic aortic disease, the first and
remost issue is to identify those who are acutely at risk for
tastrophic harm as early as possible. Establishing a set of etriggers” or “red flags” may serve as alerts to either exclude
identify life-threatening thoracic aortic disease.
Given the growing awareness of an extensive variety of
seases associated with nonemergent thoracic aortic disease,
is important to be aware of the many different physical
dings associated with extracardiovascular etiologies partic-
arly those of genetic origin (see Section 5).
1.1.1. CORONARY ARTERY DISEASE
he frequency of coexisting CAD varies widely among
tient subgroups with thoracic aortic disease as does the
Figure 28. Ascending thoracic aortic aneurysm in
a patient with calcific aortic stenosis. Top left, Ax-
ial CT image demonstrates an enlarged ascending
thoracic aorta (A) and normal caliber descending
thoracic aorta (D). Top right, Axial CT image dem-
onstrates extensive aortic valve leaflet calcification
(arrows). Middle left, Coronal CT image also dem-
onstrates the dilated ascending aorta (A) and aor-
tic valve leaflet calcification (arrows). Middle right,
Volume rendered CT image demonstrates the di-
lated ascending thoracic aorta (A), normal caliber
aortic arch and descending thoracic aorta (D) and
great vessels with a bovine arch configuration
(INN, LCCA, LSCA). Bottom, Volume rendered ro-
tating image of the thoracic aorta can be used to
depict the anatomy, particularly the relationship of
an aortic abnormality to the great vessels, for sur-
gical planning. See the accompanying full cine
video for the bottom panel. CT indicates com-
puted tomographic imaging; INN, innominate ar-
tery; LCCA, left common carotid artery; LSCA, left
subclavian artery; and LV, left ventricle.iology of the coronary artery abnormalities, if present.
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rta are at elevated risk for coronary atherosclerosis, partic-
arly if they have multiple atherosclerotic risk factors. While
tients with Type A dissection or annuloaortic ectasia may
protected from atherosclerosis (383), patients with Taka-
su arteritis may occasionally have inflammatory coronary
volvement with coronary aneurysms (less than 10%)
84,385). Similarly, an occasional patient with GCA may
ve coronary artery involvement (386,387). If ascending
rtic surgery is being considered, with or without aortic
lve surgery, then identification of the coronary anatomy
d any underlying CAD is important for planning the best
eration.
1.1.2. EMBOLI
mbolization of material thrombus, atheromatous debris, or
olesterol crystals may affect any distal arterial bed (see
ction 11.3). Embolization may occur in patients with
oracic aortic aneurysms or atheromas and in those who
ve undergone angiography, major vessel surgery, or throm-
lytic therapy (388–397). Clinical consequences of such
bolization vary considerably, from being completely
ymptomatic to presenting with acute multiorgan failure,
cluding progressive renal failure or cutaneous involvement,
ith a mortality rate as high as 70% to 90% (398).
1.1.3. ASSOCIATED RENAL ISCHEMIA
enal complications of thoracic aortic disease may be acute,
bacute, and chronic (399). Patients may present with severe
dominal or flank pain, hematuria, fever, nausea, or a
mbination of these signs and symptoms (400).
1.1.4. ASSOCIATED MESENTERIC ISCHEMIA
tients with acute intestinal ischemia have severe abdominal
in that is initially out of proportion to physical findings to01). Hours to days later, peritonits and sepsis correlate with
testinal perforation. Findings suggestive of intestinal isch-
ia as well as specific arterial or venous obstruction require
rther surgical or vascular specialist evaluation (402–406).
1.1.5. ASSOCIATED PERIPHERAL ISCHEMIA
cute limb ischemia results in pain, pallor, paraesthesias, and
ralysis (4). Noninvasive vascular diagnostic testing (e.g.,
kle- and toe-brachial indices, segmental pressure measure-
ents, pulse volume recordings, duplex ultrasound imaging,
d Doppler waveform analysis) may document ischemia
ith additional use of angiographic imaging when necessary
07).
1.2. Differential Diagnosis
1.2.1. SYMPTOMS
mptoms are most commonly related to pain or discomfort.
rticularly large thoracic aneurysms may be associated with
est discomfort. Rarely, dysphagia (dysphagia lusoria) or
spnea is present, usually related to congenital distal arch
sions, such as aberrant right subclavian artery and Kom-
erell diverticulum or Felson and Palayew Type I or II
ght-sided aortic arch lesions (408).
History of fevers may be related to inflammatory disease or
ycotic aneurysms. Occasionally, with chronic dissection
d leaking aneurysms, the reabsorption of blood may be
sociated with fever or jaundice.
1.2.2. PHYSICAL FINDINGS
ost physical findings are not specific for thoracic aortic
sease. Other findings may be related to genetic syndromes
d connective tissue disorders (see Section 5) or inflamma-
Figure 29. Descending aneurysm classification.
Descending aneurysms are classified as involving
thirds of the descending thoracic aorta and various
combinations. A involves the proximal third, B the
middle third, and C as the distal third. Thus, an
aneurysm involving the proximal two thirds is an
AB extent aneurysm. Practically, these groupings
can be combined into proximal or distal aneurysm,
because these extents influence the risk of paraly-
sis after either open or endovascular repairs. Tho-
racoabdominal aneurysms are classified according
to the Crawford classification: Type I extends from
proximal to the sixth rib and extends down to the
renal arteries. Type II extends from proximal to the
sixth rib and extends to below the renal arteries.
Type III extends from distal to the sixth rib but
from above the diaphragm into the abdominal
aorta. Type IV extends from below the diaphragm
and involves the entire visceral aortic segment and
most of the abdominal aorta. Juxtarenal and su-
praenal aneurysms are excluded (379–382). Image
reprinted with permission from the Cleveland Clinic
Foundation.ry diseases (see Section 7). Findings associated with coarc-
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urmurs.
1.3. Considerations for Imaging
ecause most cases of chronic thoracic aortic disease are
ymptomatic and difficult to detect on physical examination,
e clinician must have a low threshold for screening for
oracic aortic disease. CT or MR is required to adequately
sualize the affected aorta. There has been no cost–benefit
alysis of screening in these populations (see Section 18.1).
.2. General Medical Treatment and Risk
actor Management for Patients With
oracic Aortic Disease
2.1. Recommendation for Medical Treatment of
atients With Thoracic Aortic Diseases
ASS I
Stringent control of hypertension, lipid profile optimization,
smoking cessation, and other atherosclerosis risk-reduction
ble 13. Studies of Medical Treatment of Thoracic Aortic Aneur
eatment Studies
ta blockers Genoni M, Paul M, Jenni R,
et al (410)
Retrospectiv
medical trea
other antihy
20 (45%) fr
incidence o
40% (8 of 2
Shores J, Berger KR, Murphy EA,
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Open-label,
The treated
therapy slow
Ladouceur M, Fermanian C,
Lupoglazoff JM, et al (411)
Retrospectiv
was slowed
giotensin-converting
zyme inhibitors
Ahimastos AA, Aggarwal A,
D’Orsa KM, et al (412)
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the ascendi
reduction in
respectively
giotensin receptor
ckers
Mochizuki S, Dahlof B, Shimizu M,
et al (413)
3081 Japan
combination
other treatm
reduction in
in aortic dis
Brooke BS, Habashi JP, Judge DP,
et al (89)
The clinical
in 1 patient
root enlarge
significantly
during angio
enlargemen
mean differ
angiotension
change in d
distal ascen
atins Diehm N, Decker G, Katzen B,
et al (414)
A nonrando
of patients
Statin use w
HR 0.613, 9
1.795, 95%
AAA indicates abdominal aortic aneurysm; CI, confidence interval; SD, standameasures should be instituted for patients with small aneu- porysms not requiring surgery, as well as for patients who are not
considered to be surgical or stent graft candidates. (Level of
Evidence: C)
he patient’s general status should be optimized where
ssible. Respiratory illness, a common comorbid problem,
ay be improved by stopping smoking, clearing bronchitis,
d exercising regularly with walking. Because other athero-
lerotic disease is usually present in patients with thoracic
rtic aneurysms or atheroma, risk-reduction measures as
tlined in other guidelines are appropriate (409). Additional
edical management rationales are noted in Table 13.
Patients who are not candidates for operative intervention
clude those whose aneurysms or other aortic pathology do
t meet the criteria for surgical intervention and those in
hom the criteria are met but who are considered inoperable,
ost commonly because of coexisting disease. Patients with
rge aneurysms who are considered inoperable may benefit
om stringent control of risk factors (see Section 3.2) to
Results
-record review of 78 patients with chronic Type B dissection who received
51 of 71 received beta-blocker treatment, 20 of 71 were treated with
ve drugs. 10 of 51 (20%) of the beta-blocker–treated patients and 9 of
other treatment group needed dissection-related surgery (P0.002). The
ing aortic diameter was 12% (6 of 51) in the beta-blocker group and
e other treatment group (P0.002).
ized, control study of propranolol in 70 patients with Marfan syndrome.
eceived a mean daily propranolol dose of 21268 mg/d. Propranolol
ic root dilation (0.023 vs 0.084 per year, P0.001).
ation of aortic dilation in children with Marfan syndrome. Aortic dilatation
mm/y in children treated with beta blockers.
-blind, placebo-controlled trial of 17 patients with Marfan syndrome
therapy to perindopril or placebo. After 24 weeks of therapy, the
ubjects compared with placebo-treated subjects had smaller growth in
diameter during systole (1.2 vs 0.3 mm/m2, P0.01) and a significant
ing aortic diameter during diastole (0.4 vs 1.2 mm/m2, P0.001),
ients with hypertension, coronary heart disease, heart failure, or a
andomly assigned either to open-label valsartan (40 to 160 mg/d) or to
hout angiotension receptor blockers. Patients randomized to valsartan had
site cardiovascular outcome (OR 0.61, 95% CI 0.47 to 0.79) and reduction
(OR 0.18, 95% CI 0.04 to 0.88). Open-label, randomized.
e to angiotension receptor blockers (losartan in 17 patients and irbesartan
valuated in pediatric patients with Marfan syndrome with severe aortic
he mean (SD) rate of change in aortic root diameter decreased
.542.87 mm/y during previous medical therapy to 0.460.62 mm/y
receptor blocker therapy (P0.001). The deviation of aortic root
ormal, as expressed by the rate of change in z scores, was reduced by a
1.47 z scores/y (95% CI 0.70 to 2.24, P0.001) after the initiation of
or blocker therapy. The sinotubular junction showed a reduced rate of
during angiotension receptor blocker therapy (P0.05), whereas the
rta was not affected by angiotension receptor blocker therapy.
ropensity-score–adjusted study of statin use effect on long-term mortality
ovascular repair of AAA (731 patients) or TAA (59 patients) was done.
ciated with decreased long-term mortality in patients with AAA (adjusted
.379 to 0.993, P0.047), but not for patients with TAA (adjusted HR
7 to 21.942; P0.647).
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e noted in Section 14.
2.1.1. RECOMMENDATIONS FOR BLOOD
ESSURE CONTROL
ASS I
Antihypertensive therapy should be administered to hyperten-
sive patients with thoracic aortic diseases to achieve a goal of
less than 140/90 mm Hg (patients without diabetes) or less
than 130/80 mm Hg (patients with diabetes or chronic renal
disease) to reduce the risk of stroke, myocardial infarction,
heart failure, and cardiovascular death. (415–419) (Level of
Evidence: B)
Beta adrenergic–blocking drugs should be administered to all
patients with Marfan syndrome and aortic aneurysm to reduce
the rate of aortic dilatation unless contraindicated. (88) (Level
of Evidence: B)
ASS IIa
For patients with thoracic aortic aneurysm, it is reasonable to
reduce blood pressure with beta blockers and angiotensin-
converting enzyme inhibitors (412) or angiotensin receptor
blockers (89,413) to the lowest point patients can tolerate
without adverse effects. (88,410,411) (Level of Evidence: B)
An angiotensin receptor blocker (losartan) is reasonable for
patients with Marfan syndrome, to reduce the rate of aortic
dilatation unless contraindicated. (89,90) (Level of Evi-
dence: B)
reatment of hypertension to reduce end points of MI, stroke,
d death is well established with many randomized clinical
ials (420). In the Jikei Heart Study, Japanese patients who
ceived valsartan along with other antihypertensive therapy
d a significantly lower rate of cardiovascular morbidity and
ortality compared with patients treated without valsartan.
eductions noted in particular included lower incidence of
roke, transient ischemic attack (TIA), angina pectoris, and
art failure. Moreover, pertinent to this guideline, there was
significant reduction in the incidence of AoD in the
lsartan-treated patients, which contributed to the reduction
overall cardiovascular morbidity and mortality (413).
Currently, beta adrenergic blockade serves as the founda-
n of the medical regimen because of demonstrated inhibi-
n of aneurysm expansion in patients with Marfan syn-
ome. Shores and colleagues (88) randomized 70 patients
ith Marfan syndrome to propranolol or placebo in a open-
bel study demonstrating an attenuated rate of expansion
er the 10-year follow-up. Dietz and colleagues (91) dem-
strated that angiotensin receptor blocker therapy reduces
eurysm expansion in animal models of Marfan syndrome.
his group has also recently demonstrated that angiotension
ceptor blocker therapy slowed the rate of progression of
ogressive aortic root dilatation in a preliminary study of 18
diatric patients with Marfan syndrome (89). Both beta
ockade and angiotensin II receptor blockade therapy are
ing further investigated in a randomized trial for patients
ith Marfan syndrome (90).
Lifestyle modifications of diet, weight reduction for over-
eight or obese patients, moderation of alcohol consumption,
d aerobic exercise are standard approaches to treat hyper- plnsion (421), but pharmacological therapy is usually re-
ired for patients with thoracic aortic diseases.
2.1.2. RECOMMENDATION FOR DYSLIPIDEMIA
ASS IIa
Treatment with a statin to achieve a target LDL cholesterol of
less than 70 mg/dL is reasonable for patients with a coronary
heart disease risk equivalent such as noncoronary atheroscle-
rotic disease, atherosclerotic aortic aneurysm, and coexistent
coronary heart disease at high risk for coronary ischemic
events. (422–425) (Level of Evidence: A)
he National Cholesterol Education Program ATP III recom-
ends that patients with noncoronary atherosclerosis be
eated like patients with established coronary heart disease
26). Atherosclerosis in the aorta, like atherosclerosis in any
ncoronary vascular bed, markedly increases the risk of MI
d stroke. As a result of this high-risk status (greater than
% event rate in 10 years), the goal for hypolipidemic
erapy is an LDL level less than 100 mg/dL. Initial therapy
these patients should be a statin. After the National
holesterol Education Program ATP III guidelines were
leased in 2001, the Heart Protection Study reported in 2002
at patients with atherosclerosis and a total cholesterol level
eater than 135 mg/dL benefited from the addition of
mvastatin 40 mg/d (427). The RR reductions remained even
hen LDL started at less than 100 mg/dL. In concert with
ta from patients with acute coronary syndromes, the more
cent ACC/AHA Guidelines for the Management of Patients
ith Peripheral Arterial Disease also gave a Class IIa
commendation suggesting the use of a statin to achieve a
rget LDL of less than 70 mg/dL for patients at very high risk
ischemic events is reasonable (4).
There are experimental data demonstrating a delayed
velopment of atherosclerosis and prevention of aneurysm
velopment by statins (428–430). However, there are no
inical outcomes data that justify their use acutely or suggest
at statins prevent expansion after thoracic aortic aneurysms
ve developed.
2.1.3. RECOMMENDATION FOR SMOKING CESSATION
ASS I
Smoking cessation and avoidance of exposure to environmen-
tal tobacco smoke at work and home are recommended.
Follow-up, referral to special programs, and/or pharmacother-
apy (including nicotine replacement, buproprion, or vareni-
cline) is useful, as is adopting a stepwise strategy aimed at
smoking cessation (the 5 A’s are Ask, Advise, Assess, Assist,
and Arrange). (431–432b) (Level of Evidence: B)
here are no randomized or prospective trials that have
vestigated the effect of smoking cessation on thoracic aortic
sease. Patients with thoracic aortic aneurysm who smoke
ve double the rate of aneurysm expansion (433). Aneurysm
pansion and rupture after Type B dissection are not affected
cigarette smoking (434). Smoking cessation reduces the
te of MI and death in patients with noncoronary atheroscle-
sis (435). Patients who smoke require close follow-up in
njunction with medical and other support to achieve com-
ete smoking cessation.
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ocation of Disease
2.2.1. ASCENDING AORTA AND AORTIC SINUSES
2.2.1.1. Recommendations for Asymptomatic
atients With Ascending Aortic Aneurysm
ASS I
Asymptomatic patients with degenerative thoracic aneurysm,
chronic aortic dissection, intramural hematoma, penetrating
atherosclerotic ulcer, mycotic aneurysm, or pseudoaneurysm,
who are otherwise suitable candidates and for whom the
ascending aorta or aortic sinus diameter is 5.5 cm or greater,
should be evaluated for surgical repair. (371) (Level of Evi-
dence: C)
Patients with Marfan syndrome or other genetically mediated
disorders (vascular Ehlers-Danlos syndrome, Turner syndrome,
bicuspid aortic valve, or familial thoracic aortic aneurysm and
dissection) should undergo elective operation at smaller diam-
eters (4.0 to 5.0 cm depending on the condition; see Section
5) to avoid acute dissection or rupture. (81,114,143,371,
436–439) (Level of Evidence: C)
Patients with a growth rate of more than 0.5 cm/y in an aorta
that is less than 5.5 cm in diameter should be considered for
operation. (Level of Evidence: C)
Patients undergoing aortic valve repair or replacement and
who have an ascending aorta or aortic root of greater than 4.5
cm should be considered for concomitant repair of the aortic
root or replacement of the ascending aorta. (Level of Evi-
dence: C)
ASS IIa
Elective aortic replacement is reasonable for patients with
Marfan syndrome, other genetic diseases, or bicuspid aortic
valves, when the ratio of maximal ascending or aortic root area
( r2) in cm2 divided by the patient’s height in meters exceeds
10. (16,143) (Level of Evidence: C)
It is reasonable for patients with Loeys-Dietz syndrome or a
confirmed TGFBR1 or TGFBR2 mutation to undergo aortic
repair when the aortic diameter reaches 4.2 cm or greater by
transesophageal echocardiogram (internal diameter) or 4.4 to
4.6 cm or greater by computed tomographic imaging and/or
magnetic resonance imaging (external diameter). (78) (Level
of Evidence: C)
ortic diameter is a major criterion for recommending
ective operation in asymptomatic patients with aneurysm
the thoracic and thoracoabdominal aorta. This assumes
at the risk of operation is low (less than 5%). Currently,
rtic diameter perpendicular to the axis of flow as
easured by CT is the dimension most often used to
termine the size of the enlarged aorta. This recommen-
tion is based on the observation that the risk of an
verse event (rupture, dissection, death) exceeds the risk
elective operation when the maximum diameter exceeds
5 to 6.0 cm (374,436,437,440) (Figure 30). Formulas
at incorporate height and aortic cross-sectional area have
en developed to establish thresholds for operation in
orter patients but are less widely used (16,143). paThe morphology and histopathology of thoracic aortic
largements affect the natural history of aortic diseases,
cluding the risk of rupture or dissection, and thus can
fluence the decision to intervene (Figures 31 and 32).
usiform aneurysms are most common and behave in a
latively predictable manner. Aortic dimension can thus
used as an indication for operation. Saccular aneurysms
cur less frequently and may be associated with a greater
sk of rupture. Many of these are actually pseudoaneu-
sms, which can develop after previous trauma or aortic
rgery, or with PAUs, and which result in focal disrup-
on or weakening of the layers of the aorta.
Patients with substantial dilatation of the aortic sinuses
ay develop asymptomatic aortic regurgitation as a result
loss of coaptation of the otherwise normal aortic valve
sps. Patients with associated bicuspid aortic valve disease
ay have asymptomatic stenosis or regurgitation of the
lve. In these patients, the valvular disease may be an
dication for operative intervention (5).
2.2.1.2. Recommendation for Symptomatic Patients
ith Thoracic Aortic Aneurysm
ASS I
Patients with symptoms suggestive of expansion of a thoracic
aneurysm should be evaluated for prompt surgical intervention
unless life expectancy from comorbid conditions is limited or
quality of life is substantially impaired. (Level of Evidence: C)
ymptoms associated with thoracic aneurysms usually
velop later in the course of enlargement of the aorta and
ost commonly result from impingement of the aneurysm
adjacent structures. Aneurysms of the ascending aorta
d aortic sinuses may result in symptoms related to the
rtic regurgitation that develops as a result of the pro-
essive aortic enlargement. Chest or back pain in the
esence of an enlarged thoracic aorta is a predictor of
rtic rupture (336,441). Patients who develop an acute
ype A AoD commonly present with severe chest or back
gure 30. Effect of aortic aneurysms diameter on risk of com-
ication. For thoracic aortic aneurysms of all etiologies.
apted from Elefteriades et al (437).in.
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neurysm. At the time of this writing, endovascular stent
afts have not been approved by the US Food and Drug
dministration for treatment of aneurysms or other con-
tions of the ascending aorta.
2.2.1.4. Recommendations for Open Surgery for
scending Aortic Aneurysm
ASS I
Separate valve and ascending aortic replacement are recom-
gure 31. Ascending aortic aneurysm of degenerative etiology. C
tery disease; CT, computed tomographic imaging; and MR, magmended in patients without significant aortic root dilatation, in seelderly patients, or in young patients with minimal dilatation
who have aortic valve disease. (Level of Evidence: C)
Patients with Marfan, Loeys-Dietz, and Ehlers-Danlos syn-
dromes and other patients with dilatation of the aortic root and
sinuses of Valsalva should undergo excision of the sinuses in
combination with a modified David reimplantation operation if
technically feasible or, if not, root replacement with valved
graft conduit. (134,164,442–444) (Level of Evidence: B)
scending Aortic Aneurysms: The extent of aortic re-
dicates coronary artery bypass graft surgery; CAD, coronary
sonance imaging.ABG inction and the need for ancillary procedures are deter-
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ncillary procedures that may be performed concurrently
clude coronary artery bypass graft surgery, valve replace-
ent or repair, repair of cardiac septal defects, closure of
scular fistulas, and ablative therapy for arrhythmias.
For patients with isolated aneurysms confined to the
cending aorta, resection and graft replacement is the
ost commonly performed and recommended procedure.
lternatively, reduction aortoplasty with or without exter-
l reinforcement has only been performed in very limited
gure 32. Ascending aortic aneurysms associated with genetic d
ns for Asymptomatic Patients With Ascending Aortic Aneurysm
d Associated Congenital Variants in Adults (Section 6.1). CABG
sease; CT, computed tomographic imaging; and MR, magnetic rrcumstances (445,446). paFor patients with aortic valve stenosis who require valve
placement, the choice of valve substitute is determined
age of the patient, presence of comorbid disease, risk of
mplications related to anticoagulation and reoperation,
d life expectancy (139).
For patients with aortic regurgitation associated with a
cuspid aortic valve, repair of the aortic valve with or
ithout root remodeling or tailoring of the sinotubular
nction is preferable if the valve is not severely fibrotic or
lcified (99,140). For patients with a dilated aortic root,
. *Depends on specific genetic condition. †See Recommenda-
n 9.2.2.1.1) and Recommendations for Bicuspid Aortic Valve
es coronary artery bypass graft surgery; CAD, coronary artery
ce imaging.isorder
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lves are implanted.
Ascending aneurysms larger than 4.5 to 5.0 cm require
pair or tube graft replacement when aortic valve repair or
placement is the primary indication for operation (5). In
derly patients, ascending aortic aortoplasty when the
rtic diameter does not exceed 5.0 cm may be an
ceptable alternative.
Aortic Valve and Root: In patients with aortic valve
gurgitation and root dilatation, aortic valve repair and
ot-sparing procedure may be the primary procedure. In
tients with Marfan syndrome or with tricuspid aortic
lve regurgitation, a modification of the David reimplan-
tion operation may be considered. (94,95,97–99,447)
omposite valve grafts with either biological or mechan-
al valves are an alternative option, particularly for valvular
enosis (99,140,441,448).
2.2.2. RECOMMENDATIONS FOR AORTIC ARCH ANEURYSMS
ASS IIa
For thoracic aortic aneurysms also involving the proximal
aortic arch, partial arch replacement together with ascending
aorta repair using right subclavian/axillary artery inflow and
hypothermic circulatory arrest is reasonable. (222,449,450)
(Level of Evidence: B)
Replacement of the entire aortic arch is reasonable for acute
dissection when the arch is aneurysmal or there is extensive
aortic arch destruction and leakage. (222,450) (Level of
Evidence: B)
Replacement of the entire aortic arch is reasonable for aneu-
rysms of the entire arch, for chronic dissection when the arch
is enlarged, and for distal arch aneurysms that also involve the
proximal descending thoracic aorta, usually with the elephant
trunk procedure. (451–453) (Level of Evidence: B)
For patients with low operative risk in whom an isolated
degenerative or atherosclerotic aneurysm of the aortic arch is
present, operative treatment is reasonable for asymptomatic
patients when the diameter of the arch exceeds 5.5 cm. (374)
(Level of Evidence: B)
For patients with isolated aortic arch aneurysms less than 4.0
cm in diameter, it is reasonable to reimage using computed
tomographic imaging or magnetic resonance imaging, at 12-
month intervals, to detect enlargement of the aneurysm. (Level
of Evidence: C)
For patients with isolated aortic arch aneurysms 4.0 cm or
greater in diameter, it is reasonable to reimage using com-
puted tomographic imaging or magnetic resonance imaging, at
6-month intervals, to detect enlargement of the aneurysm.
(Level of Evidence: C)
neurysms of the aortic arch are commonly associated with
eurysmal disease or dissection of the ascending aorta or the
jacent descending thoracic aorta, and the indications for
erative intervention in these patients are those for the
jacent aortic segment. This relates to the need for hypo-
ermic cardiopulmonary bypass and an interval of hypother-
ic circulatory arrest, and to higher operative mortality and
roke rates than those observed following operation forolated aneurysms of the ascending or descending thoracic
rta (451–459). As with ascending aneurysms, a growth rate
more than 0.5 cm/y in the absence of symptoms could be
nsidered an indication for operation.
Symptoms associated with aortic arch aneurysms such as
arseness resulting from stretching of the left recurrent
ryngeal nerve, dysphagia, dyspnea, and chest or back pain
e indications for operative intervention for patients with
ch aneurysms unless life expectancy is quite limited.
itability for operative intervention involves similar risk
sessment to that for aneurysm or other disorders of the
cending aorta and aortic root.
The innominate, left carotid, and left subclavian arteries
ay require separate grafting. For short periods of circulatory
rest, the use of retrograde or antegrade brain perfusion has
t conclusively been shown to add further brain protection;
wever, use of the subclavian or axillary artery bypass with
side graft reduces the risk of stroke (449).
2.2.2.1. Open Surgery. At present, endovascular stent
afts have not been approved by the US Food and Drug
dministration for treatment of aneurysms or other con-
tions of the aortic arch. For patients with large aneu-
sms who are not candidates for conventional open
eration, experience is accumulating with operative pro-
dures that involve translocation of the brachiocephalic
teries from the aortic arch using branch grafts from the
oximal ascending aorta, and placement of an endovas-
lar graft into the distal ascending aorta, the entire aortic
ch, and a segment of the adjacent descending thoracic
rta (371,460,461).
Cardiopulmonary bypass with some degree of hypother-
ia is required for operations that require replacement of
e aortic arch. Brain protection can be achieved by
ofound hypothermia alone, direct antegrade perfusion of
or more of the brachiocephalic arteries, or retrograde
rfusion using cold oxygenated blood that is infused into
e superior vena cava during the arrest period
11,449,462–467) (see Section 14.5.1). The aortic arch is
placed with a synthetic graft. The brachiocephalic arter-
s are attached to the graft using a patch of the aorta
hich contains the origins of the 3 vessels or separately
ing a graft that contains 3 branches. The proximal and
stal ends of the aortic graft are attached to normal
gments of ascending and descending thoracic aorta.
An “elephant trunk” procedure has been used to recon-
ruct the arch and then provide a Dacron graft landing
ne for endovascular stent graft treatment of descending
oracic aortic aneurysms (Figure 33).
2.2.3. DESCENDING THORACIC AORTA AND
ORACOABDOMINAL AORTA
2.2.3.1. Recommendations for Descending Thoracic
orta and Thoracoabdominal Aortic Aneurysms
ASS I
For patients with chronic dissection, particularly if associated
with a connective tissue disorder, but without significant
2.
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exceeding 5.5 cm, open repair is recommended. (371,382,
468) (Level of Evidence: B)
For patients with degenerative or traumatic aneurysms of the
descending thoracic aorta exceeding 5.5 cm, saccular aneu-
rysms, or postoperative pseudoaneurysms, endovascular stent
grafting should be strongly considered when feasible.
(371,469) (Level of Evidence: B)
For patients with thoracoabdominal aneurysms, in whom endo-
vascular stent graft options are limited and surgical morbidity
is elevated, elective surgery is recommended if the aortic
diameter exceeds 6.0 cm, or less if a connective tissue
disorder such as Marfan or Loeys-Dietz syndrome is present.
(371) (Level of Evidence: C)
For patients with thoracoabdominal aneurysms and with end-
organ ischemia or significant stenosis from atherosclerotic
visceral artery disease, an additional revascularization proce-
dure is recommended. (470) (Level of Evidence: B)
t the time of publication of this document, 3 endovas-
lar stent grafts have been approved by the US Food and
rug Administration only for aneurysms involving the
scending thoracic aorta. Although the feasibility and
fety of endovascular stent grafting of the descending
rta have been demonstrated for other pathologic condi-
ons including acute and chronic Type B AoD, IMH,
AU, acute traumatic aortic transsection, and pseudoan-
rysms, these conditions are currently considered “off
bel.”
There are no published randomized trials that compare
e outcomes of endovascular stent grafting with conven-
onal open operation or nonoperative management. Thus,
commendations for use are based principally on obser- pational studies and nonrandomized comparisons of co-
orts of patients.
2.2.3.2. Endovascular Versus Open Surgical Ap-
roach. The potential advantages of endovascular graft-
g over open operation include the absence of a thora-
tomy incision and the need for partial or total
tracorporeal circulatory support and clamping of the
rta, as well as lower hospital morbidity rates and shorter
ngth of hospital stay.
Endovascular grafting may be of particular value in
tients with significant comorbid conditions (older age,
bstantial cardiac, pulmonary and renal dysfunction) who
ould be considered poor or noncandidates for open
rgery. Patients who are not considered candidates for
en surgery but who have undergone endovascular graft-
g have substantially poorer long-term outcomes than
tients who are reasonable candidates for open operation
d are treated with endografts (471). Furthermore, inter-
ntion (endovascular stent graft or open surgical graft
placement) for a descending aneurysm has real risks of
ortality and morbidity, including the risk of spinal cord
chemic injury. All physicians should work collaboratively
ong specialities during the initial decision-making steps
determine via consensus whether a particular patient’s
thology, risk factors, and projected natural history if
eated medically justify an intervention on the descending
oracic aorta, either a stent graft or an open procedure.
There are no data that conclusively demonstrate that the
evalence of spinal cord ischemic injury (lower extremity
Figure 33. Elephant trunk procedure. Left,
Preoperative disease. Middle, Stage I with
replacement of the ascending aorta and arch
with a Dacron graft with the distal graft su-
tured circumferentially to the aorta distal to
the left subclavian artery and the free end of
the graft (“elephant trunk”) within the de-
scending aneurysm. Right, Completion of the
procedure using an endovascular stent graft
attached proximally to the “elephant trunk”
and the distal end secured to a Dacron graft
cuff. Images reprinted with permission from
the Cleveland Clinic Foundation.ralysis or paresis) is less for endovascular approaches
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ta to indicate that overall costs of medical care are lower
ith endovascular procedures. Although the costs of the
itial hospitalization may be lower because of reduced
erative time and a shorter length of stay, these benefits
ay be negated by the cost of the devices, the need for
bsequent interventions, and the cost and dissatisfaction
repeated imaging studies, which are necessary in the
stoperative period (472,473).
Some patients are not suitable candidates for endovas-
lar grafting procedures. Absence of suitable “landing
nes” above and below the aneurysm (usually 2 to 3 cm of
rmal diameter aorta without circumferential thrombus)
a contraindication. A width of the aorta at the landing
nes that exceeds the recommended width for the largest
ailable endovascular grafts (generally 10% to 15% larger
an the width of the aorta) is also a contraindication.
Lack of vascular access sites to insert the relatively
rge-bore sheaths that are necessary for deployment of the
afts is also a contraindication. Severe atherosclerosis and
traluminal thrombus of the aorta may increase the risk of
bolic stroke during manipulation of guidewires and
theters and represents a relative contraindication (474).
2.2.3.3. End-Organ Preservation During Thoracic
ndograft Implantation. Because aneurysmal disease
n involve any portion of the aorta, organ preservation
ring repair of either aneurysmal disease or dissection is
important part of the implant procedure. Aneurysms
volving the aortic arch pose a significant risk to cerebral
d upper extremity blood flow with endovascular repair.
he need to cover either the left common carotid or the
nominate artery to treat arch aneurysmal disease is
frequent. Intentional coverage of the left subclavian
tery is more common, occurring in approximately 50% of
oracic endograft implants. Most patients tolerate cover-
e of the left subclavian artery without upper extremity
chemia (475–478), but recently several groups have
ggested that these patients may be at higher risk of
rioperative stroke and spinal cord ischemic injury (479–
1). In the Talent VALOR trial, the need for intentional
eimplant left subclavian artery bypass was only 5.2%
82). To minimize the risk associated with intentional
verage of the left subclavian artery, it is recommended
at the patency of the contralateral right subclavian and
rtebral arteries be determined preoperatively by CT,
R, or invasive angiography. Additionally, verification
at the vertebral arteries communicate at the basilar artery
either transcranial Doppler or angiography is also
commended. If these steps are taken to ensure that the
ntralateral posterior circulation is intact, the need to
rform a left subclavian artery bypass postoperatively to
event symptomatic arm claudication or vertebral basilar
sufficiency is infrequent.
Spinal cord ischemia leading to paralysis is one of the
rious potential complications of the thoracic endograft
ocedure. Intercostal arteries are intentionally covered by coe endograft. There is evidence that the risk of spinal cord
chemia may be greater when treatment involves coverage
most of the descending thoracic aorta (e.g., from left
bclavian to celiac artery) (483). Additionally, patients
ho have had previous repair of abdominal aneurysm
ither open or endovascular) are at increased risk for
inal cord ischemia and paraplegia (484). In 1 study, the
sk of spinal cord ischemia was 10% to 12% in patients
ith previous abdominal aneurysm repairs and 2% in
tients who did not have previous abdominal aneurysm
pairs (485). In circumstances where it is necessary to
ver most of the descending thoracic aorta or if the
tient has had a previous abdominal aneurysm repair,
rebrospinal fluid (CSF) pressure monitoring and drain-
e are an important strategy to minimize the risk of
raplegia (486).
Treatment of TAAs with an endograft may require
tentional coverage of the celiac and/or superior mesen-
ric arteries to achieve a seal at the distal attachment site.
these instances, a superior mesenteric-to-celiac artery
pass graft or an aorta-to-superior mesenteric and/or
liac artery bypass graft has been used as a first-stage
branching procedure before proceeding with the en-
graft implant (Figure 34). However, risk of the de-
anching operation may be no lower than conventional
en repair, and therefore these operative approaches are
rformed selectively (487). Fenestrated grafts are in
velopment and are undergoing clinical trials. Roselli et
(488) published initial results in the first 73 patients
dergoing in situ endovascular repair of extensive TAAs
ing a branch endograft with promising results in a
igh-risk population. With careful attention to preserva-
on of blood flow to the mesenteric vessels, the incidence
mesenteric ischemia with endograft implants is approx-
ately 3% (482). Most instances of mesenteric ischemia
e the result of emboli rather than malperfusion owing to
verage or occlusion of a mesenteric vessel.
AoDs pose a complex situation for intestinal, renal, or
wer extremity perfusion, as the branches of the aorta in
e abdominal cavity may be perfused from either the true
false lumen. Often, both the true and false lumens are
tent and some of the visceral, renal, or lower extremity
ssels are fed by one channel and the remainder by the
her. Thus, the operator must consider how blood flow
aches vital organs in the abdominal cavity before con-
dering treatment of an AoD with an endograft. In most
ses, where descending thoracic dissections are treated
ith an endograft, the important treatment principle is to
ver the proximal entry tear obliterating the false lumen.
owever, if the false lumen supplies blood flow to the
sceral vessels, blood flow to these organs may be com-
omised after endograft implantation. Stenting of the
ssels at risk from the true lumen or establishing flow
mmunication between true and false lumen more dis-
lly with a fenestration procedure may prevent such
mpromise. In cases of acute Type B AoD treated with
en
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasedografts, coverage of the proximal entry site into the
lse lumen may result in healing of the tear downstream
ith restoration of blood flow from the true lumen
ithout the need for adjunctive fenestration procedures
90).
2.2.3.4. Periprocedural Complications of Endograft
rocedures. The acute complications of thoracic en-
graft procedures are related to problems with access and
ith device implantation. Vascular access is a substantial
sue with thoracic endograft procedures. The sheath
quired to deploy endovascular grafts is size 20 French or
eater and can be up to size 25 French. Many patients
ave femoral arteries that are too small to accommodate
ch large sheaths. Use of the iliac artery or the aorta for
cess is required in approximately 15% of the patients.
fection at the access site is not an infrequent complica-
on. Bleeding complications are less frequent. Average
ood loss in the Talent VALOR trial was 371 mL, and
e need for transfusion in the STARZ TX2 clinical trial
tudy results on the Zenith TX2 Endovascular Graft for
gure 34. Schema of TAA treated with initial left iliac artery–to–
ft renal artery–to–superior mesenteric artery bypass graft and
bsequent placement of a thoracoabdominal endograft. Proxi-
al superior mesenteric artery and left renal arteries were li-
ted. SMA indicates superior mesenteric artery; and TAA, tho-
coabdominal aneurysm. Adapted from Flye et al (489).e Thoracic Aortic Aneurysms) was 3% (469,482). bahromboemboli to mesenteric, renal, or lower extremity
ssels can also occur (491).
Major adverse events related to the device occur in 10%
12% of patients in the initial 30-day perioperative
riod. Stroke was observed in 2.5% of the patients in the
TARZ TX2 clinical trial (469) and 3.6% in the Talent
ALOR trial (482). It has been reported to be as high as
in other studies (474,492). Most strokes occur as a
sult of atheroemboli from the transverse aortic arch with
anipulation of the guidewires and device in the arch
ssels (474). Paraplegia varied from 1.3% in the STARZ
X2 clinical trial to 1.5% in the Talent VALOR trial to
in the TAG trial (469,482,493).
Cardiac complications, principally MI, occur rarely (2%
4%) (469,482). Cardiac tamponade or rupture is rare
d may be caused by either the stiff guidewires that are
quired to deliver the devices or excessive afterload
eated by the balloons that are inflated to produce a seal
the graft to the aortic wall. Ventricular tachycardia or
ntricular fibrillation has been reported (469). Pulmonary
mplications include postoperative pneumonias, which
cur in less than 5% of patients. Acute renal failure
quiring dialysis is also uncommon, reported to occur in
3% of patients in the Talent VALOR trial (482). Device
plant infection is exceedingly rare and has been ob-
rved mainly in situations where the device was implanted
an infected medium emergently (i.e., mycotic aneu-
sms or aortoenteric fistulae) (482).
Endoleak is defined as the persistence of blood flow
tside the lumen of the endoluminal graft but within the
eurysm sac, based on imaging. Endoleaks are classified
ble 14. Classification of Endoleaks
pe Cause of Perigraft Flow Sequelae and Treatment Strategy
Inadequate seal at
proximal and/or distal
graft attachment site
Systemic arterial pressure transmitted to
the aneurysm sac, leading to expansion
and rupture. Should be repaired when
diagnosed.
Retrograde aortic
branch arterial blood
flow into aneurysm sac
May spontaneously thrombose. If
aneurysm is stable or shrinking,
observe. If aneurysm is expanding,
embolic occlusion of branch artery
indicated but often difficult.
Structural failure of
endograft (e.g., stent
graft fractures, holes in
fabric, junctional
separations)
Systemic arterial pressure transmitted to
the aneurysm sac, leading to expansion
and rupture. Should be repaired when
diagnosed.
Stent graft fabric
porosity
Noted at time of implantation and
usually resolved with reversal of
anticoagulation.
Expansion of aneurysm
without demonstrable
endoleak, also called
“endotension”
Reline the endograft with a second
endograft.
Adapted from Veith et al (494).sed on the source of blood flow (Table 14).
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on site is infrequent but usually reported with stent
stems that have uncovered or bare proximal attachment
ents (495–499). Involution or infolding of the en-
grafts may occur and has been most frequently reported
ith grafts applied to a relatively small aorta where
ersizing can be substantial, especially in trauma cases
66,500,501). Infoldings can also occur when there is
adequate conformity of the device to the aortic wall in a
gion of marked curvature or “beaking” (see Figure 27).
his leads to collapse of the endograft, gross endoleak, and
e potential for acute occlusion of flow to the descending
oracic aorta. It can be prevented (or managed after it
curs) with implantation of a reinforcing stainless steel
ent at the proximal leading edge of the implant (500).
Late complications of thoracic aortic endografting in-
ude endoleaks, continued aneurysm growth, metal fa-
gue and stent fracture and kinking, detachment, migra-
on, perforation, and infection of the implanted device.
ndoleaks occur in 10% to 20% of patients (482). The
equency is greatest in the first month following implan-
tion and declines over the ensuing 5 years (502). The
ost frequent type of endoleak is Type IA, or proximal
tachment site failure (see Section 8.6) (469,482,503–
5). Migration occurs infrequently—at 1-year follow-up
0.4% of cases in the TAG clinical trial and 3.9% of cases
the Talent VALOR trial (469,482,506).
Late perforations of the aorta by the endograft can occur
d are common with the use of oversized grafts and/or
afts with bare or uncovered stents (507,508). Most late
vice complications such as endoleak and migration are
eatable with implantation of graft extensions. The overall
ed for repeat interventions to maintain endograft integ-
ty is 6% to 7%, most commonly in the form of implan-
tion of an extension cuff. Conversions to open operation
e rarely needed (1% to 2%) (476,480,505,509,510). Late
mplications (9 to 24 months) include stent fractures,
hich are often asymptomatic (511). There are case
ports of fractures leading to endograft dysfunction,
doleak, migration, and/or embolization (512). En-
graft infection, usually as a result of an ongoing systemic
fection, or as a result of infected structures adjacent to
e graft (513,514), is uncommon, but when it occurs, it is
ry difficult to eradicate without explantation of the device
d, without explantation, can lead to aortic rupture (515).
The experience with the use of endografts for the
eatment of acute descending AoD is limited. A meta-
alysis of 609 published cases suggests that when en-
grafts are used, mortality is slightly higher (5.3%) and
te conversions to open procedures are more frequent
.5%) than data reported for treatment of aneurysms. The
sk of major complications including stroke, paraplegia,
d aneurysm rupture appears to be similar in both
nditions (516). A complication unique to endograft
eatment of acute Type B dissections is conversion of the
ssection to a retrograde Type A dissection, creating a virgical emergency (480,517). Until and unless this life-
reatening complication is understood and eliminated,
dograft treatment of acute Type B dissections should be
dertaken at institutions with a team qualified to perform
en aortic surgery.
In the absence of Level A or Level B evidence regarding
e relative efficacy of open and endovascular procedures
r treatment of descending aortic aneurysms, no firm
commendations can be made regarding the optimal
ethod of treatment. Among comparable patients treated
ith either open or endovascular procedures, the midterm
sults can be anticipated to be equivalent. The early
ortality advantage of endovascular procedures may be
st during follow-up such as that seen with endovascular
eatment of AAAs (518,519). The long-term durability of
dovascular stent grafts is uncertain; currently, available
afts may have a durability of no more than 10 years.
ounger patient age may be a relative contraindication to
dografting.
There are no data to indicate that endovascular stent
afting should be performed in patients with asymptom-
ic descending aortic aneurysms that are less than 5.5 cm
diameter, because the risk of operation (approximately
) exceeds the risk of rupture or dissection (371) (Table
). Undoubtedly, as new iterations of devices are intro-
ced, these guidelines will change.
2.2.3.5. Open Surgical. Diseases of the aorta that
quire extensive thoracoabdominal surgical or interven-
onal approaches fall into 3 large groups: 1) degenerative
eurysms, 2) AoD resulting in subsequent aneurysms or
ble 15. Summary of Society of Thoracic Surgeons
commendations for Thoracic Stent Graft Insertion
tity/Subgroup Classification
Level of
Evidence
netrating ulcer/intramural hematoma
Asymptomatic III C
Symptomatic IIa C
ute traumatic I B
ronic traumatic IIa C
ute Type B dissection
Ischemia I A
No ischemia IIb C
bacute dissection IIb B
ronic dissection IIb B
generative descending
5.5 cm, comorbidity IIa B
5.5 cm, no comorbidity IIb C
5.5 cm III C
ch
Reasonable open risk III A
Severe comorbidity IIb C
oracoabdominal/severe comorbidity IIb C
Reprinted from Svensson et al (371).sceral ischemia, and 3) occlusive disease of the visceral
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mptoms, risk of death from rupture, and end-organ
chemia, provided associated comorbidity does not pre-
nt surgical repair. In patients with lower chest or upper
dominal pain, CT or MR is performed to determine if
e patient has a contained rupture, leak, or an aneurysm
pinging on surrounding structures that may be causing
in. The perioperative risk of death is approximately 80%
ith emergency surgery; a few patients will recover with-
t a major complication limiting quality of life, and few
ill be long-term survivors because of comorbid disease. In
tients with pain from compression of surrounding struc-
res, if comorbid disease is not a factor, results are
nsiderably better with a 10% to 20% risk of death. In
tients undergoing elective surgery, the risk of death is
to 10%, depending on the extent of repair.
The extent of repair for TAA is classified by the
rawford types: Type I is a repair that extends from the
oximal descending aorta above T6 to the renal arteries;
ype II, the highest risk group, extends from the proximal
scending aorta above T6 to below the renal arteries;
ype III extends from the distal descending aorta below
6 to below the diaphragm for variable extents; and Type
extends from the diaphragm and involves most of the
dominal aorta. This classification correlates with the risk
paralysis, renal failure, and death.
Open surgical repair of TAA improved over the past 15
ars, particularly on preventing postoperative paralysis.
istorically, one of the most serious complications was
ralysis, either paraparesis or paraplegia, caused by spinal
rd injury whose risk is for Type I TAA repair, 15%; for
ype II, 30%; Type III, 7%; and for Type IV, 4% (381).
urrent risk of paralysis is 3% to 5%, depending somewhat
the extent of repair (381,382,520–526).
The risk of renal failure may be reduced by preoperative
y admission, fluid hydration starting the day before surgery,
d the addition of bicarbonate to the hydration regimen and
pothermia protection during the operative procedure.
2.2.3.6. End-Organ Preservation During Open Tho-
coabdominal Repairs. For thoracoabdominal aortic re-
irs done in combination with proximal repairs of the
rtic arch, the key vital end organs to protect are the heart
d brain. Flooding the field with CO2 appears to be
neficial (527,528). When the aortic arch requires repair,
ypothermic circulatory arrest is usually required. Protec-
on of the brain involves ensuring that calcium plaques or
heromata are not disturbed to prevent brain emboliza-
on. The temperature and where it is best measured, at
hich circulatory arrest is commenced, are debated but
ost large series have recommended circulatory arrest at a
mperature below 20°C (211).
Perfusion of the celiac artery or superior mesenteric
tery does not appear to be needed to protect the
dominal organs in most patients where moderate hypo-
ermia (30° to 32°C) is used. Protection of the left lung
ring left thoracotomy repairs is important to avoid jucerations and bleeding into the parenchyma. Deflation of
e left lung may be of benefit. However, disruption of the
sceral pleura with attendant complications of bleeding
d air leak may be unavoidable, particularly if adhesions
e present due to prior surgery or inflammatory changes.
2.2.3.7. Aortic Dissection With Malperfusion. Re-
l, mesenteric, lower extremity, or cord malperfusion
companies up to one third of acute AoD and roughly
ubles mortality (248,529,530). In the case of Type A
oD with malperfusion, there is controversy over whether
tient outcomes are improved by first repairing the aorta
d then treating persistent malperfusion (531) or by first
rrecting the malperfusion and then repairing the aorta
47,532). The general consensus is to first repair the
rta, because this will correct malperfusion in most
tients. In the case of Type B AoD, there is a general
nsensus that medical management should be supple-
ented by open or endovascular intervention when there
evidence for renal, mesenteric, lower extremity, or cord
alperfusion (248,490,533).
0. Special Considerations in Pregnant
atients With Aortic Disease
0.1. Effects of Pregnancy on the Aorta
ysiologic effects of pregnancy may have a profound effect
t only on aortic stress but potentially on arterial ultra
ructure as well. The pregnant state is characterized by
creases in maternal blood volume, heart rate, blood pres-
re, stroke volume, and cardiac output (534,535). Taken
gether, the combined effects lead to greater arterial wall
nsion as well as intimal shear forces. These changes begin
the first and second trimesters but are most notable in the
ird trimester and peripartum period. Whether arterial wall
eakening itself occurs during pregnancy remains controver-
al. Arterial dissection and/or rupture may occur with the
ghest incidence in the third trimester (approximately 50%)
d peripartum period (33%). In one of the few prospective
udies of pregnant patients with Marfan syndrome, 4.4% of
refully monitored patients developed aortic dissection
34). In unmonitored patients, the risk is likely higher.
0.2. Epidemiology of Chronic and Acute
ortic Conditions in Pregnancy
arfan syndrome, Ehlers-Danlos syndrome, and other non-
arfan aortic disease may manifest during pregnancy. Al-
ough clearly rare, it has been estimated that half of AoD
d/or ruptures in women younger than 40 years of age have
en associated with pregnancy (536). Most dissections occur
the ascending aorta, although dissection or rupture of
rtually any artery in the body has been described. In
dition, pregnancy-related expansion of the sinotubular
nction may lead to aortic valve insufficiency.
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.3.1. Recommendations for Counseling and
anagement of Chronic Aortic Diseases in Pregnancy
ASS I
Women with Marfan syndrome and aortic dilatation, as well as
patients without Marfan syndrome who have known aortic
disease, should be counseled about the risk of aortic dissec-
tion as well as the heritable nature of the disease prior to
pregnancy. (74,91) (Level of Evidence: C)
For pregnant women with known thoracic aortic dilatation or a
familial or genetic predisposition for aortic dissection, strict
blood pressure control, specifically to prevent Stage II hyper-
tension, is recommended. (Level of Evidence: C)
For all pregnant women with known aortic root or ascending
aortic dilatation, monthly or bimonthly echocardiographic mea-
surements of the ascending aortic dimensions are recom-
mended to detect aortic expansion until birth. (Level of Evi-
dence: C)
For imaging of pregnant women with aortic arch, descending,
or abdominal aortic dilatation, magnetic resonance imaging
(without gadolinium) is recommended over computed tomo-
graphic imaging to avoid exposing both the mother and fetus
to ionizing radiation. Transesophageal echocardiogram is an
option for imaging of the thoracic aorta. (Level of Evidence: C)
Pregnant women with aortic aneurysms should be delivered
where cardiothoracic surgery is available. (Level of Evi-
dence: C)
ASS IIa
Fetal delivery via cesarean section is reasonable for patients
with significant aortic enlargement, dissection, or severe
aortic valve regurgitation. (91) (Level of Evidence: C)
ASS IIb
If progressive aortic dilatation and/or advancing aortic valve
regurgitation are documented, prophylactic surgery may be
considered. (537) (Level of Evidence: C)
this regard, risk of major aortic complications during
egnancy appears to be low when the aortic root diameter is
ss than 4.0 cm (538). Such individuals may have one or
ore successful pregnancies. For patients with an aortic
ameter greater than 4.0 cm and Marfan syndrome, half will
ve come to prophylactic surgery during pregnancy, will
ve a rupture, or will have life-threatening growth. Optimal
eventive therapy in the pregnant woman with known aortic
sease includes use of beta blockers to control heart rate and
duce shear stresses, particularly in the third trimester and
ripartum period. Both angiotensin-converting enzyme in-
bitors and angiotensin receptor blockers are contraindicated
ring pregnancy.
0.4. Evaluation and Management of Acute
ortic Syndromes During Pregnancy
egnant women with Marfan syndrome, bicuspid aortic
lve and ascending aneurysms, Ehlers-Danlos syndrome,
d non-Marfan familial thoracic aortic aneurysm and dis-
ction may present with acute aortic syndromes at any point prring the pregnancy but are particularly prone to do so in the
st trimester, during delivery, or in the early postpartum
riod. Such women may have no knowledge of their
derlying aortic condition until presentation with their acute
rtic problem.
Obviously, acute AoD poses a huge risk for both the
other and the unborn child. Optimal treatment parallels that
nonpregnant women but with the added complication of
hen and how to deliver the child. Optimal care includes
volvement with a high-risk maternal-fetal team along with
aortic specialty team capable of medical, percutaneous,
d surgical aortic treatment. For Type A AoD occurring
ring the first or second trimester, urgent surgical repair with
gressive fetal monitoring is preferred. Fetal loss during
pothermia and cardiopulmonary bypass is common. When
ssection complicates the third trimester, urgent cesarean
ction followed by aortic repair appears to offer the best
ance for survival for the unborn child and the mother. For
ute arch or Type B AoD, medical therapy is preferred
less percutaneous stent grafting or open surgery is man-
ted by malperfusion, aortic rupture, or subacute aortic
aking (539).
1. Aortic Arch and Thoracic Aortic
theroma and Atheroembolic Disease
1.1. Recommendations for Aortic Arch
nd Thoracic Aortic Atheroma and
theroembolic Disease
ASS IIa
Treatment with a statin is a reasonable option for patients with
aortic arch atheroma to reduce the risk of stroke. (540) (Level
of Evidence: C)
ASS IIb
Oral anticoagulation therapy with warfarin (INR 2.0 to 3.0) or
antiplatelet therapy may be considered in stroke patients with
aortic arch atheroma 4.0 mm or greater to prevent recurrent
stroke. (Level of Evidence: C)
1.2. Clinical Description
ortic arch atheroma is a risk factor for ischemic stroke based
autopsy (541,542), TEE (543–548), and intraoperative
trasonographic studies (549) (Figure 35). In particular,
aques 4 mm or greater in thickness proximal to the origin of
e left subclavian artery are associated with stroke and
nstitute one third of patients with otherwise unexplained
roke (542). These patients, even on antiplatelet therapy,
rry a risk of recurrent ischemic stroke as high as 11% at 1
ar, and the risk of a new vascular event (ischemic stroke,
I, peripheral event, and vascular death) is 20%, 36%, and
% at 1, 2, and 3 years, respectively (550). The RR of new
chemic stroke was 3.8 (95% CI 1.8 to 7.8, P0.002), and
at of new vascular events was 3.5 (95% CI 2.1 to 5.9,
0.001), independent of carotid stenosis, atrial fibrillation,
ripheral artery disease, or other risk factors (550). Other
udies showed that aortic arch plaques were independent
edictors of recurrent strokes, MI and vascular death
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sk for recurrent vascular events (554).
Regarding the natural history of aortic arch atheroma, Sen
al (555) noted progression in 29% and regression (defined
an increase or decrease in plaque thickness by 1 grade or
eater, respectively) in 9%. Montgomery et al (556) reported
patients with moderate-to-severe aortic plaque noted on
itial bi/multiplanar TEE as part of a workup for cardiac or
embolic event. Over a mean of 1 year, progression was
ported in 23% and regression in 10%. Pistavos et al (557)
ed monoplanar TEE in 16 patients with familial hypercho-
sterolemia taking pravastatin to show progression in 19%
d regression in 38% over 2 years. Geraci and Weinberger
58), using supraclavicular B-mode ultrasonography of the
oximal aortic arch in 89 patients evaluated for transient
urologic symptom, noted a progression rate of 19% and a
gression rate of 18% over a mean of 7.7 months (range 3 to
months). Sen et al (559) confirmed that in patients with
roke/TIA, aortic arch atheroma progression over 12 months
associated with more vascular events.
1.3. Risk Factors
isk factors for the development of aortic atheroma include
e, sex, heredity, hypertension, diabetes mellitus, hyperlip-
emia, sedentary lifestyle, smoking, and endothelial dys-
nction. Other factors include elevated levels of inflamma-
ry markers (i.e., serum C-reactive protein), homocysteine,
lipoprotein (560,561). Risk factors for embolic complica-
ns include inflammation, shear forces of hypertension,
aque hemorrhage aneurysm formation, and iatrogenic ma-
pulation. The likelihood of embolization is also increased
ith complex aortic plaque, defined as plaque that contains
obile thrombi or ulcerations or is 4 mm or greater in
ickness (562). Plaques with a larger lipid core, a predomi-
nce of macrophages, a thin fibrous cap, and a lack of
lcification are more “vulnerable” to disruption or rupture.
alcified plaques are more stable and less likely to result in
gure 35. Ultrasound image of aortic atheroma.bolic syndromes (562,564–565). ag1.4. Diagnosis
ethods of imaging the aortic arch to detect and/or measure
aque include:
Transesophageal Echocardiography. TEE can provide
formation of plaque mobility, ulceration, and composition
66), as well as details on the anatomic relationship of the
aque to the origin of the great vessels (69) with excellent
terobserver and intraobserver reliability (567). Limitations
TEE in patients with stroke include the need for conscious
dation, patient cooperation for swallowing the probe, and
sk of structural damage (566). A small portion of the
cending aorta is masked by the tracheal air column near the
igin of the innominate artery, with an estimated 2% of
aques being missed (568). Multiplanar probes may reduce
acheal shadowing seen with monoplanar and biplanar
obes (569).
Transthoracic Echocardiography. TTE can usually im-
e the aortic root and proximal ascending aorta but cannot
equately assess aortic arch plaque (570,571).
Epiaortic Ultrasonography. Epiaortic imaging is useful
detect aortic arch plaque in the operative setting when the
ansducer may be placed directly over the aortic arch. The
formation may be used to select operative techniques such
off-pump coronary artery bypass grafting to avoid cannu-
tion or cross-clamping of the aorta and reduce risk of
rioperative strokes (572,573).
Contrast Aortography. The risk of invasive angiography
d the need for contrast injection and radiation make
ntrast aortography less useful to assess aortic arch plaque in
tients with stroke (574).
Magnetic Resonance Imaging. MR has been validated
ainst TEE for detection and measurement of aortic arch
aque (80% overall agreement) (568,575). It has limited use
patients who are obese, have metallic implants, or are
austrophobic. Contrast MR angiography underestimates the
aque thickness but can identify morphologic features in-
uding calcification, fibrocellular tissue, lipid, thrombus, and
atures used to detect plaque stability and may be used to
onitor aortic arch plaque progression and regression (572).
Computed Tomography. CT can reliably detect and
easure protruding aortic arch plaques (568,576) and is the
st of choice for detecting vascular calcification. Nonen-
nced dual-helical CT may underestimate the amount of
ncalcified plaque and mobile thrombus that presumably is
high risk for embolization (568). In conjunction with
sitron emission tomography it can be used to localize
orodeoxyglucose uptake by the plaque, identifying active
aques and unstable plaques (577), but its clinical utility has
t to be established.
1.5. Treatment
here is no definitive therapeutic regimen for this high-risk
tient group because no randomized trial has been com-
eted.
.5.1. Anticoagulation Versus Antiplatelet Therapy
obile aortic atheroma have been noted to disappear during
ticoagulant therapy (546) or with the use of a thrombolytic
ent (578). However, there is concern about the use of
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eoretical risk of plaque hemorrhage resulting in atheroem-
li syndrome (i.e., blue toes, renal failure, intestinal infarc-
n) (579). Anticoagulation has been associated with wors-
ing (580,581), as well as improvement of an aortic
rombus on anticoagulation in a patient with the atheroem-
li syndrome (582). Cholesterol emboli have been docu-
ented on skin, muscle, and renal biopsy samples in patients
ith aortic arch atheroma seen on TEE (553,583). However,
e risk of clinical atheroemboli syndrome during warfarin
erapy in such patients appears to be low (only 1 episode in
4 patients according to the SPAF [Stroke Prevention in
trial Fibrillation] trial) (562).
Three reports shed light on the potential benefit of warfarin
patients with aortic arch atheroma. The first described 31
tients with mobile lesions in the aorta on TEE (585) where
higher incidence of vascular events was seen in patients
ho were not treated with warfarin compared with those
eated with warfarin (at the discretion of the referring
ysicians) (45% versus 5%). In the SPAF randomized trial
patients with “high-risk” nonvalvular atrial fibrillation, the
sk of stroke at 1 year in 134 patients with complex aortic
aque was found to be reduced from 15.8% (11 events) in
ose treated with fixed low-dose warfarin plus aspirin (INR
2 to 1.5) to only 4% (3 events) in those treated with
justed-dose warfarin (INR 2.0 to 3.0), a 75% RR reduction
0.02) for patients with atheromas who received “thera-
utic range” anticoagulation (562). A third observational
udy reported on 129 patients with aortic arch atheroma on
EE performed to look for a source of cerebral or peripheral
bolization (586). Treatment with oral anticoagulation,
pirin, or ticlopidine was not randomly assigned. There was
significant reduction in the number of embolic events in
tients with plaques greater than or equal to 4 mm who
ceived oral anticoagulants (0 events in 27 patients versus 5
ents in 23 patients treated with antiplatelet agents) (OR
06, 95% CI 0.003 to 1.2, P0.016). For patients with
obile lesions, there was a significant reduction in mortality
hile on anticoagulants, although the trend toward fewer
bolic events did not reach statistical significance in this group.
These 3 reports suggest that warfarin is not harmful in
tients with aortic arch atheroma and may reduce stroke
tes. However, these studies are not randomized trials of
eatment for patients with atheromas, and the numbers are
latively small. The current ARCH (Aortic Arch Related
erebral Hazard) trial is an open-label trial where patients
ith aortic arch atheroma (4 mm or greater) and nondisabling
roke are being assigned to oral anticoagulation (target INR
0 to 3.0) versus aspirin (75 mg/d) plus clopidogrel (75
g/d) and followed longitudinally for recurrence of vascular
ents.
.5.2. Lipid-Lowering Agent
here are no randomized trials to support specific lipid-
wering drug therapy for a patient with stroke caused by
heroembolism. However, 2 randomized studies of low-dose
d higher-dose statin in patients with aortic and/or carotid
aques showed significant regression in plaque seen on MR,
hich in 1 study was related to LDL cholesterol level but not neatin dosage (587) and, in the other study, was related to both
DL lowering and the statin dosage (588). It seems likely that
atin therapy decreases the risk of stroke. Mechanisms for
is effect may involve pleiotropic effects of statins, including
aque regression, plaque stabilization, decreased inflamma-
n, and inhibitory effects on the coagulation cascade at
fferent levels.
No randomized trial on the use of statins in patients with
vere aortic plaque has been published. However, in an
servational study of 519 patients with severe aortic plaque
TEE (540), statin use was associated with an RR reduction
r ischemic stroke of 59%. Statins have reduced both
imary and secondary stroke in a variety of patient popula-
ns (589,590). Hence, a majority of patients with stroke and
IA with identified aortic plaque already have other stronger
dications for statin therapy (409). Recommendations for
atins are noted for other manifestations of atherosclerotic
seases (409) (see Section 9.2.1.2). Clinical trials are needed
determine the effects of statins in patients with severe
rtic atheroma and risk of atheroembolism.
.5.3. Surgical and Interventional Approaches
ortic arch endarterectomy has been attempted for patients
ith thromboembolism originating from aortic arch ather-
a. Although successful in a handful of case reports, this
ocedure resulted in a relatively high rate (34.9% with
darterectomy versus 11.6% without endarterectomy) of
rioperative stroke and mortality when it was performed to
it stroke during cardiac surgical procedures requiring
rdiopulmonary bypass (coronary bypass surgery and valve
rgery) (545). Covered stents offer the potential advantage of
ielding severely diseased aortic segments to prevent further
bolization. However, periprocedural embolization may
cur during diagnosis or interventional endovascular manip-
ations. There is insufficient evidence to recommend pro-
ylactic endarterectomy or aortic arch stenting for purposes
stroke prevention.
2. Porcelain Aorta
ascular calcification occurs in the media and represents a
ntral component of atherogenesis, typically signaling long-
anding inflammation. The amount of calcification directly
sociates with the extent of atherosclerosis, and the presence
aortic calcium predicts the presence of coronary heart
sease (443).
With severe atherosclerosis of the aorta, calcification may
severe and diffuse, causing an eggshell appearance seen on
est x-ray or CT (444). Also termed “porcelain aorta,” this
ding is usually noted during operation for coronary heart or
lvular heart disease at the time of surgery. The calcification
terferes significantly with cannulation of the aorta, cross-
amping, and placement of coronary bypass grafts, increas-
g the risk of stroke and distal embolism significantly
igure 36).
In these patients, direct manipulation of the aorta may
sult in an unrepairable aortic injury and/or distal emboliza-
n. Surgeons have used several techniques to reduce adverse
urologic events in these patients: internal aortic balloon
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chnique to avoid the ascending aorta, alternate locations for
nnulation or coronary bypass graft anastomoses, replace-
ent of the ascending aorta, and intra-aortic filtration of
herosclerotic debris (591–599).
3. Tumors of the Thoracic Aorta
eoplasms of the thoracic aorta are usually secondary and
lated to contiguous spread of adjacent primary malignan-
es, particularly lung and adjacent primary malignancies, or
bsequent metastases, particularly lung and esophagus
00–603).
Primary neoplasms of the thoracic aorta are rare. A review
the literature between 1873 and 2002 collated a total of 53
oracic and 10 thoracoabdominal tumors with most lesions
otruding into the aortic lumen (604) (Table 16).
Metastatic disease is often demonstrated at the time of
agnosis of primary aortic neoplasms, so that constitutional
mptoms of malaise, fatigue, weight loss, and nausea may be
e presenting complaints. Other presentations can include
stal arterial embolization (with histopathologic examination
owing neoplasm or identified by imaging techniques during
search for an embolic source) (604–606). AoD may
iginate in the area of the neoplasm or the aortic occlusion
07). Resection and reconstruction of the segment of aorta
ntaining the neoplasm have been described, but because
ost patients present with metastatic disease, overall prog-
sis is poor (608).4. Perioperative Care for Open
urgical and Endovascular Thoracic
ortic Repairs
4.1. Recommendations for
reoperative Evaluation
ASS I
In preparation for surgery, imaging studies adequate to estab-
lish the extent of disease and the potential limits of the
planned procedure are recommended. (Level of Evidence: C)
Patients with thoracic aortic disease requiring a surgical or
catheter-based intervention who have symptoms or other find-
ings of myocardial ischemia should undergo additional studies
to determine the presence of significant coronary artery dis-
ease. (Level of Evidence: C)
Patients with unstable coronary syndromes and significant
coronary artery disease should undergo revascularization prior
to or at the time of thoracic aortic surgery or endovascular
intervention with percutaneous coronary intervention or con-
comitant coronary artery bypass graft surgery. (Level of Evi-
dence: C)
ASS IIa
Additional testing is reasonable to quantitate the patient’s
comorbid states and develop a risk profile. These may include
pulmonary function tests, cardiac catheterization, aortogra-
Figure 36. Porcelain aorta. Top left and right, PA and
lateral chest x-ray show an anterior mediastinal mass
with curvilinear calcifications most likely representing
the wall of an ascending aortic aneurysm. Bottom left,
CT scan slice at the level of the right pulmonary artery
confirms a 10-cm aneurysm of the ascending aorta
with dense mural calcifications. Bottom right, A maxi-
mum intensity projection in the oblique sagittal plane
better demonstrates the fusiform aneurysm beginning
at the sinotubular ridge and extending into the aortic
arch. Dense mural calcification extends into the proxi-
mal descending aorta. CT indicates computed tomo-
graphic imaging; and PA, posteroanterior.phy, 24-hour Holter monitoring, noninvasive carotid artery
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tive testing. (Level of Evidence: C)
For patients who are to undergo surgery for ascending or arch
aortic disease, and who have clinically stable, but significant
(flow limiting), coronary artery disease, it is reasonable to
perform concomitant coronary artery bypass graft surgery.
(Level of Evidence: C)
ASS IIb
For patients who are to undergo surgery or endovascular
intervention for descending thoracic aortic disease, and who
have clinically stable, but significant (flow limiting), coronary
artery disease, the benefits of coronary revascularization are
not well established. (609–611) (Level of Evidence: B)
eoperative evaluation usually includes imaging studies
cessary to establish the extent of disease, the limits of the
anned procedure, and the clinical risks attendant to the
ocedure. When the writing committee was polled regarding
e extent of usual preoperative laboratory testing, a variety
approaches emerged. In some centers, extensive testing
cludes pulmonary function tests (particularly for smokers
d those with Marfan syndrome), Holter monitoring, and
rotid duplex scans. In some centers, brain imaging and
urocognitive testing are performed in patients with aortic
ch disease for whom arch repair or replacement requiring a
riod of deep hypothermic circulatory arrest or low pump
w is planned (463). Other centers obtain fewer preopera-
e tests and individualize such testing as cardiac catheter-
ation, 24-hour Holter monitoring, brain imaging, and neu-
cognitive studies for patients to establish baseline states and
sk.
In many centers, where the diagnosis of acute AoD is either
ade or highly suspected, patients are immediately taken to
rgery, and TEE is performed in the operating room to either
tablish or confirm the diagnosis. Most of the writing
ble 16. Neoplasms of the Thoracic Aorta (Collective
view Incidence)
stology
Thoracic Aorta
(N53)
Thoracoabdominal
Aorta (N10)
rcoma 15 1
alignant fibrous histiocytoma 11 1
giosarcoma 5 0
iomyosarcoma 6 2
rosarcoma 4 0
yxoma 3 1
romyxosarcoma 1 1
mangiopericytoma 2 0
mangioendothelioma 2 0
alignant endothelioma 2 0
rtic intimal sarcoma 0 2
yxosarcoma 0 1
dotheliosarcoma 1 0
romyxoma 0 1
roxanthosarcoma 1 0
Adapted from Oldenburg et al (604).mmittee believes that the delay to obtain coronary angiog- diphy was potentially dangerous unless patients had a history
coronary artery bypass graft surgery or a high likelihood of
existing CAD.
Most patients undergoing elective aortic root and ascend-
g aortic surgery can be admitted the day of surgery.
owever, some of the writing committee members routinely
mit patients the day before surgery primarily for fluid
dration (using 5% dextrose/0.5 normal saline with addi-
nal potassium and sodium bicarbonate at 100 to 120 mL/h),
rticularly those who are to have extensive open surgery for
ch, descending thoracic, or thoracoabdominal aortic dis-
se. Preoperative use of acetylcysteine (600 mg by mouth at
ght and in the morning, or 500 mg in 500 mL of normal
line solution over 3 hours before CT or surgery) has also
en described (612,613). However, the effectiveness of these
rategies has not been tested in a clinical trial. Placement of
oracic epidural catheters for postoperative analgesia or
mbar spinal drains for CSF drainage is performed on the
y prior to surgery in some centers. Despite lack of evi-
nce, there is concern that neuraxial hemorrhage is more
ely if blood returns through the placement needle on the
y of surgery.
.1.1. Preoperative Risk Assessment
I, low cardiac output, respiratory failure, renal failure, and
roke are the principal causes of mortality and morbidity
ter operations on the thoracic aorta, and preoperative
sessment of these organ systems prior to elective operation
essential (381,441,614–617), especially in patients with a
story of MI, angina pectoris, or symptoms of heart failure
d those older than 40 years. Patients with valvular heart
sease are evaluated with echocardiography and cardiac
theterization.
Elderly patients with thoracic aortic disease are likely to
ve coexisting CAD. The benefits of prior or concomitant
ronary revascularization are controversial. Several studies
ggested that prior coronary bypass graft surgery was of
nefit to patients undergoing major vascular surgery to
duce cardiovascular mortality (618–622).
More recent clinical trials comparing outcomes of patients
ith stable CAD treated with optimal medical therapy versus
vascularization have not shown any significant reductions
cardiovascular events associated with revascularization
rategies (609–611). Major thoracic aortic surgery falls into
e highest-risk group for cardiac morbidity and mortality
23), prompting some writing committee members to ag-
essively screen for and treat coexisting CAD, but the
fectiveness of such a strategy in patients with stable CAD
s not been clearly established. For patients with unstable
AD, left main stenosis, or 3-vessel disease, revasculariza-
n is generally warranted prior to or concomitant with the
oracic aortic procedure. The use of drug-eluting stents for
ngle- or double-vessel disease may be problematic because
quired antiplatelet therapies may significantly raise the risk
bleeding with the thoracic aortic procedure and withhold-
g antiplatelet therapies clearly increases the risk of stent
rombosis.
History of smoking and presence of chronic pulmonarysease are important predictors of postoperative respiratory
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasemplications and are frequently present in patients with
oracic aortic disease (624). Pulmonary function tests and
terial blood-gas analyses help to risk-stratify patients with
ronic pulmonary disease. If reversible restrictive disease or
cessive sputum production is present, antibiotics and bron-
odilators should be administered. Cessation of smoking is
visable.
Preoperative renal dysfunction is the most important pre-
ctor of acute renal failure after operations on the thoracic
rta (617,625,626). Preoperative hydration and avoidance of
potension, low cardiac output, and hypovolemia in the
rioperative period may reduce the prevalence of this
mplication.
To minimize the risk of stroke or reversible ischemic
urologic deficits and to determine the potential magnitude
risk, duplex imaging of the carotid arteries and angiogra-
y of the brachiocephalic arteries is often performed preop-
atively particularly in patients with a history of stroke, TIA,
other risk factors for cerebrovascular disease (627). How-
er, the efficacy of treatment of significant carotid stenosis
ior to endovascular or open surgery for thoracic aortic
sease has not been evaluated in a randomized clinical trial.
Although older age is a risk factor for increased early and
te death after operations on the thoracic aorta
82,441,617,625,627–630), operations can be carried out
ccessfully with satisfactory outcomes in appropriately se-
cted older patients. Emergency operation for aortic rupture
acute dissection is associated with a higher risk of early
ath after operation compared with elective operation (47).
4.2. Recommendations for Choice of
nesthetic and Monitoring Techniques
ASS I
The choice of anesthetic techniques and agents and patient
monitoring techniques should be tailored to individual patient
needs to facilitate surgical and perfusion techniques and the
monitoring of hemodynamics and organ function. (Level of
Evidence: C)
ASS IIa
Transesophageal echocardiography is reasonable in all open
surgical repairs of the thoracic aorta, unless there are specific
contraindications to its use. Transesophageal echocardiogra-
phy is reasonable in endovascular thoracic aortic procedures
for monitoring, procedural guidance, and/or endovascular
graft leak detection. (631–633) (Level of Evidence: B)
Motor or somatosensory evoked potential monitoring can be
useful when the data will help to guide therapy. It is reasonable
to base the decision to use neurophysiologic monitoring on
individual patient needs, institutional resources, the urgency
of the procedure, and the surgical and perfusion techniques to
be employed in the open or endovascular thoracic aortic repair.
(634,635) (Level of Evidence: B)
ASS III
Regional anesthetic techniques are not recommended in pa-
tients at risk of neuraxial hematoma formation due to thien-
opyridine antiplatelet therapy, low-molecular-weight heparins, tioor clinically significant anticoagulation. (636) (Level of Evi-
dence: C)
Routinely changing double-lumen endotracheal (endobron-
chial) tubes to single-lumen tubes at the end of surgical
procedures complicated by significant upper airway edema or
hemorrhage is not recommended. (Level of Evidence: C)
hoice of anesthetic technique is dependent on the planned
rgical interventions and the patient’s comorbid conditions.
r placement of endovascular aortic stent grafts, different
esthetic (local, regional, general) techniques have been
scribed, although adequate comparative studies are lacking
37–643). Percutaneous placement of catheters with a lim-
d incision may be tolerated with local anesthesia and
dation. Extensive inguinal dissection or the construction of
femoro–femoral bypass may favor either regional or general
esthesia. If surgical dissection is extended into the retro-
ritoneum, a higher level of regional anesthesia or general
esthesia is required. If the patient is undergoing local
esthesia or regional anesthesia, adequate intravenous seda-
n is necessary because of agitation secondary to restless-
ss and pain from lying in one position for a prolonged
riod of time.
Retrospective studies indicate that patients having local
rsus regional or general anesthesia for endovascular stent
afts tend to have lower use of vasoactive agents and lower
id requirements, shorter intensive care and hospital stays
42), earlier ambulation and gastrointestinal function (637),
d lower incidence of respiratory and renal complications
43). In a large multicenter retrospective study of 5557
tients undergoing endovascular aortic repairs (644), 69%
ceived general anesthesia, 25% received regional anesthe-
a, and 6% received local anesthesia. The incidence of
rdiac complications were significantly lower in both the
cal or regional anesthesia group compared with general
esthesia (1.0% versus 2.9% versus 3.7%), and the inci-
nce of sepsis was significantly lower in the regional
esthesia group compared with general anesthesia (0.2%
rsus 1.0%). Selection bias and complexity of disease likely
fect these results.
.2.1. Temperature Monitoring
t most centers, temperature is monitored in at least 2
cations that estimate the brain/core (e.g., blood, esophageal,
mpanic membrane, nasopharynx) temperature and the vis-
ral (e.g., bladder or rectal) temperature (645).
.2.2. Hemodynamic Monitoring
vasive arterial pressure monitoring is required in 1 or more
tes depending on the surgical plan for cannulation and
rfusion, particularly for thoracoabdominal aortic repairs.
rterial pressure is universally monitored proximal to aortic
oss-clamping sites, but there is institutional variability in
e monitoring of distal arterial (aortic) pressure, even when
stal aortic perfusion is performed.
Central venous cannulation allows measurement of cardiac
ling pressures, providing a route for vasoactive drug and fluid
ministration. Femoral venous catheterization is discouraged
current central line–associated bloodstream infection preven-
n guidelines, but the literature does not address the subject in
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enced centers use short-term catheterization of the femoral vein
r volume management during surgery.
Pulmonary artery catheterization is performed routinely in
any institutions for thoracic aortic surgery. The literature
es not specifically address the subject of thoracic aortic
rgery, but the general perioperative literature does not
pport the use of pulmonary artery catheterization (631).
.2.3. Transesophageal Echocardiography
EE is safe (648) and is used to confirm the preoperative
agnoses and detect pericardial or pleural effusions, aortic
gurgitation, the extent of dissection, the location of intimal
ars, the size and integrity of aneurysms, and the presence of
propriate flow in the true lumen upon commencement of
rdiopulmonary bypass. Current American Society of Anes-
esiologists and the Society of Cardiovascular Anesthesiol-
ists guidelines for TEE include the following (631):
Category I Indications (supported by the strongest evi-
nce or expert opinion):
Preoperative use in unstable patients with suspected tho-
racic aortic aneurysms, dissection, or disruptions that need
to be evaluated quickly.
Intraoperative assessment of aortic valve function in repair
of AoDs with possible aortic valve involvement.
Category II Indications (supported by weaker evidence or
pert opinion):
Preoperative assessment of patients with suspected tho-
racic AoDs, aneurysms, or disruption.
Intraoperative use during repair of thoracic AoDs without
suspected aortic valve involvement.
.2.4. Transesophageal Echocardiography for
ndovascular Repairs of the Descending Thoracic Aorta
EE can provide views of the aorta and location of guide-
ires and endografts prior to deployment in relation to the
rmal and diseased thoracic aorta (649,650). TEE has
stinct advantages over angiography by providing exact
ssel and lesion sizing and localization and can also be used
estimate endograft size and location. Although not imaged
all patients, large intercostal arteries have been imaged,
us avoiding inadvertent obstruction by the aortic stent graft.
fter stent graft placement, the presence or absence of
doleaks can be determined by TEE with a high degree of
nsitivity and specificity particularly compared with contrast
giography (632,633,650). Finally, because most of these
tients have severe concomitant cardiac disease, periopera-
e TEE allows dynamic assessments of cardiac function.
Intravascular ultrasound is used for endovascular proce-
res to visualize precise localization of branch arteries and
r measurement of aortic and branch artery sizes. Plaques,
ars, and saccular aneurysms can also be very accurately
monstrated.
4.3. Airway Management for Descending
oracic Aortic Repairs
double-lumen endotracheal tube or various types of endo-
onchial blockers facilitate surgical exposure (651). For setensive surgery of the left thorax, single-lung ventilation
ovides better surgical exposure, reduces the need for
lmonary retraction, may decrease the severity of iatrogenic
lmonary contusion, and protects the right lung from con-
mination by blood and secretions. A large descending
oracic aortic aneurysm may compress or distort the left
ain bronchus such that left-sided endobronchial tubes must
used with caution. If a right-sided double-lumen endotra-
eal tube is placed, endoscopic confirmation of tube position
o ensure right upper lobe ventilation) is necessary. Forceful
dobronchial tube placement has been associated with tho-
cic aortic aneurysm rupture. Therefore, using a different
be or lung isolation method may be required when severe
rway distortion is encountered.
At the end of surgery, some centers have advocated
anging a double-lumen endotracheal tube to a single-lumen
be to facilitate pulmonary toilet and to avoid the complica-
ns associated with tube malposition in the intensive care
it. The decision to change the double-lumen endotracheal
be to a single-lumen tube should be made after carefully
aluating the extent of airway edema, as these procedures
e associated with significant facial and laryngeal edema.
dvanced airway management devices, such as tube ex-
anges and video laryngoscopy, may be of benefit; however,
ere is no literature addressing this subject.
4.4. Recommendation for Transfusion
anagement and Anticoagulation in Thoracic
ortic Surgery
ASS IIa
An algorithmic approach to transfusion, antifibrinolytic, and
anticoagulation management is reasonable to use in both open
and endovascular thoracic aortic repairs during the periopera-
tive period. Institutional variations in coagulation testing ca-
pability and availability of transfusion products and other
prothrombotic and antithrombotic agents are important con-
siderations in defining such an approach. (652) (Level of
Evidence: C)
horacic aortic surgery is associated with hemorrhage from
veral interrelated causes, including extensive surgical dis-
ction, arterial and venous bleeding, hypothermia, cardio-
lmonary bypass, fibrinolysis, dilution or consumption of
agulation factors, thrombocytopenia, poor platelet function,
parin and other anticoagulants, preoperative antithrombotic
erapy, and other congenital and acquired coagulopathies.
he extensive blood product and fluid requirements of open
oracic aortic surgical repairs may exceed the total blood
lume of the patient in the most complicated cases. Clinical
actice guidelines for perioperative blood transfusion and
ood conservation in cardiac surgery have been published by
e STS and the SCA (652).
These guidelines do not specifically address open or
dovascular descending thoracic aortic repairs, but the
riting committee supports treatment strategies provided by
ese guidelines.
Coagulopathies in open descending thoracic aortic and
oracoabdominal repairs mirror many of the abnormalities
en in cardiac and thoracic aortic procedures requiring
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaserdiopulmonary bypass. Illig and colleagues (653) reported
gnificantly decreased euglobulin clot lysis times, elevated
sue plasminogen activator levels, elevated tissue plasmin-
en activator–to–plasminogen activator inhibitor-1 ratios,
d reduced alpha 2-antiplasmin levels within 20 minutes
ter supraceliac cross-clamping, compared with infrarenal
clusion, consistent with a primary fibrinolytic state. Vis-
ral ischemia may be the condition that initiates fibrinolysis.
uring supraceliac occlusion, fibrinolysis was attenuated
hen superior mesenteric artery perfusion was maintained
a a shunt (654). Peripheral ischemia may also result in
rinolysis. Within 30 minutes of the onset of acute periph-
al ischemia (with infrarenal aortic occlusion) fibrinolytic
tivity increased, as demonstrated by an increase in tissue-
pe plasminogen activity and a decrease in plasminogen
tivator inhibitor activity. This increase in tissue-type plas-
inogen activity resulted from release of stores from isch-
ic vascular tissues (655). Endotoxemia during aortic oc-
usion may also be associated with fibrinolysis (656).
To counteract fibrinolysis, the use of lysine analogs
silon-aminocaproic acid and tranexamic acid has been
ported in cardiac surgery. The epsilon-aminocaproic acid
ading or bolus dose ranged from 75 to 150 mg/kg, with
ditional dosing from 12.5 to 30 mg/kg/h infused over
rying time periods. For tranexamic acid, loading or bolus
se, ranged from 2.5 to 100 mg/kg, with additional dosing
om 0.25 to 4.0 mg/kg/h delivered over 1 to 12 hours (657).
a study of 21 adult cardiac surgical patients, the tranexamic
id dosing regimen of 10 mg/kg initial dose, followed by an
fusion of 1 mg/kg/h resulted in adequate plasma concen-
ations defined by in vitro studies to prevent fibrinolysis,
ith relatively stable drug levels throughout cardiopulmonary
pass (658). Antifibrinolytic therapy for thoracoabdominal
rtic surgery with distal perfusion was not associated with
creased bleeding or transfusion in a retrospective cohort of
patients (659). The strong evidence derived from other
rdiac surgical studies has led to very common use of
tifibrinolytic therapy in thoracic aortic surgery, despite the
sence of specific evidence in this surgical subset.
4.5. Organ Protection
.5.1. Recommendations for Brain Protection During
scending Aortic and Transverse Aortic Arch Surgery
ASS I
A brain protection strategy to prevent stroke and preserve
cognitive function should be a key element of the surgical,
anesthetic, and perfusion techniques used to accomplish
repairs of the ascending aorta and transverse aortic arch.
(660–666) (Level of Evidence: B)
ASS IIa
Deep hypothermic circulatory arrest, selective antegrade brain
perfusion, and retrograde brain perfusion are techniques that
alone or in combination are reasonable to minimize brain injury
during surgical repairs of the ascending aorta and transverse
aortic arch. Institutional experience is an important factor in
selecting these techniques. (211,615,667–688) (Level of
Evidence: B) mASS III
Perioperative brain hyperthermia is not recommended in re-
pairs of the ascending aortic and transverse aortic arch as it is
probably injurious to the brain. (689–691) (Level of Evi-
dence: B)
brain protection strategy is an essential component of the
erative technique for open surgical repairs of the ascending
rta and/or the aortic arch. Moderate or profound hypother-
ia with periods of circulatory arrest and/or selective ante-
ade brain perfusion and/or retrograde brain perfusion are
e common strategies for achieving brain protection. The
perience and outcomes of the operating surgeon and the
stitution are important considerations in selecting a brain
otection strategy.
Achieving brain hypothermia is nearly universally per-
rmed using extracorporeal circulation, with temperatures
nging from 12° to 30°C. Retrograde (via jugular vein) brain
rfusion is usually performed at a perfusion pressure of 20 to
mm Hg at a mildly or profoundly hypothermic tempera-
re. Antegrade brain perfusion is usually performed at a
rfusion pressure of 50 to 80 mm Hg and may be instituted
direct cannulation of the brachiocephalic arteries, side-
aft anastomosis to the axillary artery, or direct cannulation
a portion of graft material that was anastomosed to the
achiocephalic arteries during a period of hypothermic
rculatory arrest. The rewarming of a patient following
mpletion of the repair of the thoracic aorta is usually
rformed at a measured rate so as not to induce brain
perthermia.
The reviewed literature describes an evolution of brain
otection techniques over the past 2 to 3 decades. Deep
pothermic circulatory arrest emerged as the first technique,
t as a sole method of brain protection, it was limited by
creasing rates of neurologic morbidity, other adverse out-
mes, and mortality as the period of arrest exceeded 25 to 45
inutes (671,692). Deep hypothermic arrest without perfu-
on adjuncts has been successful, especially when arrest
tervals are less than 40 minutes (693). Subsequently,
rious combinations of retrograde brain perfusion and se-
ctive antegrade brain perfusion were developed to extend
e “safe period” of interruption of full extracorporeal circu-
tion. Monitoring of brain function and metabolic suppres-
on by electroencephalography, evoked potentials, bispectral
dex, noninvasive cerebral oximetry, and jugular bulb oxy-
moglobin saturation are additional means used to guide the
set of extracorporeal circulation interruption for repairing
e distal ascending aorta and/or aortic arch. Some centers use
rbiturates, calcium channel blockers, or steroids for added
otection, but no prospective randomized trials have been
rformed to test the efficacy of pharmacological agents
11,459).
There is controversy regarding the ability of retrograde
ain perfusion to support brain metabolic function and to
prove neurologic outcomes, including transient postopera-
ve neurologic dysfunction, stroke rates, and mortality
61,671,673–675,694–699). However, this technique can
aintain brain hypothermia (700) and has been associated
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imary neuroprotection strategy.
Selective antegrade brain perfusion may be provided by
rect cannulation of 1 or more of the brachiocephalic
teries, which permits brain perfusion with minimal
riods of interruption. If unilateral cannulation is per-
rmed, success may depend on patency of the circle of
illis. Alternatively, unilateral direct or side-graft cannu-
tion of the (usually right) axillary artery permits extra-
rporeal circulation and cooling without manipulation of
e diseased thoracic aorta. This same cannula can then be
ed for delivering antegrade brain perfusion immediately
ter the section of aorta from which the brachiocephalic
teries originate is sutured to the graft or immediately
ter the brachiocephalic vessels are individually anasto-
osed to a trifurcated graft. The time required to complete
ese maneuvers requires a relatively shorter period of
pothermic circulatory arrest compared with compete
construction of the aortic arch (681,683,701–704). Bilat-
al brachiocephalic artery cannulation has also been
ported (705). The literature is insufficient to determine
hether unilateral or bilateral perfusion or complete avoid-
ce of circulatory arrest is associated with improved
tcomes. A retrospective analysis by Svensson et al (449)
ggested that axillary artery perfusion via a prosthetic
de-graft was associated with improved outcomes com-
red with femoral arterial cannulation.
Finally, direct cannulation of the aortic replacement graft
ay be used to institute antegrade brain perfusion following
period of circulatory arrest. The variability of techniques
ong surgical centers makes direct comparison difficult;
wever, most studies with some type of antegrade arterial
ain perfusion report outcomes that are comparable to or
tter than those using hypothermic circulatory arrest alone
retrograde brain perfusion (660,662,666,685,686,706,707).
rthermore, selective antegrade brain perfusion may reduce
e period of brain ischemia and permit less profound
pothermia, which may be associated with good clinical
tcomes (676,687,708–712).
Our ability to create evidence-based guidelines from the
erature is particularly difficult in the case of brain protec-
n. Changes in surgical technique, perfusion technology,
esthetic and intensive care management, coagulation man-
ement, prosthetic graft materials, and the experience of the
porting centers and lack of randomized clinical trials are
nfounding factors.
.5.2. Recommendations for Spinal Cord Protection
uring Descending Aortic Open Surgical and
ndovascular Repairs
ASS I
Cerebrospinal fluid drainage is recommended as a spinal cord
protective strategy in open and endovascular thoracic aortic
repair for patients at high risk of spinal cord ischemic injury.
(522,523,713) (Level of Evidence: B)
ASS IIa
Spinal cord perfusion pressure optimization using techniques,
such as proximal aortic pressure maintenance and distal aortic reperfusion, is reasonable as an integral part of the surgical,
anesthetic, and perfusion strategy in open and endovascular
thoracic aortic repair patients at high risk of spinal cord
ischemic injury. Institutional experience is an important factor
in selecting these techniques. (380,382,714,715) (Level of
Evidence: B)
Moderate systemic hypothermia is reasonable for protection of
the spinal cord during open repairs of the descending thoracic
aorta. (525) (Level of Evidence: B)
ASS IIb
Adjunctive techniques to increase the tolerance of the spinal
cord to impaired perfusion may be considered during open and
endovascular thoracic aortic repair for patients at high risk of
spinal cord injury. These include distal perfusion, epidural
irrigation with hypothermic solutions, high-dose systemic glu-
cocorticoids, osmotic diuresis with mannitol, intrathecal pa-
paverine, and cellular metabolic suppression with anesthetic
agents. (520,715–717) (Level of Evidence: B)
Neurophysiological monitoring of the spinal cord (somatosen-
sory evoked potentials or motor evoked potentials) may be
considered as a strategy to detect spinal cord ischemia and to
guide reimplantation of intercostal arteries and/or hemody-
namic optimization to prevent or treat spinal cord ischemia.
(483,634,718,719) (Level of Evidence: B)
raparesis and paraplegia are perhaps the most feared
mplications following repair of the descending thoracic
rta. Although rates as high as 23% have previously been
ported, the current incidence is probably somewhere around
to 6% (483,521,634,718,720). In any specific patient,
wever, the likelihood of neurological complications de-
nds highly on individual anatomy, on whether the aorta is
ssected or aneurysmal, and on whether the pathology is
ute, chronic, or both.
Risk factors for perioperative spinal cord injury include
ergency surgery, dissection, extensive disease, prolonged
rtic cross-clamp time, aortic rupture, level of aortic cross-
amp, patient age, prior abdominal aortic surgery, and, in
rticular, hypogastric artery exclusion (143,144,721), as
ell as a history of renal dysfunction. The risk of paraplegia
paraparesis is minimal if the aortic cross-clamp time is less
an 15 minutes (722). Svensson et al (381) reported a 20%
sk of neurological injury if aortic cross-clamp time was
eater than 60 minutes and less than 10% if aortic cross-
amp time was less than 30 minutes. Although paraplegia or
raparesis has been reported with aortic cross-clamp times
less than 20 minutes (723), others have concluded that
rtic cross-clamp times greater than 40 minutes did not
sult in increases in adverse spinal cord outcome, if distal
rfusion was used (382). One study of patients undergoing
en or endovascular repair of descending thoracic or thora-
abdominal aortic aneurysms demonstrated a higher risk of
inal cord injury related to the extent of aorta treated but no
fference between the operative approaches (724).
Another option for spinal cord protection is deep hypother-
ic circulatory arrest (630). This has been a useful technique
r complex descending thoracic or thoracoabdominal aortic
pairs performed via a left thoracotomy approach.
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Disease.5.2.1. MONITORING OF SPINAL CORD FUNCTION IN
ESCENDING THORACIC AORTIC REPAIRS
general, the comparatively low current incidence of neu-
logic complications is attributable to the routine use of
ultimodal neurophysiologic monitoring such as somatosen-
ry evoked potentials (SSEP) and motor evoked potentials
EP) in conjunction with neuroprotective strategies noted
ter (526). Although these neuroprotective strategies con-
ue to evolve and may differ slightly in their implementation
om center to center, monitoring of evoked potentials during
ese cases has become common because it provides the
rgeon and anesthesiologist the opportunity to promptly
tervene if alterations in monitored potentials indicate neu-
logic compromise is occurring (524,526,719,725,726).
SSEPs are cerbral cortical electrical potentials recorded
ith scalp electrodes during electrical stimulation of the
sterior tibial or peroneal nerves of the lower extremities,
nducted via the lateral and posterior columns of the spinal
rd (727). Because SSEP monitoring is less sensitive to
esthetic drugs and paralytic agents may be used, its use is
ss complex than MEP monitoring. SSEP monitoring is
ited because it is only dependent on the integrity of the
teral and posterior columns. The anterior motor column is
ore likely to be affected by ischemic injury during aortic
construction. It is thus possible to sustain an isolated
rioperative anterior column injury without changes in
EPs. In 1 study, SSEP monitoring influenced the surgical
rategy in 17 of 63 patients (27%) undergoing descending
rtic reconstruction (719). Corrective interventions included
rtial cardiopulmonary bypass initiated in 1 patient with
aumatic aortic rupture; reimplantation of critical intercostal,
mbar, or sacral arteries in 11 patients; suture closure of
ofusely back-bleeding intercoastal arteries in 1 patient;
stening the proximal suture line in 1 patient; distal clamp
positioning to a more proximal position in 1 patient; and
oximal clamp repositioning in 2 patients with left carotid
chemia. The authors reported no cases of unexplained SSEP
normalities. New immediate paraplegia was observed in 1
tient with sustained SSEP absence, and 2 patients presented
ith delayed paraplegia despite normal inoperative SSEP.
In contrast, MEPs are performed by stimulating the motor
rtex (by either high-voltage short-duration electrical stim-
us or magnetic induction) (728) and recording at the level
the spinal cord, peripheral nerves, or muscles
24,526,725–727). Neurogenic MEPs are responses re-
rded at the peripheral nerves, whereas myogenic MEPs are
rge biphasic responses recorded over the muscle belly.
ecause the amplitude of the response is proportional to the
mber of motor neurons being stimulated, these evoked
tentials are very sensitive to neuromuscular blocking and
esthetic agents (729–738).
Monitoring of SSEPs alone has not been demonstrated to
prove outcomes in patients undergoing TAA repair. SSEP
onitoring is associated with delayed ischemia detection
mpared with transcranial MEPs (739), as well as high rates
both false-negative and false-positive results (635,739).
yon et al (740) reported a significantly higher voltage
reshold for the generation of a 50 microV amplitude signal cothe end of the procedure compared with the beginning of
e procedure (“anesthetic fade”). This increased voltage
reshold was directly proportional to the length of anesthetic
posure. Recognition of this phenomenon is important to
oid false-positive MEP interpretation.
To demonstrate the greater sensitivity of MEP than SSEP
onitoring, Dong et al (634) reported their experience with
patients undergoing descending aortic reconstruction. All
tients were monitored with both MEPs and SSEPs. Sixteen
tients (29%) had MEP evidence of perioperative spinal
rd ischemia compared with 4 patients (7%) with SSEP
anges. These changes were reversed in 13 patients with
ther segmental artery reimplantation or optimization of
modynamics. Although one of these 13 patients awoke
ith immediate paraplegia, the remaining 3 patients awoke
raplegic. All 3 patients had normal perioperative SSEPs.
.5.2.2. MAINTENANCEOF SPINALCORDARTERIAL PRESSURE
oximal hypertension may increase the contribution of the
rtebral artery–derived blood flow to the spinal cord as well
collateral flow. Other methods of maintaining arterial flow
the spinal cord include the aggressive reimplantation of
ajor intercostal arteries into the aortic graft (715). Griepp et
(742) emphasized the importance of prompt ligation of
nimplanted intercostal arteries to avoid “steal” from bleed-
g during periods of ischemia to this collateral bed (741).
trathecal papaverine has also been described as a method of
ducing spinal cord arterial dilation, and thus increasing
inal cord blood flow.
The literature is unclear with respect to the benefits of
stal perfusion alone on spinal cord protection because the
chnique is not used in isolation. Several studies support the
ncept that distal perfusion combined with CSF drainage is
neficial (380,382,468,714). The minimum desirable distal
terial pressure is 60 mm Hg to ensure adequate spinal cord
ood flow, whereas maximal proximal mean arterial pressure
ould be about 90 to 100 mm Hg (743).
.5.2.3. CEREBROSPINAL FLUID PRESSURE AND DRAINAGE
pplication of a cross-clamp to the proximal descending aorta
t only creates a major hemodynamic load on the heart but also
uses an acute elevation in CSF pressure (744). Surgical
traction of the aortic arch may also produce significant in-
eases in CSF pressures (745). When CSF pressure exceeds
inal venous pressure, a “critical closing pressure” is achieved,
d the veins collapse independent of inflow pressure. The
inal cord perfusion pressure is therefore the difference between
inal arterial pressure and CSF pressure.
Coselli et al (522) randomized 145 patients undergoing
oracoabdominal aortic repair with or without CSF drainage.
ine patients (13.0%) in the control group developed para-
egia or paraparesis. In contrast, only 2 patients in the CSF
ainage group (2.6%) had deficits develop (P0.03). No
tients with CSF drainage had immediate paraplegia. A
eta-analysis by Khan and Stansby (713) and the retrospec-
e analysis by Safi and colleagues (523) also concluded that
SF drainage was advantageous in reducing the risk of spinal
rd injury in open TAA repairs.
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2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129Possible complications of CSF drainage include headache,
inal or epidural hematoma formation or inflammatory
action, meningitis, and persistent CSF leaks. Subdural
matoma has been reported after thoracic aortic repair with
inal fluid drainage (746). Introduction of blood into the
barachnoid space may result in vasospasm and decreases in
inal blood flow (747). Decreases in CSF pressure may
cur with phlebotomy, and aggressive use of hyperosmotic
ents and hyperventilation may be as effective as spinal
ainage in maintaining spinal cord perfusion pressure
48,749). In a single-center report of 162 patients with CSF
ains, 6 patients (3.7%) had catheter-related complications:
mporary abducens nerve palsy, 1 patient; retained catheter
agments, 2 patients; retained catheter fragments and men-
gitis, 1 patient; isolated meningitis, 1 patient; and spinal
adache, 1 patient. There were no neuraxial hemorrhagic
mplications in this series (750).
.5.2.4. HYPOTHERMIA
ild hypothermia may provide significant neuronal protec-
n by mechanisms such as reducing excitatory neurotrans-
itter release, decreasing free oxygen radical production,
creasing postischemic edema, and stabilizing central ner-
us system blood flow (751,752). Hypothermia occurs via
ssive cooling in a cold operating room with a major
cision in addition to cooling blankets and unwarmed intra-
nous fluids. If an extracorporeal circuit is used, a heat
changer permits warming or cooling of the body tempera-
re. A temperature of 32°C is usually well tolerated by
tients not undergoing full cardiopulmonary bypass. Mod-
ate systemic hypothermia has been associated with im-
oved outcomes following TAA surgery (525). Arrhythmias,
ch as atrial fibrillation and even ventricular fibrillation, can
cur if hypothermia is too severe.
Epidural infusion of cooled saline may be used to induce
gional hypothermia. Although this technique was associ-
ed with substantial increases in CSF pressure, a significant
duction in postoperative neurologic deficits was noted
20,716). A new, self-contained catheter for topical cooling
the spinal cord without infusion into the CSF or CSF
essure rise has been shown in the laboratory to provide
pical spinal cord hypothermia, while systemic normother-
ia is maintained; clinical trials are being organized (753).
Postischemic hyperemia occurs in the spinal cord (754). The
agnitude of this hyperemia has been demonstrated to be
oportional to the incidence of paraplegia. Possible mecha-
sms for the increased neurologic injury associated with vas-
lar hyperemia include edema formation with the development
a compartment syndrome and subsequently decreased spinal
rd perfusion and increased oxygen delivery that may result in
eater free oxygen radical species generation.
.5.2.5. GLUCOCORTICOIDS AND MANNITOL
dministration of methylprednisolone (30 mg/kg) before and
ter aortic occlusion may result in better spinal cord protec-
n (717). The mechanism of this protection is unclear, but it
ay be related to decreased spinal cord edema and improved
ee oxygen radical scavenging. Similarly, mannitol (0.25 to
0 g/kg) has been used to modulate the extent of ischemic fainal cord injury. Mannitol is hypothesized to act in similar
shion to methylprednisolone (715).
.5.3. Recommendations for Renal Protection
uring Descending Aortic Open Surgical and
ndovascular Repairs
ASS IIb
Preoperative hydration and intraoperative mannitol administra-
tion may be reasonable strategies for preservation of renal
function in open repairs of the descending aorta. (Level of
Evidence: C)
During thoracoabdominal or descending aortic repairs with
exposure of the renal arteries, renal protection by either cold
crystalloid or blood perfusion may be considered. (626,755,
756) (Level of Evidence: B)
ASS III
Furosemide, mannitol, or dopamine should not be given solely
for the purpose of renal protection in descending aortic repairs.
(757,758) (Level of Evidence: B)
a cohort of 475 patients who underwent descending
oracic aortic repair, 25% developed acute postoperative
nal failure, whereas 8% required hemodialysis (759). Risk
ctors that are associated with postoperative renal failure
ter descending thoracic aortic repair include age greater
an 50 years, preexisting renal dysfunction, duration of renal
chemia, administration of greater than 5 units or either
cked red cells or salvaged washed autologous blood,
modynamic instability, and diffuse atherosclerosis
26,759).
There is controversy regarding the protective nature of
stal perfusion during aortic occlusion (626,759). Godet et al
59) observed a decrease in the incidence of renal failure
ith the use of distal aortic perfusion. Others have observed
creases in renal failure with distal perfusion (626). Selective
nal artery perfusion during descending thoracic aortic repair
ay result in uninterrupted urine production throughout the
ocedure and may decrease the incidence of renal failure
stoperatively (755).
Pharmacological agents, including mannitol (760,761),
rosemide (758), or dopamine (757,761–764), have not been
monstrated to provide renal protection during descending
oracic aortic repair.
4.6. Complications of Open Surgical
pproaches
yocardial infarction (1% to 5%): This is an uncommon
mplication but it is associated with CAD or dissection of
e coronary artery ostia (228–234,250,441).
Heart failure (1% to 5%): Myocardial protection difficul-
s and ventricular distention from either aortic valve regur-
tation or high right-sided pressures are often factors (765).
Infections (1% to 5% superficial, less than 1% deep):
traoperative contamination or inadequate or improperly
ed antibiotic coverage, obesity, immunosuppression, pul-
onary disease, or suboptimal glucose control may be a
ctor (766).
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic DiseaseStroke (2% to 8% permanent): As noted earlier, brain
otection is important in preventing the complication of
roke. The causes are either embolic or ischemic. Patients
ho on preoperative MR have evidence of ischemic changes
d/or reduced neurocognitive function, who are elderly, or
ho have a history of stroke are at increased risk of a
rioperative stroke (76,99,139,211,449,453,466,767).
Neurocognitive deficit: The exact incidence of deficits has
t been studied much after circulatory arrest; however, in 1
ospective randomized study, using 51 neurocognitive tests,
2 to 3 weeks after surgery, 9% of patients had new deficits,
d by 6 months, all new deficits had resolved. Patients with
eoperative deficits were proved to have further deteriora-
n; indeed, 38% of patients had preoperative deficits
11,466).
Reoperation for bleeding (1% to 6%): Reoperation for
eeding is dependent on the extent of surgery, length of
rdiopulmonary bypass, reoperative status, underlying dis-
der, and surgical technique. Obtaining hemostasis prior to
ming off cardiopulmonary bypass and correcting all blood
agulation defects are paramount (765,766).
Respiratory failure (5% to 15%): Preoperative pulmonary
nction testing helps to warn the surgeon about potential
stoperative respiratory problems. Sometimes operative
chnique can be adapted to lessen the risks—for example,
ortening pump time and avoiding overtransfusion. Left
aphragmatic incisions and trauma may add to postoperative
lmonary dysfunction. In patients with more than 7 kg of
creased weight after surgery, delaying extubation until
cess fluid has been eliminated by diuresis is worthwhile.
hite cell filtration and plasmapharesis on pump may be
eful but have not been tested in randomized trials.
Ventricular arrhythmias (1% to 5%): Ventricular tachycar-
a or ventricular fibrillation was a common complication
ter composite valve graft insertion a decade ago, with
ports of 19% to 21% risk. Some of these events were related
undiagnosed myocardial ischemia from coronary button
attachment problems, which are usually apparent during
eration or shortly thereafter. Inadequate myocardial protec-
n may also lead to both ventricular arrhythmias and low
rdiac output. The increasing use of amiodarone, optimiza-
n of potassium and magnesium levels, and better methods
myocardial protection including blood cardioplegia may
ve reduced this risk. Twenty-four–hour Holter monitoring
udies may reveal underlying pathology, such as ischemic
anges or prolonged QT interval, particularly in patients
ith Marfan syndrome, that needs to be addressed.
Paralysis: The most feared complication after these types
operations is lower limb paralysis and neurogenic bladder.
his occurs in 2% to 4% of descending thoracic aortic repairs
d in 3% to 10% of thoracoabdominal aortic repairs
82,526,724,768–773). Most lesions predominantly involve
otor function because the anterior motor nerve cells of the
inal cord are most likely to be involved. The protective
easures were discussed earlier. Two thirds of patients with
raparesis will recover, and about half with paraplegia will
cover to the point of walking again. Prevention of postop-
ative hypotension in the intensive care unit and continued
SF drainage for longer than 40 hours is deemed by most lethors to be beneficial in reducing the incidence of parapa-
sis (380,522,523,525,713).
Hoarseness: The incidence of hoarseness is related to
hether the arch needs to be clamped and whether the
oximal descending aorta at the left subclavian artery needs
be transected. Transsection at this level is recommended to
oid damage to the esophagus and to prevent the formation
late aortoesophageal fistulae. This, however, may result in
mage to the recurrent laryngeal nerve as it wraps around the
rta and ligamentum arteriosum, resulting in left vocal cord
ralysis. This can usually be improved by vocal cord
jection with either gel or collagen.
4.7. Mortality Risk for Thoracic
ortic Surgery
xpected results for risk of death are summarized next.
Composite valve graft (1% to 5%): With modern tech-
ques, death after elective repair is unusual (76,98,99,448).
dditional comorbid states and the need for emergency
eration are associated with increased risk (765).
Separate aortic valve replacement with ascending aorta
pair (1% to 5%) (448,628): Comorbid conditions such as
vanced age and concomitant coronary bypass graft surgery,
well as emergency operation, are associated with increased
sk (76,99,448,765,774,775).
Valve-sparing aortic root reconstruction (less than 1% to
5%): These patients are mostly young and otherwise
althy, and thus excellent results are expected compared
ith other aortic operations. Indeed, in 1 series of over 200
odified David reimplantations, there were no operative
aths (99). Late 10-year freedom from reoperation is better
an 92% for reimplantation procedures but lower for root
modeling procedures (76,95,98,99,448,776).
Bicuspid aortic valve and ascending aorta repair (1.5%):
a large series of over 2000 patients with bicuspid aortic
lve surgery, the operative risk of death (1.5%) for patients
ho had both a bicuspid valve procedure and ascending
rtic repair (n200) was no different than the risk for those
ho underwent only a bicuspid valve procedure. For patients
ith Marfan syndrome or connective tissue disorders or
cuspid aortic valves, the long-term prognosis is excellent
d reaches an average survival of 70 years (76,99). Late
-year risk of reoperation is not as low as for tricuspid aortic
lve repair but still is only 9% for bicuspid aortic valve
pairs.
Acute AoD (3.5% to 10% in experienced centers, but
gher overall): The risk of death after surgical repair of acute
oD is strongly influenced by associated stroke, mesenteric
chemia, renal failure, and myocardial ischemia
37,375,765,777).
Total arch replacement: A 2% to 6% risk of death and a
to 7% risk of stroke have been reported for these
tensive and high-risk procedures. Emergency operation
ortality and stroke rates are higher (15% and 14%, respec-
ely) (778). Careful brain and myocardial protection, cor-
ction of coagulopathies, and improved operative tech-
ques, including the use of elephant trunk procedure, have
d to improved outcomes (680,779).
bi
tw
cu
th
in
ex
re
do
de
ce
su
in
at
er
re
su
re
re
im
pa
de
tiv
5-
be
ex
a
re
st
el
ha
ri
fo
pe
si
ce
fr
do
hi
ab
tie
tr
1
14
T
pr
ca
ao
hi
gr
si
no
ru
in
(s
14
A
CL
1.
2.
3.
4.
5.
T
ap
in
fo
ao
M
w
T
no
pr
di
an
A
st
an
fr
be
es
bl
pr
in
th
an
ra
(3
m
di
pe
fu
e102 Hiratzka et al. JACC Vol. 55, No. 14, 2010
2010 Guidelines on Thoracic Aortic Disease April 6, 2010:e27–129Reoperations: The risk factors for reoperations are comor-
d disease and extent of surgery with results varying be-
een 2% to 6% for the risk of death (464).
Descending aortic replacement: The risk of death with
rrent techniques is 2% to 5% and the risk of paralysis is less
an 3% for elective surgical repairs (382).
Thoracoabdominal repairs: The risk of death is strongly
fluenced by the urgency of surgery, comorbid disease, and
tent of repair. Thus, Crawford Type I thoracoabdominal
pairs have a risk of death of approximately 5%, but this is
ubled to approximately 10% for Type II repairs. The results
picted earlier represent the work performed in high-volume
nters and may not reflect results of all institutions at which
ch surgery is performed (381,525,768,773,780,781).
The late risk of death after aortic repair is strongly
fluenced by age and comorbid disease. Furthermore, aortic
herosclerosis disease is a marker for more extensive ath-
osclerosis. For patients undergoing degenerative and AoD
pairs, usually at an average age of the lower 70s, 5-year
rvival rates of only 60% have been reported for ascending
pairs, arch repairs, descending repairs, thoracoabdominal
pairs, and infrarenal repairs (3,381). Thus, it is initially
portant to identify and to treat all comorbid disease,
rticularly CAD, which is the most common cause of late
aths in this population (381). In patients undergoing elec-
e root-sparing procedures or bicuspid valve procedures, the
and 10-year survival rates are considerably improved—
tter than 80% to 90% 10-year survival rates can be
pected (76,139). Sadly, even young patients with AoD have
dismal 5-year survival rate of 50% after surgery due to
sidual events related to unresected dissected aorta. This
resses the importance of treating young patients with
ective surgery, with a less than 1% risk of death, if they
ve aortic root dilatation (75,76).
Repair of TAAs is one of the most extensive and highest-
sk operations done in patients. Hence, selection of patients
r repair and workup for surgery needs to be diligently
rformed. Furthermore, the cited results are from reports of
ngle-center experiences and therefore representative of
nters of excellence in the treatment of aortic disease. Data
om “real world” experiences have demonstrated nearly
uble the morbidity and mortality rates, especially for
gh-risk indications like acute aortic dissection and thoraco-
dominal aortic aneurysms, suggesting that high-risk pa-
nts may have better outcomes in centers specializing in the
eatment of thoracic aortic diseases (782,783).
4.8. Postprocedural Care
.8.1. Postoperative Risk Factor Management
he recognition and treatment of thoracic aortic disease
ovide the opportunity to engage the patient in long-term
rdiovascular risk factor management. Conditions such as
rtic atherosclerosis and aortic aneurysm are recognized as
gh-risk states by the National Cholesterol Education Pro-
am, Adult Treatment Panel III and require maximal inten-
ty therapy (784). In these patients, the risk of a fatal or
nfatal MI is higher than the risk of amputation or aortic
pture. The risk factors with clinical trial evidence of benefit siclude hypertension, dyslipidemia, and cigarette smoking
ee Section 9.2.1).
.8.2. Recommendations for Surveillance of Thoracic
ortic Disease or Previously Repaired Patients
ASS IIa
Computed tomographic imaging or magnetic resonance imag-
ing of the thoracic aorta is reasonable after a Type A or B aortic
dissection or after prophylactic repair of the aortic root/
ascending aorta. (74) (Level of Evidence: C)
Computed tomographic imaging or magnetic resonance imag-
ing of the aorta is reasonable at 1, 3, 6, and 12 months
postdissection and, if stable, annually thereafter so that any
threatening enlargement can be detected in a timely fashion.
(Level of Evidence: C)
When following patients with imaging, utilization of the same
modality at the same institution is reasonable, so that similar
images of matching anatomic segments can be compared side
by side. (Level of Evidence: C)
If a thoracic aortic aneurysm is only moderate in size and
remains relatively stable over time, magnetic resonance imag-
ing instead of computed tomographic imaging is reasonable to
minimize the patient’s radiation exposure. (Level of Evi-
dence: C)
Surveillance imaging similar to classic aortic dissection is
reasonable in patients with intramural hematoma. (Level of
Evidence: C)
he mean rate of growth for all thoracic aortic aneurysms is
proximately 1 mm/y, but that growth rate increases with
creasing aneurysm diameter. Growth rates tend to be faster
r aneurysms involving the descending versus the ascending
rta, for dissected versus nondissected aortas, for those with
arfan syndrome versus those without (375), and for those
ith bicuspid versus those with tricuspid aortic valves (785).
he frequency of surveillance imaging is not clear as there are
data to accurately dictate surveillance intervals. It seems
udent to obtain an initial follow-up imaging study before
scharge; at 1, 3, 6, and 12 months postoperatively; and then
nually after a thoracic aortic aneurysm is first detected.
ssuming the aneurysm is stable in size on the first follow-up
udy, repeat imaging can reasonably be repeated on an
nual basis. For relatively small aneurysms that are stable
om year to year on annual imaging, the writing committee
lieves that an imaging frequency of every 2 to 3 years,
pecially in older patients, is currently reasonable (Ta-
e 17).
The writing committee believes that the anatomical detail
ovided by CT may be better than that for MR in many
stances. However, for surveillance of stable and moderate
oracic aortic aneurysms, MR provides adequate information
d avoids the potential problems associated with repeated
diation exposure of CT angiography.
Dissected aortas also tend to dilate progressively over time
75,786). Therefore, those with a Type B AoD managed
edically or those with a Type A AoD with a persistent distal
ssection following ascending aortic repair must also undergo
riodic surveillance imaging to monitor the affected aorta for
rther dilatation. When the dissected aorta is relatively stable in
ze, annual surveillance imaging is usually sufficient. The most
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April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseaseoximal portion of the descending thoracic aorta, just beyond
e ostium of the left subclavian artery, is most prone to both
rly and late dilatation. If this segment expands to 6.0 cm or
eater or if there is rapid growth, intervention or an open repair
ay become necessary. Predictors of progressive dilatation or
pture of a dissected aorta include complete patency of the false
men (787) and a large false lumen size (788). Those with
ronic AoD are also at risk for a second acute dissection arising
om the chronic dissection itself or de novo from undissected
rta.
Those with IMH are also at risk of late complications,
cluding conversion to a classic AoD and progressive aortic
latation. Conversely, in other cases there may be progres-
ve reabsorption of the IMH, and in time the radiographic
pearance of the thoracic aorta normalizes. While this is a
ore favorable outcome, such patients remain at increased
sk of late complications as the apparently healed aorta is
one to the development of “ulcer-like projections and
ccular aneurysm,” which are associated with an increased
sk of late aneurysm formation and rupture (297). Other
ctors that predict adverse events are age greater than 70
ars (297), a maximum aortic diameter of 40 mm or greater,
d a maximum aortic wall thickness of 10 mm or greater
98). The natural history of PAUs remains poorly defined.
ertainly those who present with symptoms of an acute aortic
ndrome are likely to have increased risk of aortic rupture,
hereas those without symptoms whose ulcers are discovered
cidentally are more likely to have a chronic or slowly
owing ulcer. Those with uncomplicated ulcers are often
ble 17. Suggested Follow-Up of Aortic Pathologies After
pair or Treatment
thology Interval Study
ute
section
Before discharge, 1 mo, 6
mo, yearly
CT or MR, chest plus
abdomen TTE
ronic
section
Before discharge, 1 y, 2
to 3 y
CT or MR, chest plus
abdomen TTE
rtic root
pair
Before discharge, yearly TTE
R plus
cending
Before discharge, yearly TTE
rtic arch Before discharge, 1 y, 2
to 3 y
CT or MR, chest plus
abdomen
oracic aortic
nt
Before discharge, 1 mo, 2
mo, 6 mo, yearly Or 30
days*
CXR, CT, chest plus
abdomen
ute IMH/PAU Before discharge, 1 mo, 3
mo, 6 mo, yearly
CT or MR, chest plus
abdomen
*US Food and Drug Administration stent graft studies usually required
fore discharge or at 30-day CT scan to detect endovascular leaks. If there is
ncern about a leak, a predischarge study is recommended; however, the risk
renal injury should be borne in mind. All patients should be receiving beta
ockers after surgery or medically managed aortic dissection, if tolerated.
apted from Erbel et al (539).
AVR indicates aortic valve replacement; CT, computed tomographic imaging;
R, chest x-ray; IMH, intramural hematoma; MR, magnetic resonance
aging; PAU, penetrating atherosclerotic ulcer; and TTE, transthoracic
hocardiography.eated medically with antihypertensive medications and tioose monitoring with serial imaging studies, similar to the
anagement of a patient with a distal AoD (789).
5. Nursing Care and Patient/Family
ducation
5.1. Nursing Care of Medically
anaged Patients
ursing care for patients with thoracic aortic disease requires
ucation to ensure that both patient and family understand
e disease process, the importance of therapy including
ntrol of hypertension and other risk factors (790,791), and
e need for continued follow-up, including surveillance
aging. Because some aortic diseases are hereditary,
llow-up might also include family member screening and
unseling (792). For patients with acute aortic syndromes,
mediate control of hypertension and pain, as well as
peated assessments of symptoms and hemodynamic status,
e key elements (345).
Patients transported from smaller hospitals to larger ones
e often alone, without the immediate support of their
milies, and will be dependent on nursing personnel for
otional support and reassurance, as well as clinical and
iritual care. Family members need to have their questions
swered honestly and in a way they can understand, to be
tified of any changes in the patient’s condition, and to have
cess to their loved one(s) (793).
5.2. Preprocedural Nursing Care
urses play a key role in answering questions that remain
ter initial explanations by physicians. Table 18 outlines
pics that should be discussed as part of informed consent
ior to an endovascular or open surgical procedure.
5.3. Postprocedural Nursing Care
tients with a lower acuity level after thoracic aortic
ocedures, including endovascular repair, are often admitted
a postanesthesia care unit for initial recovery and then to an
tensive care unit that can provide frequent monitoring of
tal signs, peripheral pulses, urine output, and neurological
atus including lower extremity motor strength and sensa-
n. Assessment of the skin in the extremities and lower torso
performed to look for cyanotic discoloration and skin
mperature changes, which may be signs of embolization
94). Embolization to cerebral vessels is another potential
sk of these procedures, so frequent monitoring of mentation,
vel of consciousness, vision, speech, motor strength, and
nsory function in the extremities is required. Thromboem-
li to mesenteric, renal, and peripheral vascular beds may
ad to complaints of abdominal pain or the presence of
oody diarrhea or vomiting. Flank pain with changes in urine
tput might indicate potential renal infarction from throm-
emboli.
The initial postprocedural management focuses on blood
essure control. Hypertension can result in stent migration
d bleeding from aortic suture lines. Hypotension can be
ually problematic with the potential to impair renal func-
n and spinal cord perfusion pressure. Hypotension presents
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ith fluids or vasopressors. The risk of inadequate spinal cord
rfusion is spinal cord ischemia, dysfunction, and potential
raplegia. Any decrease in lower extremity function must be
ported to the physician team immediately as it could
present the onset of early and potentially reversible paral-
is. A typical assessment consists of asking patients to
monstrate motor strength holding their extended, straight
gs off the bed one at a time for at least 5 seconds (781), with
peated assessments performed frequently for the first hours
d days after an endovascular or open procedure. An
jective scale that can be useful is outlined in Table 19. CSF
ains are used for many patients undergoing endovascular
d surgical procedures, and the nursing care is critically
portant (see Section 14.4).
Any new back or chest pain warrants further investigation
rule out the possibility of myocardial ischemia or infarction
well as a potential endoleak. New-onset pain of this nature
quires notification of the physician team for further evalu-
ion.
A phenomenon associated with stent graft placement is
stimplantation syndrome, which can occur within 24 hours
ble 18. Topics of Discussion for Preoperative Instruction
d Informed Consent
arification of the intervention or surgical procedure
ngth of the intervention or surgical procedure
tential complications
Endovascular leak
Stroke
Paralysis
Respiratory dysfunction/failure
Renal dysfunction/failure
Myocardial infarction (especially if known coronary disease)
eoperative preparation for elective procedures
Smoking cessation
Antiplatelet or anticoagulation adjustment
Preoperative testing and instructions for obtaining tests
Chlorhexidine showers or other skin preparation
ensive care stay and environment
What to expect: monitoring, staffing ratios, equipment
Length of stay
Visiting restrictions if any
Intravascular access
Central venous lines
Arterial lines
Ventilator support and weaning
Lumbar drains
Other lines and tubes
Pain management
ansitional care unit transfer
What to expect: monitoring, staffing ratios
Length of stay
tivity progression
ernal and other activity/lifestyle precautions
rable power of attorney for health careplacement of the graft. It is characterized by fever,ukocytosis, and occasionally thrombocytopenia. The symp-
ms, which usually resolve within 1 week, are managed with
algesics and anti-inflammatory agents (794). Heparin-
duced thrombocytopenia can be another source for throm-
embolic events and may require treatment.
Routine assessment of the cannulation site used to deploy
e graft is necessary. Large sheaths are used to deliver stents
d can traumatize and occlude the femoral or iliac artery.
he postoperative period presents an optimal opportunity to
sess and manage cardiovascular risk factors and to educate
e patient and family on the benefits of risk-reduction
easures. The AHA/ACC Guidelines for Secondary Preven-
n for Patients With Coronary and Other Atherosclerotic
ascular Disease (409) outlines guides to risk factor assess-
ent, patient education, and possible interventions (see the
line-only Data Supplement).
Patient and family preparation for discharge includes
phasis of the importance of medication compliance, inci-
on care, and the need for follow-up. They must be made
are of the signs and symptoms of infection, such as
dness, swelling, drainage, and fever. Unusual or severe
in, change in motor strength or sensation in the extremities,
d sudden weakness or dizziness, which may be symptoms
new-onset bleeding or changes in spinal cord perfusion,
ould be promptly reported.
5.4. Nursing Care of Surgically
anaged Patients
tients who have undergone open repair of aortic aneurysms
dissection will require more intensive care. A distinguish-
g feature will be whether the patient had an ascending aortic
ch, or descending thoracic aortic repair. Patients who have
d a dissection or an aneurysm of the ascending aorta or arch
ill have a median sternotomy incision. Patients undergoing
rtic arch procedures may also have an incision over the
illary artery site. Cardiopulmonary bypass is required for
ese procedures and can be associated with fluid retention,
ectrolyte abnormalities, coagulopathies, and hypothermia.
addition, patients with aortic arch repairs are subjected to
tervals of circulatory arrest and retrograde or selective
rebral perfusion. These adjuncts can result in neurologic
sfunction in the postoperative period.
Patients with Type B aortic dissections or descending
oracic aneurysms will have lateral thoracic or thoracoab-
minal incisions. These incisions are often extensive.
These patients will often have lumbar drains that have been
aced to monitor CSF pressure and CSF fluid drainage. The
essure used as a target for drainage varies but will generally
ble 19. Lower Extremity Motor Function Assessment Scale
No movement
Flicker of movement
Able to bend knee to move leg
Unable to perform straight leg raise against gravity, but better leg
movement
Normal movement with expected later or demonstrated ambulation
Note: A score of 3 may be an indication for a neurological evaluation.
Adapted from Svensson et al (781).
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equently in the early postoperative period. Care must be
ken to prevent drainage that is too rapid or too excessive to
event subdural hematoma formation (746). Any change in
vel of consciousness or onset of irritability, confusion,
adache, or pupillary reactivity requires immediate notifica-
n of the physician team and clamping of the drain.
eurologic monitoring also involves assessment of lower
tremity motor and sensory function. Any deterioration may
dicate inadequate spinal cord perfusion.
Standard postoperative care of these patients includes
ntilator adjustments, optimization of blood volume, coag-
ation parameters, and monitoring of other organ system
nctions (795–799). Following the transfer of patients from
e intensive care unit, nursing care is focused on pain
anagement, progression to independent ambulation, pulmo-
ry physiotherapy and incentive spirometry, and wound
re. Preparation for discharge is similar to that described for
wer-activity patients earlier in this section.
6. Long-Term Issues
6.1. Recommendation for Employment and
ifestyle in Patients With Thoracic
ortic Disease
ASS IIa
For patients with a current thoracic aortic aneurysm or dissec-
tion, or previously repaired aortic dissection, employment and
lifestyle restrictions are reasonable, including the avoidance of
strenuous lifting, pushing, or straining that would require a
Valsalva maneuver. (Level of Evidence: C)
stablishing clear lifestyle goals for patients with thoracic
rtic disease is important in improving long-term health and
ducing the risk of complications. Because regular aerobic
ercise, a low-fat and low-salt diet, and achieving an ideal
dy weight are tied to the ability to effectively control blood
essure, cholesterol, and associated aortic wall stress, pro-
ding patients with clear lifestyle targets is important.
voidance of tobacco is critical because it is linked to the
velopment of thoracic aortic disease and to aortic rupture.
ot using cocaine or other stimulating drugs such as meth-
phetamine is important as sudden surges in blood pressure
d pulse attributed to such agents have been described as a
igger for aortic catastrophes (800).
The prescription of exercise represents a dilemma in the
anagement of patients with thoracic aortic disease. Because
is thought that the sudden increases in dP/dt and systemic
ood pressure associated with physical and mental stress
ay be a trigger for AoD in many patients, the concept of
oiding such stresses makes sense (801). However, main-
ining a regular routine of aerobic exercise has day-to-day
nefits in helping patients achieve an ideal blood pressure,
art rate, and body weight. Moreover, many patients simply
joy engaging in sports such as tennis, basketball, golf, bike
ding, etc. and wish to continue in such activities if at all
ssible. thThere are no outcomes data, and scant data of any variety
r that matter, to indicate how much exercise is safe or
neficial for patients with thoracic aortic disease. However,
robic exercise, sometimes referred to as dynamic exercise,
associated with only a modest increase in mean arterial
essure (802), and AoD rarely occurs during aerobic exer-
se. Consequently, most experts believe that aerobic exer-
se, particularly when heart rate and blood pressure are well
ntrolled with medications, is beneficial overall. Neverthe-
ss, if patients wish to engage in vigorous aerobic exercise,
ch as running or basketball, one might consider performing
symptom-limited stress test to ensure that the patient does
t have a hypertensive response to exercise.
Conversely, with isometric exercise, there is a significant
crease in mean arterial pressure. When the Valsalva ma-
uver is used for the lifting of heavy weights, there is a
perimposed increase in intrathoracic pressure, followed by
dramatic increase in systemic arterial pressure (802), with
stolic pressures reaching 300 mm Hg or greater (803). As a
sult, most experts believe that heavy weight lifting or
mpetitive athletics involving isometric exercise may trigger
oD and/or rupture and that such activities should be avoided
04). Working with patients on an individualized basis to
reamline these goals based on insufficient data can be
allenging. For patients who are very much interested in
aintaining some sort of weight lifting program, choosing
ts of repetitive light weights appears to make more sense
an permitting heavy weight lifting (802). For example,
stead of bench-pressing 200 pounds, one might recommend
lecting much lighter weights in repetitive sets to minimize
e hemodynamic consequences. Patients often ask exactly
w much weight is permissible to lift. Unfortunately, it is
t possible to provide a blanket answer to that question, as
all depends on the patient’s size, muscular strength,
ysical fitness, and how the weight is actually lifted. Rather
an try to define a numerical limit, it may be useful to
plain that patients can lift whatever weight they can
mfortably lift without having to “bear down” or perform
e Valsalva maneuver.
In addition to the physiologic stress of exercise, certain
orts, recreational activities, or sudden stress or trauma to
e thorax can potentially precipitate aortic rupture and/or
ssection. Thoracic stress or trauma can occur during com-
titive football, ice hockey, or soccer or may result from a
iing accident, a fall while water skiing, etc. Therefore,
perts often advise patients with thoracic aortic disease to
oid these types of sports (805). Furthermore, rapid chest
tational movement while straining or breath holding (Val-
lva maneuver) may be a common denominator in many
tients who develop aortic dissection (i.e., basketball, tennis,
lf, baseball bat swing, chopping wood with an ax, shovel-
g snow, and rapidly lifting heavy objects).
In addition to the importance of setting clear lifestyle goals
ith patients with thoracic aortic disease, it is wise to
phasize the importance of adherence to their medications,
pecially to beta blockers and other antihypertensive agents.
tients who suddenly discontinue their medications because
ey fail to obtain a refill or perhaps forget their medications
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ve crisis with a potentially catastrophic result.
Even patients who are compliant with their medications
ay find that their blood pressure may fluctuate between
utine visits to their physician, resulting in months of
cessive hypertension. Therefore, patients may achieve
ore consistent control of their hypertension if they regularly
ack their heart rate and blood pressure with a home
onitoring system. In addition, by regularly tracking their
eight and activity profile, they can provide their physician
d other care members with accurate data with which to
ake adjustments in medication and lifestyle going forward.
In terms of work, patients with thoracic aortic disease
nerally can function normally in most types of occupations.
he exception is any job involving heavy physical and
anual labor accompanied by extreme isometric exercise
.g., lifting heavy boxes in a stockroom, carrying furniture
and down stairs). As with the heavy weight lifting
scribed earlier, this type of unusual sudden stress on the
rta may predispose to a triggering of either aortic rupture or
oD (806). Therefore, when patients have a vocation in
hich such extreme lifting might be required, it is important
discuss the details of their daily job responsibilities and to
escribe avoidance of activities that might put them at risk.
some cases patients can readily avoid such heavy lifting on
e job, but in many cases a letter from a physician explaining
e restrictions may be required.
Finally, patients with thoracic aortic disease should recog-
ze that aortic disease is usually a lifelong condition that puts
em at future risk for acute aortic syndromes. Even those
ho have received advanced surgical or endovascular therapy
ust understand that their aortic disease has not been “cured”
the interventions. Educating them about what to do in the
ent of the sudden onset of chest, back, or abdominal pain or
e sudden development of an ischemic complication (i.e.,
urological or limb) and the critical nature of getting to an
ergency department promptly is of the utmost importance.
milarly, those who live with or care for such patients should
derstand what action needs to be taken should concerning
mptoms arise.
7. Institutional/Hospital
uality Concerns
7.1. Recommendations for Quality
ssessment and Improvement for Thoracic
ortic Disease
ASS I
Hospitals that provide regional care for patients with acute
sequelae of thoracic aortic disease (e.g., procedures for tho-
racic aortic dissection and rupture) should participate in
standardized quality assessment and improvement activities,
including thoracic aortic disease registries. Such activities
should include periodic measurement and regional/national
interfacility comparisons of thoracic aortic disease–related
procedural volumes, complications, and risk-adjusted mortality
rates. (Level of Evidence: C) adHospitals that provide regional care for patients with acute
sequelae of thoracic aortic disease (e.g., procedures for tho-
racic aortic dissection and rupture) should facilitate and coor-
dinate standardized quality assessment and improvement ac-
tivities with transferring facilities and emergency medical
services teams. Such activities might include:
a. Cooperative joint facility meetings to discuss opportunities
for quality improvement and
b. Interfacility and emergency medical services team compar-
isons of pretransfer care based on available outcome data
and future performance measures developed in accordance
with this guideline. (Level of Evidence: C)
uality assessment of outcomes for thoracic aortic disease
s been ongoing. Creation of one or more standardized
oracic aortic disease registries may significantly improve
pacity for quality assessment and provide outcome results
d meaningful performance benchmarks. IRAD is an exam-
e of such a registry and consists of 12 large referral centers
6 countries and contains information on 290 variables,
cluding demographics, history, physical findings, manage-
ent, imaging studies, and outcomes (227). Commitment to
ta collection, analysis, measurement, validation, and re-
rting should be factored into the payment structures, as all
this will consume time, effort, and infrastructure to do it
ell (47).
Moderate evidence supports “evidence-based referral”—
at is, limiting specific procedures only to hospitals and
ysicians with experience, expertise, and capacity to take
re of complex problems, especially those requiring special-
ed surgical skills and support teams. To date, there is no
plicit evidence supporting such a recommendation for
ute thoracic aortic diseases (807), although this evidence
ists for infrarenal aortic surgery (808–811). Data courtesy
the UHC Clinical DataBase/Resource Manager for 2006q4
rough 2007q3 indicates that for patients with:
Ruptured thoracic aortic aneurysm:
30% transferred from a different hospital
34% were admitted from the emergency department
19% referred from a clinic or physician’s office
14% transferred from a skilled nursing facility or another
nonhospital facility
3% other
Thoracic AoD:
28% transferred from a different hospital
35% were admitted from the emergency department
23% referred from a clinic, physician’s office, or health
maintenance organization
9% transferred from a skilled nursing facility or another
nonhospital facility
5% other
Performance measures and quality metrics (811a) have
en developed to evaluate quality of care for many areas of
rdiac and vascular disease (5,812–814), but none have yet
en established for patients with thoracic aortic diseases.
ssible domains of quality to assess could include proce-
ral volumes (facility and operator), outcomes (e.g., risk-
justed mortality, readmission, complications), time to di-
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nce to nearest referral center, services available, and con-
gency planning) (815). The well-established evidence base
r the regionalization of care for STEMI patients (816) may
rve as a model for similar initiatives for patients with
oracic aortic disease (Table 20).
Claims have been made that some centers either do or will
it referrals of critically ill patients that may adversely
pact hospital mortality rates, although there are no discrete
ta to confirm or disprove this behavior (817). Hence,
nchmarking and profiling efforts must recognize and ac-
unt for the most physiologically precise severity-of-illness
formation and accurate and appropriate case-mix adjust-
ents; otherwise, referral centers may have an incentive to
fuse care for patients who could benefit from being trans-
rred to their facility (818).
Effective medical record systems are being developed and
n enhance communication and provide caregivers with
ear documentation of a patient’s course and medications, as
ell as plans for future (819,820).
7.2. Interinstitutional Issues
cute AoD or other acute problems involving any portion of
e aorta are life-threatening conditions and require placing
e patient in a location where all appropriate diagnostic and
erapeutic measures are available. The minimum require-
ents for the care of patients with acute AoDs include
aging with CT, echocardiography, and angiography; the
ailability of cardiovascular surgery including cardiopulmo-
ry bypass and endovascular interventions; an intensive care
tting that allows continuous monitoring of blood pressure
d intravenous management of blood pressure; and physi-
ans with personal experience and expertise in the manage-
ent of patients with acute AoD (820).
Transfer of patients with acute AoD from one institution to
other represents a period of danger to the patient and must
planned and carried out efficiently. It is incumbent on the
ble 20. Standardized Transferring Facility Assessment,
mmunication, and Documentation for the Following Domains
Blood pressure control for hypertension
Heart rate control for tachycardia
Hemodynamic instability
Blood volume
Cardiac ischemia
Neurologic ischemia
Renal function
Mesenteric ischemia
Peripheral arterial pulses and perfusion
Activation of receiving team
Imaging expectations and communications
Timeliness and efficiency
EMS characteristics of transferring facility, including requisite personnel,
requisite in-transport equipment, including catastrophic resuscitation
capabilities, in-transfer contingency planning, weather conditions,
estimated transfer time, etc.
EMS indicates emergency medical services.ansferring institution to provide prior physician-to- mysician communication, to stabilize and maintain blood
essure control throughout transport, and to send copies of
aging studies (821).
Because patients with acute thoracic aortic diseases present
any emergency department or primary care setting, there
e opportunities for retrospective and comprehensive quality
view. Typical areas of quality assessment could include the
aluation of timely detection in centers that typically are not
uipped to manage such patients.
Retrospective evaluation of patients with thoracic aortic
seases, especially those for whom diagnosis was delayed or
issed, is critical for learning about how best to more rapidly
d effectively identify future patients with life-threatening
oracic aortic aneurysm and/or dissection. Independent ex-
rnal review of poor outcomes may be necessary and
propriately constructed using de-identified clinical records
that bias is not introduced into the evaluation process.
With the dissemination of this guideline, it is hoped that
ese practice standards can form the basis for more wide-
read use of a data registry for quality assessment and
provement for patients with thoracic aortic disease. The
als of such a data system would be to establish an extensive
pulation of thoracic aortic disease patients with the intent
evaluating clinical effectiveness. Domains could include
lume and outcome relationships, process of care patterns,
velopment of standardized performance measures (struc-
re, process, and outcomes), and facility and operator feed-
ck quality data systems. It may also be possible to use
isting data that use relevant ICD-9 codes (Table 2A and
) and appropriate risk-adjusted methods to evaluate mor-
lity and complications.
8. Future Research Directions
nd Issues
he writing committee believes that there are many opportu-
ties for additional meritorious research in thoracic aortic
seases. Emerging research appears promising for the fol-
wing areas, in addition to much needed research in other
eas.
8.1. Risks and Benefits of Current
aging Technologies
here is a great need to balance the rapid identification of
tients with acute AoD or rupture, and the relatively infre-
ent occurrence against the potential risks of radiation
posure and contrast toxicity incurred by current imaging
ethods, for the millions of patients who present with chest,
ck, and/or abdominal pain. The rapid and correct diagnosis
acute thoracic aortic diseases must not impose delays in
eatment of patients with acute MI. Additionally, screening
d serial radiographic imaging of younger patients clearly
poses those individuals to a risk of later radiation-related
seases. Clinical studies of safety and efficacy of screening
otocols using current imaging methods to correctly identify
tients who will benefit from surgical, endovascular, and/or
edical intervention are needed.
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he year 2010 is the 250th anniversary of the death, attrib-
able to AoD, of King George II of England, whose last
oments were memorably described by his valet (822).
lthough a number of conditions are known to be associated
ith dissection, such as hypertension and old age, the cause
spontaneous AoD is still unknown. Is an intimal tear
llowed by a dissecting hematoma (823), or does an intra-
ural hemorrhage ruptures into the lumen causing an intimal
ar? (824,825) In approximately 4% to 10% of dissections,
aortic intimal tear is not found. Bleeding from the vasa
sorum is hypothesized to be responsible for the intramural
morrhage, but little is known about the microstructure of
e vasa vasorum walls; changes in the vasa vasorum in
sponse to aging, hypertension, and inflammation; and rela-
n of extracellular and intracellular metalloproteinases to
otein turnover in the walls of the vasa vasorum. Research
to these questions may shed light on the pathogenesis of
ssection and provide opportunities for prevention and treat-
ent.
8.3. Treatment of Malperfusion and
eperfusion Injury
alperfusion of the gut, spinal cord, kidneys, and lower
tremities doubles the mortality of AoD (247,826). New
eatment strategies for malperfusion and reperfusion injury
e needed to improve the dismal prognosis of patients with
ute dissection and malperfusion syndromes.
8.4. Gene-Based Mechanisms and Models
.4.1. Aortic Disease Management Based on the
nderlying Genetic Defects
s genes are identified leading to an inherited predisposition
r thoracic aortic disease, it is becoming increasingly evident
at the clinical management of thoracic aortic disease asso-
ated with different gene mutations may differ. For example,
utations in TGFBR1 and TGFBR2 predispose patients to
rtic dissection at an aortic diameter of 5.0 cm or less,
ading to the recommendation that the aorta be replaced at
ameters as small as 4.0 cm. As genes are identified that can
use predisposition to thoracic aortic disease, clinical studies
e needed on these patients to determine their optimal
anagement.
.4.2. Biomarkers for Acute Aortic Dissection
quick laboratory test with at least a high sensitivity, if not
ecificity, could lead to fewer missed or delayed diagnoses
acute AoD. None currently exists. D-dimer has been
oposed as a screening test for acute AoD (see Section
6.1.2). A prospective study regarding the safety and efficacy
such a strategy is needed.
.4.3. Genetic Defects and Molecular
athway Analyses
ecent studies in the mouse model of Marfan syndrome and
e identification of TGFBR1 and TGFBR2 mutations sug-
sts that alteration of TGF-Beta signaling is involved. The
entification of mutations in 2 components of the contractile
it in smooth muscle cells, beta-myosin heavy chain and tepha actin, has indicated a role of maintenance of smooth
uscle cell contractile function in preserving aortic structure
d preventing these aortic diseases. Further studies identi-
ing defective genes and analyzing pathways using human
sues or mouse models will be the basis for understanding
e molecular pathology and will be the first step toward
velopment of rational medical therapies for thoracic aortic
sease.
.4.4. Clinical Trials for Medical Therapy for
ortic Aneurysms
ecent studies in the mouse model of Marfan syndrome with
rtic disease similar to that seen in humans showed the
eatment with losartan normalized aortic root growth and
rtic wall architecture (6). Doxycycline, an inhibitor of
MP, significantly delayed aneurysm rupture in this mouse
odel. A clinical trial is ongoing in patients with Marfan
ndrome under the age of 25 years to determine if losartan
lays aortic progression. More aggressive trials (other
ents, 2 or 3 agent therapies) based on the results in mouse
odels to prevent the onset of aortic disease in individuals
netically predisposed or to delay the enlargement of al-
ady formed aneurysms are needed.
8.5. Aortic Atheroma and Atherosclerosis
entification and Treatment
s noted in Section 11, there is a need for research into the
echanistic aspects of aortic arch atheroma in causing
bolic events. Additionally, for those patients with known
rtic arch atheroma, a randomized blinded controlled trial is
eded to test currently available treatment options, both
edical and surgical, to prevent embolic vascular events.
The value of current imaging (MR, CT, TEE) technologies
identify and quantitate risk for patients with aortic arch
heroma is unknown.
8.6. Prediction Models of Aortic Rupture
nd the Need for Preemptive Interventions
e need to have models or indices that are better than just
rtic diameter to predict rupture and to better determine the
st timing for surgical or endovascular intervention. Since
e advent of CT and MR scanning, a massive amount of
diological data has accumulated with multiple studies in
dividual patients that could be linked to clinical data and
ed for this purpose. The evidence base regarding the
inical course of patients with Marfan syndrome is more
bust than for patients with degenerative aneurysms and
her thoracic aortic conditions. An ongoing registry similar
that used for patients with Marfan syndrome would be a
ace to start.
8.7. National Heart, Lung, and Blood
stitute Working Group Recommendations
he National Heart, Lung, and Blood Institute Working
roup on Research in Marfan Syndrome and Related Disor-
rs (827) posted a summary of recommendations for future
search which apply to the broad range of patients with
oracic aortic disease. The importance of multidisciplinary
ams and collaborative research models were stressed:
••
•
•
•
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developed to define the presentation, natural history, and
clinical history of aneurysm syndromes.
Biological and aortic tissue sample collection should be
incorporated into every clinical research program on
Marfan syndrome and related disorders and funds should
be provided to ensure that this occurs. Such resources,
once established, should be widely shared among investi-
gators.
An Aortic Aneurysm Clinical Trials Network should be
developed to test both surgical and medical therapies in
patients with thoracic aortic aneurysms. Partnership in this
effort should be sought with industry, academic organiza-
tions, foundations, and other governmental entities.
The identification of novel therapeutic targets and biomar-
kers should be facilitated by the development of geneti-
cally defined animal models and the expanded use of
genomic, proteomic and functional analyses. There is a
specific need to understand cellular pathways that are
altered leading to aneurysms and dissections, and to
develop robust in vivo reporter assays to monitor TGF-
Beta and other cellular signaling cascades.
The developmental underpinnings of apparently acquired
phenotypes should be explored. This effort will be facili-
tated by the dedicated analysis of both prenatal and early
postnatal tissues in genetically defined animal models and
through the expanded availability to researchers of surgical
specimens from affected children and young adults.
The writing committee enthusiastically endorses these
ncepts.
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Aabdominal aortic aneurysm
Daortic dissection
Dcoronary artery disease
Fcerebrospinal fluid
computed tomographic imaging
Gelectrocardiogram
Agiant cell arteritis
Hintramural hematoma
Rinternational normalized ratio
ADInternational Registry of Acute Aortic Dissection
EPmotor evoked potential
Imyocardial infarction
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Rmagnetic resonance imaging
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FPsteady-state free precession
EMIST-elevation myocardial infarction
Athoracoabdominal aneurysm
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Atraumatic rupture of the aorta
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